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Abstract
Immunological disorders, including those of an autoimmune nature, cause 
chronic morbidity and disability. Common conditions, such as rheumatoid 
arthritis and psoriasis as well, as the less commonly occurring multiple 
sclerosis and myasthenia gravis are known to have an autoimmune basis. These 
disorders are not well controlled with current therapies. The main problems 
include the lack of specificity of action thereby leading to a number of adverse 
drug effects. For example, severe nephrotoxicity is associated with tacrolimus 
and ciclosporin; newer monoclonal antibody therapies have the potential for 
immunological toxicity. Thus the search for alternative immune modulating 
agents is a well sought after objective.
Recently, the quorum sensing signal molecules, !-(3-oxododecanoyl)-L-
homoserine lactone (OdDHL) and 2-"-heptyl-3-hydroxy-4(1#)-quinolone 
(PQS), isolated from $%&'()*)"+% +&,'-.")%+, were found to possess the 
ability to modulate the immune response. Structure activity relationship (SAR) 
studies using OdDHL as the lead molecule had been undertaken but no work 
has been done to maximise the potential of PQS. The immune modulatory 
activity of PQS suggests that an evaluation of its synthetic analogues may 
provide better understanding of the structural components that influence its 
activity and may lead to the development of novel therapeutic agents. In order 
for a SAR study to be attempted with PQS a more efficient synthetic route has 
to be developed to obtain practical quantities of this material.
To address these issues, the research in this thesis firstly investigates a number 
of synthetic routes towards the preparation of PQS and its synthetic analogues. 
The successful synthetic routes yielded analogues with alterations to the main 
structural components of PQS, namely the alkyl side chain, !’-substitution, 3-
hydroxyl group and substitution on, and in, the carbocyclic ring. Structural 
alterations were made singularly or in combination in these areas of the 
molecule. Besides these quinolone-based analogues, a number of 
quinazolinone-based variants were also elaborated.
All analogues were characterised for identity and purity, then tested for 
immune modulatory activity in a concanavalin A mitogen stimulated murine 
cell proliferation assay and their cytotoxicity using a dye exclusion assay. 
Bioactivity was shown to be dependent on the length of the 2-akyl side chain, 
with extensions to the chain more tolerated than a reduction. The nature of the 
substitution at the 3-position has an influence on activity, whereas a proton on 
the nitrogen is not essential. The less polar and more lipophilic molecules 
displayed increased bioactivity. The core quinolone structure can tolerate 
insertion of extra heteroatoms the heterocyclic ring and substitution of chlorine 
on the carbocyclic ring, while retaining an acceptable level of activity. A 
similar trend was observed in the quinazolinone derivatives.
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1Chapter 1
Introduction
The human immune system provides a defence against a wide range of 
pathogenic organisms, such as bacteria, viruses and parasites. It consists of 
physical barriers, including skin and mucous membranes, non-specific cellular 
defences, referred to as the innate response, and targeted cellular responses, 
specific to the invading organism, which forms the adaptive response. 
Disorders of the immune system may be due to immune deficiency, 
hypersensitivity and autoimmunity. Autoimmunity occurs when the distinction 
between self and non-self, crucial to the function of the immune response, is 
lost and there is an immune response mounted against the body’s own tissues. 
These disorders may be treated by the use of immune suppressants, such as 
steroids, ciclosporin and cytokine inhibitors, although these therapies are not 
ideal, due to the potential for serious adverse drug reactions. Due to this, the 
identification and development of novel immune modulating therapies is 
warranted. The recent discovery of the ability for signal molecules, involved in 
the bacterial communication method known as quorum sensing, to modulate 
the immune system has led to interest in investigating this ability further.
1.1 Immune system
The immune system serves as a defence against microbes which possess the 
ability to cause harm to a host organism via a diverse range of pathogenic 
mechanisms, concurrently avoiding responses that cause damage of host 
tissues. To combat this wide range of pathogenic mechanisms, the immune 
response utilises complex and varied processes to eradicate or control 
organisms that present a threat.
The immune system consists of two main parts, defined by the speed 
and specificity of the response mounted. These two parts are not independent 
and there is a great deal of interaction between the two but they remain distinct 
2in their components and their mode of response. These two parts of the 
immune system are termed the innate and adaptive responses.
1.1.1 Innate Immunity
Innate immunity consists of relatively non-specific elements that operate 
against nearly all substances that threaten the body and are able to act rapidly 
in providing the initial host response.  These elements include physical or 
chemical barriers and cellular defences
1
. The lack of specificity of the response 
of innate cellular defence means that the innate response may lead to harm 
being caused to the host. A level of innate immunity passed from mother to 
child is present for a time following birth.
1.1.1.1 Physical and chemical barriers
These can be considered as the first line of defence employed by the host 
against infection. The main function of these barriers is to prevent access of 
foreign or infectious bodies to the host and may not commonly be seen as part 
of the immune system.
1.1.1.1.1 Physical Barriers
Physical barriers mainly comprise of the skin and mucous membranes.  Most 
substances and organisms cannot gain access to the host through intact skin, 
but will be able to through areas of damage where the integrity of the skin is 
compromised. Mucous membranes are present on the respiratory, genitourinary 
and gastrointestinal tracts and aid in immunity by trapping organisms, thereby 
preventing them entering the host. The organisms are then removed towards 
external openings via ciliated epithelial cells.
31.1.1.1.2 Innate Chemical Factors
Chemical factors, such as an acidic pH, fatty acids and hydrolytic enzymes can 
prevent entry through hair follicles and sebaceous glands.  The presence of 
various hydrolytic enzymes in saliva, low pH of the stomach and proteolytic 
enzymes in the small intestine also contributes to a hostile environment for 
microorganisms
1
.
Additionally, small molecules and proteins, such as interferons and 
components of the complement system
2
that are found in the serum contribute 
to non-specific immune defences. Activation of complement components 
produced in response to various organisms can induce an enzymatic cascade, 
which will target the membrane of pathogenic organisms, leading to their 
death.
1.1.1.1.3 Cellular defences
If an invading organism gains access to the body, past the chemical and 
physical barriers referred to above, the next line of defence involves a range of 
specialised cells intended to remove the foreign body.
Although the innate response is not antigen-specific, it still exhibits the
ability to distinguish between foreign molecules and self. Phagocytes can 
recognise pathogen-associated molecular patterns that are present on microbes 
but not on host cells. Examples of these are found on Gram negative bacteria
(lipopolysaccharide), Gram positive bacteria (lipotechoic acid) and yeast cells 
(mannans).
The ability for the innate immune response to have this recognition is 
one factor that shows the close relationship between the innate and adaptive 
response. The pattern-recognition receptor can recognise the broad patterns on 
microbes and can then present the processed product onto the antigen specific 
T cells.
The innate response is largely confined to extracellular organisms, as 
the majority of the processes required to remove the pathogen needs exposure 
to the surface of the organism. Hence the innate system is not able to recognise,
or remove, intracellular organisms such as viruses.
41.1.1.1.3.1 Granulocytes
!&'/,)35.6%
One of the most important aspects of the innate immune response is the 
recruitment and activation of neutrophils at the site of the infection, in order to 
remove the pathogenic organism
3
. Neutrophils are normally constantly present 
in the blood stream and can localise on a site of infection through a multistep 
process involving proinflammatory mediators, adhesion molecules, chemo 
attractants and chemokines
4
.
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Macrophages are highly phagocytic towards microbes that have been bound by 
immunoglobulins (Ig) or complement. They are mobilised following the 
recruitment of neutrophils and remain at sites of inflammation and infection for 
extended periods
4
.
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The main role of eosinophils is to protect the host from parasitic infections. 
Infections of this type cause the production of IgE, which coats the cell. 
Eosinophils have low affinity receptors for IgE and bind to the cell surface, 
secreting highly cytotoxic materials onto the surface of the invading cells.
!+/',+6 :.66&, ;&66%
Natural killer (NK) cells have two methods of recognising abnormal cells. 
They are able to bind to targets coated with antibody, leading to a cytotoxic 
response. Additionally, they can interact with major histocompatibility (MHC) 
class 1, normally expressed on all nucleated cells. If they are not able to bind to 
the MHC, the NK cells lyse the target
5
. This is achieved by the secretion of 
perforins onto the surface of the adhered cell, leading to the formation of pores 
in the cell membrane. Granzymes are injected through these pores, initiating 
apoptosis
1
.
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Basophils and mast cells are the initiators of immediate hypersensitivity 
reactions. This is achieved through the release of histamine and other 
mediators, leading to tissue inflammation, oedema and smooth muscle 
contraction.
1.1.1.1.4 Cell Targeting
For the cells involved in the innate immune response to be effective they need 
to be targeted to the site of infection. This may be achieved internally by the 
interaction of cellular receptors or externally through signals that influence the 
direction of these cells, such as adhesion molecules and chemokines.
1.1.2 Adaptive Immunity
Adaptive immunity is a more specific form of immunity, involving an 
encounter with a foreign substance leading to the production of a specific 
immune response to that foreign agent. The ability to mount such an immune 
response against specific invaders is present from birth but requires the initial 
exposure to foreign material, termed an antigen. The specificity of the adaptive 
immune response means that there is much less chance of damage to the host 
as the response is targeted against the foreign body.
Alongside the specificity of this response, another important feature is 
the memory that is retained following previous exposure to foreign material.
The length of time that this is retained varies but may last the lifetime of the 
individual. This memory allows the host to respond more rapidly, and to a 
greater extent, following re-exposure to a foreign material.
The two major types of cell involved in acquired immunity are T-
lymphocytes, originating from the thymus, and B-lymphocytes, originating in 
the bone marrow. 
61.1.2.1 T-Lymphocytes
There are a number of different types of T-lymphocyte and these are 
distinguished by the expression of the glycoproteins CD4 and CD8 on the cell 
surface. The majority of T cells present in circulation are CD4
+
(60 – 70%) 
with the rest being CD8
+
. These two types of T cells will develop into subsets 
with distinctly different function after exposure to antigen
6
. CD4
+ 
T cells 
develop into two different types of T helper cells (T
H1
and T
H2
) following the 
stimulation of an antigen and the type of T helper cell they become depends on 
the cytokines present at the site of infection
7
. At the beginning of an immune 
response a T
H
cell can exhibit characteristics of both T
H1
and T
H2
but after 
prolonged time the response will be predominately one of the two types. T 
helper cells are characterised by the immune products they release and T
H1
generally support cell mediated immune response, whereas T
H2
aid in humoral, 
anthelmintic and allergic responses. CD8
+
T cells can develop into cytotoxic T 
cells, designated either T
C1
or T
C2
cells
8
.
Acquired immunity that is regulated by T-lymphocytes is termed cell-
mediated immunity (CMI). In order for the T cell to recognise an infected host 
cell, thereby recognising both self and non-self, the cell surface glycoproteins, 
MHC molecules, are made use of. Class I MHCs are those that have been 
synthesised within the cell
9
, whereas class II MHCs have been proteolytically 
processed following ingestion.
1.1.2.2 B-Lymphocytes
B cells develop from stem cells and their development depends on stromal cells 
and their release of IL-7 and through their maturation and development will 
assemble an antigen binding component within the B cell receptor. There are 
two types of B-lymphocytes, T dependent, requiring T cells to produce 
antibodies, and T independent
1
.
Antigens may activate both T and B cells and this will cause the B cell 
to mature under the influence of helper T cells. Following exposure to the 
antigen, random mutations in the antigen binding region of the B cell will take 
place
4
. If these mutations cause less affinity with the antigen, these cells will 
7not receive important growth signals and will die. If the mutations increase the 
affinity for the antigen the cell will proliferate and dominate the responding 
cells
10
. This process allows the development and retention of B cell memory
11
.
T cell independent responses are possible when a B cell is stimulated by 
a polymeric antigen. The somatic mutation does not happen in these responses 
and the resulting memory is therefore weak
4
.
1.1.2.3 Cytokines and Chemokines
Cytokines and chemokines are secreted proteins whose functions include 
growth, differentiation and activation. They regulate the nature of the immune 
response and control many factors in the immune cellular response.
Cytokines and chemokines are also involved in allergic responses and 
play a roll in, amongst other things, mast cell growth and histamine release.
1.1.2.3.1 Cytokines
Cytokines are involved in almost every area of immunity and inflammation. 
Their influence extends across innate immunity, antigen presentation, cellular 
recruitment and adhesion molecule production.
A cascade response can be seen following the production of cytokines. 
The function of a cytokine can vary depending on its source, target and phase 
in the immune response in which the cytokine is presented. The cytokines 
produced when responding to an immune incident can determine the nature of 
the immune response, whether it is cytotoxic, allergic, cell mediated or 
humoral.
Cytokines may be divided into interleukins (ILs), interferons (IFNs), 
colony-stimulating factors (CSFs) and tumour necrosis factors (TNFs). 
Examples of where a range of cytokines act within the immune response and 
their results are shown in Table 1.1. Important members of this class of 
molecule are further discussed below.
8Table 1.1 Areas and results of cytokine action within the immune system
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Innate IL-1, IL-6, IFN-α, TNF-
α, IFN-γ
Acute phase response in 
liver
Cellular IL-2, 10, 12, 18, 23, 
IFN-γ
T cell proliferation
Macrophage activation
Humoral and allergic IL-3, IL-4, IL-5, IL-9, 
IL-10, IL-13 IL-25, 
TNF-α
IgE production
Inflammatory cell 
recruitment
B"/&,6&'@."4C
Interleukin-2 (IL-2) expression is important in the proliferation of T cells. IL-2 
is able to allow the proliferation of T cells that will be specific to the antigen 
that incites the immune response. T cells are initially stimulated, causing the 
release of IL-2, which then leads to the T cell proliferation.
D'*)', !&8,)%.% =+8/),
Tumour necrosis factor (TNF) consists of two homologous proteins TNF-α and 
TNF-β, produced primarily by mononuclear phagocytes and lymphocytes 
respectively. TNFs bring about antitumour immunity and are able to initiate 
direct cytotoxic effects on cancerous cells. They are also able to induce 
adhesion molecules, activate neutrophils therefore mediating chemotaxis, 
adherence and degranulation.
B"/&,>&,)"%
Interferons (IFN) are a group of cytokines that are so called due to their ability 
to “interfere” with viral growth. There are three types of interferons, IFN-α, 
IFN-β and IFN-γ. IFN-α has a significant antiviral activity through inhibiting 
viral replication, protecting uninfected cells and stimulating antiviral immunity. 
IFN-β is similar in biological effect to IFN-α. IFN-γ has a weak antiviral 
activity but is the primary cytokine responsible for cell-mediated immunity
12
. It 
9induces the accumulation of macrophages at the site of cellular immune 
responses, allowing these macrophages to remove intracellular pathogens.
1.1.2.3.2 Chemokines
Chemokines are small molecules whose prime function is to induce chemotaxis 
in a range of cells, including neutrophils, lymphocytes and eosinophils. New 
functions for chemokines are still being discovered, extending their role 
beyond chemotaxis. Haemostatic functions associated with the adaptive 
immune response, such as lymphocyte trafficking and haematopoiesis, are now 
recognised to involve the action of chemokines. Chemokine receptors can bind 
to more than one ligand, allowing an overlap of function. Table 1.2, shows the 
main functions of chemokines divided into inflammation and homeostasis but 
the functions of many known chemokines remain unknown. Chemokines can 
be divided into four sub-families dependent on the positioning of their N-
terminal cysteine residues.
Table 1.2 Functions of chemokine action within the immune system
Physiological function Chemokine
Inflammation CCL1, CCL2, CCL3, CCL4, CCL5, 
CCL7, CCL8, CCL11, CCL13, 
CCL17, CCL20, CCL22, CCL2, 
CCL26, CCL28, CXCL1, CXCL2, 
CXCL3, CXCL8, CXCL9, CXCL10, 
CXCL11, CXCL16, CX3CL1
Homeostasis CCL17, CCL18, CCL19, CCL20, 
CCL21, CCL22, CCL25, CCL27, 
CCL28, CXCL13, CXCL14
Unknown CCL6, CCL9, CCL10, CCL12, 
CCL14, CCL15, CCL16, CCL23, 
XCL1, XCL2, CXCL4, CXCL5, 
CXCL6, CXCL7, CXCL12, CXCL15
10
1.2 Immunopathology
The immune system is able to protect the host organism against the threat 
posed by a large range of pathogens and other environmental challenges. It is 
extremely adaptive and able to account for some deficiency in its function. 
Despite this it is still liable to fail and may do this in three main ways. The 
balance of the immune system may be restored though immune modulation.
1.2.1 Immunodeficiency
When the immune system is unable to defend the host against pathogenic 
organisms it may be seen to have become deficient. The causes may be genetic 
in nature, secondary to disorders such as leukaemia or non-immunological 
abnormalities, or the result of cytotoxic chemotherapy in the treatment of 
malignancy.
An example of how immunodeficiency may be treated is the use of 
filgrastim, which is recombinant human granulocyte-colony stimulating factor
(GCSF), in the case of neutropenia occurring due to chemotherapy
13
.
1.2.2 Hypersensitivity
Hypersensitivity occurs when the response to an allergen, or non-microbial 
antigen, is out of proportion and causes an adverse reaction above and beyond 
the capability of the original stimulus. The term “allergy” refers to the 
symptoms and signs that are present with exposure to allergens. This type of 
disease may be termed atopic in nature. There appears to be a genetic element 
to atopic illness
14
. The most serious example of this type of immunopathology 
is the massive immune response of anaphylaxis which can be caused by a 
seemingly innocuous material. Other types of atopic disease include hay fever, 
asthma and eczema.
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1.2.3 Autoimmunity
The immune system normally differentiates between self and non-self. In 
some cases this distinction can break down, leading to an immune response 
directed at the host, termed autoimmunity. Autoimmune disease is when 
recognition of self as non-self leads to pathological consequences, involving 
antibody, complement, immune complexes and cell-mediated immunity.
A growing number of diseases are thought to have an autoimmune 
basis, although it is not always straightforward to class diseases as such. The 
cause of autoimmune disease is thought to be multifactorial, with possible 
genetic bases, environmental factors and the involvement of a number of 
potential triggering factors. Two main ways in which autoimmune diseases 
develop are the bypassing of unreactive T cells or the stimulating of 
autoreactive T cells.
1.2.3.1 Genetic Factors
Genetic factors are important in the development of autoimmune conditions
15
, 
although the area is not currently well understood. The majority of autoimmune 
conditions appear to be polygenic
16
and therefore are difficult to study 
effectively. There are a small number of conditions in which a single mutant 
gene is responsible, such as polyendocrinopathy syndrome type 1
17
. 
1.2.3.2 Environmental Factors
Environmental factors also play a central role in the initiation of autoimmune 
conditions, with viruses being the main focus of attention. Again, this area is 
not fully understood currently and the role of environmental factors in the
development of autoimmune conditions needs further investigation. 
Infection appears to be a major environmental factor in the 
development of autoimmune conditions, as can be seen from epidemiological 
and clinical data
18
. The mechanisms that have been suggested to cause 
autoimmunity as a result of virus infection are polyclonal lymphocyte 
12
activation
18
, antigen mimicry
19-21
and increased immunogenicity of organ 
autoantigens following inflammation due to infection
22,23
.
Another example of infection causing autoimmune disease is the 
development of Chagas’ disease during infection with D,?3+")%)*+ 8,'1., 
causing autoimmune myocardial damage. The antigens of the pathogen bind to 
host cells, causing antibodies and T cells to lyse these cells.
1.2.3.3 Division of autoimmune diseases
Autoimmune diseases can be divided according to the dominant mechanism 
involved in pathogenesis: antibody, immune complex formation or effector 
mechanisms of cell-mediated immunity.
Antibody-mediated autoimmune diseases include haemolytic anaemia, 
when antibodies react with red blood cells, and myasthenia gravis, where the 
target for the antibodies is the acetylcholine receptor at the neuromuscular 
junction.  
Systemic lupus erythematosus is an example of immune complex-
mediated autoimmune disease. The disease attacks many organs of the body 
and the central nervous system, due to the unnaturally high levels of anti-DNA 
antibodies produced, possibly due to enhanced helper T cell activity or the
inability of phagocytic complexes to clear immune complexes.  
T cell-mediated autoimmune diseases include Type 1 diabetes mellitus, 
involving the destruction of insulin producing β-islet cells by inflammation and 
rheumatoid arthritis, in which the synovium can be stimulated to produce pro-
inflammatory cytokines and enzymes that break down tissue This results in 
inflamed joints and destruction of cartilage and bone
1
.
1.2.3.4 Treatment of autoimmune diseases
The treatment of autoimmune disorders is currently based in suppression of the 
immune response to lessen the damage caused by the self directed immune 
response.
The most commonly used current immune modulating drugs have been 
isolated from soil bacteria and soil fungi. The potential for a drug developed 
13
from a human pathogen may allow a more targeted effect and reduce the side 
effects that are associated with immune therapy.
1.3 Immune Therapies
1.3.1 Irradiation
A non-drug method for immune suppression therapy is the use of radiation. 
This can be in the form of total body irradiation (TBI) or irradiation of relevant 
areas of the body and the immune system, such as total lymphoid irradiation.
TBI is used for the conditioning of patients before they undergo
haematopoietic cell transplantation. After the exposure 80 % of lymphocytes 
undergo intermitotic death, including B lymphocytes and the precursors to all T
cells. There is an additional effect in the ability for cells to localise to sites 
around the body.
Total lymphoid irradiation is used in treatment of Hodgkin’s disease, 
solid organ graft rejection and severe cases of rheumatoid arthritis. The local 
irradiation does not increase susceptibility to infection but does produce 
lymphopenia and affects hypersensitivity responses.
1.3.2 Immune modulating drugs
There are a number of drugs in clinical use which modulate the immune 
response. The majority of these are for the area of immune suppression and are 
commonly used following organ transplant or in the treatment of autoimmune 
conditions. There are also immune stimulants but the use of these in a clinical 
setting is more limited.
1.3.2.1 Immune Suppressants
Immune suppressants can be divided into groups based on their principal mode 
of action although some agents may have modes of action that can be 
categorised in more than one area.  These mechanisms are limited to five main 
groups; regulation of gene expression, alkylation, inhibition of (& ")E) purine 
14
synthesis, inhibition of pyrimidine synthesis and kinase and phosphatase 
inhibitors 
24
. Table 1.3 summarises the various drugs currently used and groups 
them in relation to their mode of action
Table 1.3 Mechanisms of action in immunosuppressive drugs
Mechanism of Action Drug
Regulation of gene expression Glucocorticoids
Alkylation Cyclophosphamide
Kinase and phosphatase inhibitors Ciclosporin
Tacrolimus
Sirolimus
Inhibition of de novo purine synthesis Azathioprine
Mycophenolate Mofetil
Mizoribine
Methotrexate
Inhibition of de novo pyrimidine 
synthesis
Leflunomide
Brequinar
Methotrexate
More recently there has been the introduction of another group of immune 
modulating drugs, these having their action through cytokine inhibition.
1.3.2.1.1 Glucocorticosteroids
Glucocorticosteroids are hormones that have a wide range effect on the 
immune system and inflammatory response. The first steroid to be available 
was cortisone, a naturally occurring hormone, in 1949. Subsequent to the 
discovery of cortisol, alterations to its structure produced glucocorticoids with 
greater potency and duration of action. Steroids have both an immune 
suppressant action and an anti-inflammatory action. There is a range in 
15
potency, ranging from the least potent, hydrocortisone, to dexamethasone, 
which is 30 times more potent. Glucocorticosteroids have effects on target gene 
transcription
25
, alteration of circulating levels of neutrophils, eosinophils, 
macrophages and lymphocytes
26
and inhibition of pro-inflammatory 
cytokines
27
.  The diverse mode of action of the glucocorticosteroids makes 
them useful for the treatment of dermatological, allergic and autoimmune 
disorders. 
Examples of glucocorticosteroids include hydrocortisone 1.1, used for 
the treatment of rheumatic disease and inflammatory bowel disease and 
prednisolone 1.2, indicated for asthma and prevention of organ rejection 
following transplantation.
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The diversity of the mode of action unfortunately leads to complications, with 
adverse effects associated with this class of drugs. These adverse reactions 
most commonly include hypertension, weight gain, glucose intolerance, 
gastritis, adrenal suppression, diabetes and osteoporosis. The use of steroids in 
children is also associated with growth failure.
This wide range and frequent occurrence of side effects means there 
needs to be a risk versus benefit approach to the use of steroids. The usual 
approach is to use sufficient quantities to control the disease and then reduce 
the dose to the lowest possible to limit the side effects.
1.3.2.1.2 Cyclophosphamide
Cyclophosphamide 1.3 is an alkylating agent, which can form transition 
complexes with the 7-nitrogen atom of guanine and other components of 
DNA
24
.  This leads to DNA fragmentation, mutations and cell death
27
.
16
Cyclophosphamide was first investigated for use as chemical warfare agents 
and following World War II research was carried out regarding their potential 
therapeutic effects.
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When given orally cyclophosphamide is relatively inactive until the cleavage 
of the phosphorus-nitrogen linkage, eventually leading to the formation of the 
phosphoramide mustard 1.4 and the metabolite acrolein 1.5, shown in scheme 
1.1.
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Scheme 1.1 Formation of phosphoramide mustard from cyclophosphamide
The phosphoramide mustard 1.4 is an alkylating agent
28
and is able to crosslink 
the DNA base guanine 1.6 (scheme 1.2) thereby inhibiting DNA replication, 
suppressing cell division or triggering apoptosis. Cyclophosphamide’s main 
effect is on B cells, suppressing cellular immunity and antibody production
24
.
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Scheme 1.2 The crosslinking of guanine by phosphoramide mustard
The drug’s main clinical use is as a cytotoxic agent in oncology and 
haematology. It is used for its immune modulating effect prior to bone marrow 
transplantation, following organ transplantation or for severe rheumatoid 
arthritis. Cyclophosphamide causes severe systemic side effects including 
alopecia, cardiotoxicity and leukopenia. During its use, regular blood counts 
need to be undertaken to ascertain any damage on the production of cells. Also, 
the active metabolite acrolein 1.5 can cause severe haemorrhagic cystitis. Due 
to its high toxicity, cyclophosphamide is only used if other therapies have 
proved unsuccessful.
1.3.2.1.3 Azathioprine
Azathioprine 1.7 was one of the first generation of immunosuppressive drugs 
to be used in the area of organ transplant. It was originally synthesised in 1949 
and was later found to have a range of effects on the immune system
29-31
.
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Azathioprine is metabolised to 6-mercaptopurine 1.8 after oral administration
(Scheme 1.3). The metabolism of azathioprine has been reviewed by Chan &/ 
18
+6.
32
. 6-Mercaptopurine is a purine analogue, causing effects on purine 
synthesis, and is incorporated into DNA in a non-specific way, leading to the 
death of rapidly dividing cells in the bone marrow and intestine
27
. This was 
originally developed to be a drug in its own right but it was found that its
imidazol derivative, azathioprine, was less toxic.
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Scheme 1.3 The formation of 6-mercaptopurine via the metabolism of 
azathioprine 
As a purine analogue it will form 6-thioinosine monophosphate 1.9, inhibiting 
the production of purine nucleotides and, therefore, inhibiting DNA replication.
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Azathioprine is used for transplant recipients and to treat a number of 
autoimmune conditions, commonly when a corticosteroid does not provide 
sufficient control.  
Even though azathioprine is less toxic than it predecessor, 6-
mercaptopurine, it still carries with it a large range of adverse effects. Severe 
myelosuppression is the most common side effect observed. An additional 
active metabolite of Azathioprine, 6-thioinosinic acid, is able to be 
19
incorporated into both RNA and DNA nucleic acids. As a result there is 
widespread chromosomal breakage in a large number of cell types. There is 
also the possibility of hepatic toxicity, as the drug is metabolised by the liver.
Azathioprine is widely used following organ transplant and is used to 
treat a range of autoimmune disorders, mainly rheumatoid arthritis. Patients 
who are having treatment with azathioprine have to undergo regular monitoring 
due to the large risk of myelosuppression. The drug’s generality of action is the 
main limitation in its use.
1.3.2.1.4 Mycophenolate Mofetil
Mycophenolate mofetil (MMF) 1.10 is a pro drug of mycophenolic acid 1.11
that inhibits the enzyme inosine monophosphate dehydrogenase (IMDP) types 
I and II 
33
, which leads to the inhibition of guanosine nucleotide synthesis 
without incorporating into DNA
27
.
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MMF 1.10 undergoes ester hydrolysis in the liver to yield mycophenolic acid
1.11, the active metabolite of the drug, shown in scheme 1.4. Mycophenolic 
acid is now available in medicinal form as Myfortic
®
produced by Novartis.
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Scheme 1.4 Hydrolysis of Mycophenolate Mofetil 
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In the S phase of the cell cycle, guanine monophosphate is produced via the 
pathway shown in Fig 1.1
34
. During the activation of T cells, the activity of 
types I and II inosine monophosphate dehydrogenase enzymes increases 
tenfold.
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Figure 1.1 Mechanism of action of Mycophenolate Mofetil
Following the ester hydrolysis, mycophenolic acid non-competitively and 
reversibly inhibits types I and II inosine monophosphate dehydrogenase 
activity, leading to an inhibition of DNA synthesis in the G2 phase of the cell 
cycle
34
. MMF inhibits the proliferation of T-lymphocytes and antibody 
production by B-lymphocytes, as these processes are dependent on (& ")E)
purine synthesis for DNA replication. In addition, it prevents glycosylation of 
adhesion proteins, inhibiting migration of lymphocytes to areas of 
inflammation
27
.  
Mycophenolate mofetil is classified by the British National Formulary 
as an antiproliferative immune suppressant. It is licensed for the prophylaxis of 
acute rejection in renal or cardiac transplantation, when it is used in 
combination with ciclosporin and corticosteroids
13
.
Clinical trials have shown that MMF is useful in decreasing the 
incidence and severity of acute rejection episodes but does not significantly 
affect the overall long-term rate of graft survival. There is evidence showing 
that MMF is a better option than azathioprine in a number of combination 
therapies, such as ciclosporin or tacrolimus, and reduces the risk of acute 
rejection episodes.
21
1.3.2.1.5 Methotrexate
Methotrexate 1.12 was synthesised initially for the treatment of malignancies 
and was subsequently found to have an effect on the immune system. 
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Methotrexate is a folate antagonist, inhibiting dihydrofolate reductase. The 
synthesis of thymidine nucleotides involves the conversion of dihydrofolate
1.13 to tetrahydrofolic acid 1.14 by dihydrofolate reductase (DHFR), shown in 
scheme 1.5.
&
& &
"
&
&
"
&
"
!
!"
")&
'!)"
'!)"
&
& &
"
"
&
&
"
&
"
!
!"
")&
'!)"
'!)"
A"B+
1.13
1.14
Scheme 1.5 Conversion of dihydrofolate to tetrahydrofolic acid by 
dihydrofolate reductase
22
Methotrexate is a dihydrofolate analogue, possessing a very similar structure to 
dihydrofolate, and competitively inhibits dihydrofolate reductase and prevents 
DNA replication and proliferation of lymphocytes. This inhibition prevents the 
regeneration of the active tetrahydrofolate from the inactive dihydrofolate and 
results in cessation of nucleotide synthesis
24
. This action kills cells that are in 
the S-phase of the cell cycle, in which DNA is synthesised, but has no effect on 
non-proliferating cells
27
. Methotrexate may also be considered to be an 
inhibitor of (& ")E) pyrimidine synthesis.
 Methotrexate is used to treat severe uncontrolled psoriasis, rheumatoid 
arthritis and malignant disease
13
. There is a risk of potentially fatal blood 
dyscrasias and liver cirrhosis even with low dose Methotrexate, thus requiring 
ongoing monitoring of blood counts while undergoing therapy.
1.3.2.1.6 Leflunomide
Leflunomide 1.15 was originally developed as an agricultural pesticide and its 
anti-inflammatory and immune suppressant capabilities were discovered 
sometime later.
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1.15
Leflunomide is an isoxazole derivative that acts as prodrug for its open-ring 
metabolite, AA771726 1.16 (Scheme 1.6). Leflunomide is advantageous as it 
exhibits less gastrointestinal toxicity than the active metabolite.
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Scheme 1.6 Metabolism of leflunomide
This metabolite inhibits dihydroorotate dehydrogenase
35
causing an inhibition 
of pyrimidine nucleotide synthesis
36-38
which in turn leads to a suppression of
lymphocyte proliferation.  
Leflunomide is used as a disease-modifying antirheumatic drug 
(DMARD).  The side effects associated with Leflunomide include bone 
marrow suppression and an increase in the risk of infection and malignancy
13
.
1.3.2.1.7 Ciclosporin
Ciclosporin 1.17 is a lipophilic cyclic undecapeptide and was discovered by 
Sandoz during screening for materials with antibiotic properties produced the
fungi, #?3)86+(.'* .">6+/'* -+*%.
1.17
,83 #$D$? E8( #$D$? F(8 A.F(8 #$D$? #$D$? #$E8( #$G<9 F5?
Ciclosporin inhibits T cell activation at an early step, causing failure to activate 
the transcription of genes which normally function in coordinating the immune 
response, such as those encoding the cytokines. As a result, a primary effect 
that is largely confined to the T cells leads to a process in which a therapeutic 
useful immune suppression is the outcome.
Ciclosporin was one of the first drugs to offer a selective, T cell 
targeted, immune suppression. This was advantageous as the myelosuppression
24
caused complications in azathioprine based therapies and had reduced the 
number of transplantations being carried out. The discovery and 
implementation of ciclosporin reinvigorated the area of transplantation.
Ciclosporin’s exact mechanism of action was not known for a number 
of years following its discovery and use. The mode of action was subsequently 
found to involve targeting calcineurin and that ciclosporin only becomes active 
after interaction with the immunophilin, cyclophilin, to form an inhibitory 
immunophilin-drug complex. This then binds with calcineurin, a phosphatase,
and effectively brings together two proteins that would not normally interact.
This inhibits the up-regulation of various cytokines, mainly IL-2, which is 
essential for the proliferation and maturation of T cells. Ciclosporin also affects
the production of interferon gamma (IFN-γ), essential for the activation of 
macrophages.
Ciclosporin is indicated for organ transplantation, alone and in 
combination with other immunosuppressant therapy, bone-marrow 
transplantation, nephrotic syndrome, rheumatoid arthritis, atopic dermatitis and 
psoriasis.
The main limitation for the use of ciclosporin is its side effect profile, 
mainly its nephrotoxicity. There are a range of side effects associated with 
ciclosporin, largely due to three main mechanisms. Firstly, it activates 
endothelin-converting enzyme, thereby increasing production of ET-1. This 
causes systemic hypertension, renal vasoconstriction and decreases glomerular 
filtration rate. Secondly, ciclosporin induces apoptosis of renal tubular 
epithelial cells, leading to drop out of tubular lining cells. Lastly, it augments 
production of transforming growth factor-β (TGF-β) which causes tubular 
interstitial fibrosis.
Despite its side effects ciclosporin is a potent immune suppressant and 
has been effective in improving the outcome of organ transplants. However it 
is increasingly being used in combination with other therapies in order to keep 
the dose of ciclosporin as low as possible, thereby minimising the associated
side effects.
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1.3.2.1.8 Tacrolimus
Tacrolimus 1.18, also known as FK506, is a macrolide produced by the 
bacteria F/,&3/)*?8&% /%'@'G+&"%.%H an organism found in the Tsukuba area of 
northern Japan
39
. The first studies on the compound were carried out in 1988 
by Ochiai &/ +6
40
.
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Tacrolimus has a similar mode of action to ciclosporin, despite bearing little 
similarity structurally, in that it is a calcineurin inhibitor. Tacrolimus inhibits 
the production of IL-2, resulting in the decreased proliferation of activated T 
cells
41-43
. Tacrolimus interacts with FK-binding proteins (FKBPs), with the 
resulting complex able to bind to calcineurin, thereby inhibiting its phosphatase 
activity
41-43
. This leads to a range of effects that interfere with T cell receptor-
dependent cell activation. Tacrolimus is also able to affect the corticoid 
receptor
42
, providing an additional site of action.
The advantage of tacrolimus over ciclosporin is an increased 
potency
44,45
meaning there is the ability for clinical combination therapies 
using corticosteroids to be tapered more rapidly and the ability to be more
useful as a monotherapy.
The side effects of tacrolimus are the limiting factor in its use, 
especially in the chronic use. It exhibits the same side effect profile as 
ciclosporin.
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1.3.2.1.9 Sirolimus
Sirolimus 1.19 was first isolated from a strain of F/,&3/)*?8&% 5?-,)%8)3.8'%
collected from Rapa Nui (Easter Island)
46
, hence its other name of rapamycin. 
Sirolimus was initially found to have potent anti-fungal activity
47
but 
subsequent studies have shown it possesses impressive antitumour, 
antiproliferative and immune suppressive properties
48
.
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Sirolimus is a lipophilic macrocyclic lactone and is structurally very similar to 
tacrolimus but has a distinctly different mode of action. It forms an immune 
suppressive complex with the intracellular protein FK binding protein-12 
(FKBP12). Through this, sirolimus inhibits a number of cytokine-mediated 
signal transduction pathways, in particular the mammalian target of rapamycin 
(mTOR). This action stops the progression of T cells from the G phase to the S 
phase of the cell cycle. The action effectively stops the proliferative response 
of lymphocytes caused by IL-2
49
.
Sirolimus is used for prophylaxis of organ rejection in kidney allograft 
recipients. Initially it is used in combination with ciclosporin and corticosteroid 
and subsequently only with corticosteroid. 
Sirolimus is potentially hepatotoxic, teratogenic and will cause renal 
impairment. It also has a range of effects on blood counts, including 
27
thrombocytopenia, neutropenia and leucopenia. Sirolimus does not exhibit the 
characteristic nephrotoxicity of the calcineurin inhibitors
50
.
1.3.2.1.10 Cytokine Inhibitors
This class of immune modulating agents are genetically engineered proteins 
and monoclonal antibodies (mAb), and are used to treat severe rheumatoid 
arthritis that has failed to respond to two DMARDs, juvenile idiopathic arthritis 
where there has been a failure to respond to, or tolerate, methotrexate; severe 
active Crohn’s disease when treatment with immune modulating agents or 
corticosteroids has failed or not tolerated; and moderate to severe chronic 
psoriasis, where the patient is unresponsive to other systemic therapy and 
photochemotherapy.
These differ from the therapies already described as they are 
recombinant antibody therapies. They mainly inhibit the pro-inflammatory 
cytokine, TNF-α which is a key mediator in chronic inflammatory conditions
51
.
These agents are able to offer an effective treatment for conditions such as 
rheumatoid arthritis, with little associated side effects. There is a potential for 
allergic reactions when treatment is initiated due to the presence of murine 
elements in the some of the antibodies.
Infliximab is a combination of human constant and murine variable 
region IgG monoclonal antibody which is able to bind TNF-α and TNF-β as 
well as be able to lyse TNF producing cells
52
. It has shown efficacy in the 
treatment of rheumatoid arthritis and Crohn’s disease.
Entanercept consists of two recombinant human TNF-receptor chains 
fused with IgG1
53
. This inhibits TNF activity at cell receptor, competitively 
binding and inactivating free TNF.
Adalimumab is a recombinant IgG monoclonal anti-TNF-α antibody
that is able to bind with high affinity with TNF-α. The advantage of 
adalimumab is that its composition is fully human and should therefore not 
cause allergic problems that are seen with the other TNF inhibitors
54
.
Anakinra inhibits the activity of IL-1, therefore differing from the 
other cytokine inhibitors. It is able to treat rheumatoid arthritis but is not 
recommended unless it is part of a controlled long-term clinical study.
28
The major adverse effects are injections site reactions, increased 
susceptibility to infection, lymphoproliferative diseases, demyelinating 
diseases and aggravation of congestive heart failure
54
.
1.3.2.2 Search for new immune suppressant therapies
There is a common origin of many of the immune suppressants reviewed in 
that they are derived from natural sources. These are either steroids or 
cytokines of human origin or the isolation of active compounds from fungal 
and bacterial sources. The latter source remains of interest in the search for 
novel immune modulating agents
55
, due to the observed ability for bacteria to 
exert an effect on the host’s immune response
56
. The high toxicity associated 
with existing immune suppressants necessitates the search for new agents. A 
major way in which bacteria can avoid the immune response is the control of 
virulence factors due to a form of cell-to-cell communication termed quorum 
sensing.
1.4 Quorum sensing
Quorum sensing (QS) is a form of intercellular communication used by 
bacteria for controlling gene expression in response to population density. It 
was known that bacteria were able to respond to external stimuli, such as 
changes in pH, temperature or osmolarity, and that this response was controlled 
due to the stimulation, or repression, of various target genes but it was not 
thought that there was any coordination within bacterial populations. It is now 
known that bacterial populations can communicate and coordinate their 
actions, as a population.
Quorum sensing was first observed in the bioluminescent marine 
bacteria I.G,.) >.%85&,.
57
and I.G,.) 5+,E&?.
58
. It was observed that these 
bacteria only produced light when there was a high population density. This 
was part of a symbiotic relationship between the bacteria and the Hawaiian 
bobtail squid, 9'3,?*"+ %8)6)3&%
59
, enabling the production of light for the 
avoidance of predators. 
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Quorum sensing was initially thought to be a factor in a few obscure 
examples of bacterial species but it has now been established that most, if not 
all, bacteria can perceive and respond to neighbouring microbial populations
through quorum sensing systems.
1.4.1 Quorum sensing system in Gram positive bacteria
Quorum sensing systems generally consist of a small, diffusible signalling 
molecule, commonly known as a quorum sensing signal molecule (QSSM),
and a transcriptional activator protein. Gram-positive bacteria commonly 
produce amino acids and short peptides as signalling molecules, whereas 
Gram-negative bacteria produce small molecules, predominantly !-acyl 
homoserine lactones (AHLs), which have the general structure 1.20, where R 
relates to differences in length, substitution and saturation in the side chain.
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The essentials of a simple quorum sensing system are shown in Fig. 1.2
60
.
Figure 1.2 Quorum sensing in Gram-
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At low cell density bacteria produce a basal level of signalling molecule, 
termed the autoinducer (AI), which diffuses out of the cell down a
concentration gradient, although there are active transport mechanisms used in 
some cases. As the population increases in size, the concentration of
extracellular AI increases.  When an optimum population density is reached the 
AI reaches a threshold concentration and binds to a transcriptional R protein, 
causing its activation and subsequent modulation of specific target genes.
The AHL signal molecules are commonly synthesised by the LuxI-type 
AHL synthases and interact with LuxR-type transcriptional regulator proteins. 
Due to this interaction the expression of target genes are activated. This is 
illustrated by the QS system of I.G,.) >.%85&,. as, shown in Fig. 1.3
Figure 1.3 Quorum sensing system of I.G,.) >.%85&,.
The 6'J6 produces the AHL signal molecule, !-(3-oxohexanoyl)-L-homoserine 
lactone (OHHL)
58
, and, when the population is of the required size, OHHL
binds to and activates the LuxR protein. LuxR is then able to induce 
transcription of the required 6'J6 operon, thereby allowing bioluminesence
61,62
. 
There are a vast assortment of classes of chemical signals that are 
employed in quorum sensing, with individual bacteria able to produce more 
than one type of signalling molecule and complex, hierarchical circuits existing 
to integrate and process sensory information. Inter-species communication is 
also observed, possibly for either synergistic or competitive ends.
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These chemical signals control a large range of phenotypes across a 
vast range of bacterial species. Some examples of those present in Gram-
negative bacteria are summarised in Table 1.4.
Table 1.4 Examples of phenotypes controlled by quorum sensing
Organism Signal Molecule Phenotype
K&,)*)"+% 5?(,)35.6+ !-butanoyl-L-
homoserine lactone
(BHL)
Exoprotease production
63
K-,)G+8/&,.'* 
/'*&>+8.&"%
!-(3-oxooctanoyl)-
L-homoserine 
lactone 
(OOHL)
Ti plasmid conjugation
64-66
<',@5)6(&,.+ 8&3+8.+ !-octanoyl-L-
homoserine lactone
(OHL)
Protease production
67
9,L.".+ %/&L+,/.. !-(3-oxohexanoyl)-
L-homoserine 
lactone 
(OHHL)
Capsular polysaccharide 
biosynthesis, virulence
68
9%85&,.+ 8)6. Unknown Cell division, attachment, 
lesion formation
69-71
$%&'()*)"+%
+&,)>+8.&"%
!-hexanoyl-L-
homoserine lactone
(HHL)
Phenazine antibiotic 
biosynthesis
72,73
A5.1)G.'* &/6. Unknown Restriction of number of 
nitrogen fixing nodules
74
A5)()G+8/&, 
%35+&,).(&%
!-tetradec-7-enoyl-
L-homoserine 
lactone
(7-8.%-TDHL)
Prevents bacterial 
aggregation
75
I.G,.) +"-'.66+,'* Unknown AHL production
76
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1.4.2 Additional classes of signalling molecule
Although the majority of quorum sensing signalling molecules produced by 
Gram-negative bacteria are AHLs, there is also evidence of other classes of 
compound produced. A+6%/)".+ %)6+"+8&+,'*, a plant pathogen, produces 3-
hydroxy-palmitic acid methyl ester 1.21, involved in regulating virulence
77
and 
$%&'()*)"+% +',&)>+8.&"% produces butyrolactones
78
1.22. Diketopiperazines 
(DKPs) 1.23 have been shown to be produced by a range of bacteria, including 
$%&'()*)"+% >6'),&%8&"%, 9"/&,)G+8/&, +--6)*&,+"% and ;./,)G+8/&, 
>,&'(..
79
. These are unlikely to activate LuxR-based biosensors strongly but are 
able to antagonise the action of AHLs
79
. However, their role in cell-to-cell
signalling has not been established.
"&
&"
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!
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1.21
1.22
1.23
1.4.3 Novel target for antimicrobial therapy
The identification of quorum sensing systems and QSSMs has highlighted a 
possible target for the development of novel antimicrobial therapies. The 
interference or antagonism of QSSMs that control virulence factors could 
potentially remove the pathogenicity from those bacteria.
This has already been demonstrated in a range of bacteria, where 
autoinducer analogues have inhibited the activation of R proteins
63,76,80,81
.
Further options for targeting QS systems is the degradation of AHLs 
via the use of enzymes
82
or interference with the biosynthesis of QSSMs
83-86
.
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1.4.4 Quorum sensing in Pseudomonas aeruginosa
$%&'()*)"+% +&,'-.")%+ is an opportunistic pathogen that causes morbidity in 
immunocompromised patients and is a particularly prevalent pathogen in cystic 
fibrosis (CF), where it is the main perpetrator of decline in lung function and
mortality in the disease. Its pathogenic effects are due to its ability to secrete 
extracellular virulence factors, including proteases and haemolysins, as well as 
being able to form biofilms, which provide protection from host defences
during colonisation. The bacteria may be present with no effect in a healthy 
individual but will cause damage once the ability of the immune system 
declines.
1.4.4.1 QSSMs produced by Pseudomonas aeruginosa
$2 +&,'-.")%+ was initially found to produce two major signalling molecules, 
!-(3-oxododecanoyl)-L-homoserine lactone (OdDHL) 1.24 and !-butanoyl-L-
homoserine lactone (BHL) 1.25 and two minor ones, !-(3-oxohexanoyl)-L-
homoserine lactone (OHHL) 1.26 and !-hexanoyl-L-homoserine lactone
(HHL)
87-89
1.27. All of these molecules are members of the AHL family.
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1.24 1.25
1.26 1.27
The structural differences between these molecules allow for specificity in the 
overall quorum sensing system and the expression of genes associated with the 
individual AHLs. 
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1.4.4.1.1 AHLs in Pseudomonas aeruginosa quorum sensing
The quorum sensing system for $2 +&,'-.")%+ is one of the most studied and 
best understood QS systems. Research into the system has shown that there is 
the potential for more complexity in QS than was first thought.
It has been shown that at least two discrete quorum sensing systems 
exist, both regulated by different AHLs, and that these systems are able to exert 
an influence over the other
90
, as shown in Fig 1.4.
Figure 1.4 Hierarchical $2 +&,'-.")%+ quorum sensing system
LasI causes the synthesis of !-(3-oxododecanoyl)-L-homoserine lactone which 
then binds to and activates the transcriptional activator protein LasR
91,92
, which 
regulates the production of virulence factors including LasA protease, alkaline 
protease, elastase and exotoxin A
92,93
. The 6+% system also exerts transitional 
control over the ,56 system
90
.
RhlR is another LuxR-type protein which is responsive to !-butanoyl-
L-homoserine lactone
94,95
, the synthesis of which is directed by RhlI
89
. This 
leads to the production of more virulence factors such as pyocynin, hydrogen 
cyanide, cytotoxic lectins, rhamnolipid and siderophores
89,96-99
. There is 
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evidence of the potential of hierarchical cascades within quorum sensing 
systems
90
.
1.4.4.2 Pseudomonas Quinolone Signal
Subsequent to the discovery of the AHLs produced by $2 +&,'-.")%+, it was 
then discovered that another type of signal molecule was produced by $2 
+&,'-.")%+ during the analysis of !-butyryl-L-homoserine lactone
100
. This 
molecule belonged to the 4-quinolone family of compounds and its structure 
was identified as 2-"-heptyl-3-hydroxy-4(1#)-quinolone 1.28. The compound 
was designated the name $%&'()*)"+% quinolone signal (PQS) by Pesci &/ 
+6
100
. 
&
"
!"
!
1.28
PQS was initially found to induce 6+%< and was dependent on the other quorum 
sensing systems for its biosynthesis and bioactivity
100
.
Molecules bearing quinolone structures, termed “Pyo” compounds, had 
previously been isolated from $2 +&,'-.")%+ cultures and investigated as 
antibiotic substances
101,102
. PQS was first isolated and identified in 1959
103
.
The discovery of PQS was evidence of small, heterocyclic, molecules being 
present as quorum sensing signals other than AHLs.
Since the initial identification of PQS it has been shown that $2 
+&,'-.")%+ produces a range of similar molecules, such as the PQS precursor 
2-heptyl-4(1#)-quinolone (HHQ) and 2-nonyl-4(1#)-quinolone. These 
compounds have been collectively termed 4-hydroxy-2-alkylquinolines 
(HAQs)
104
. The HAQs include 2-alkyl-4(1#)-quinolones 1.29, 2-alkyl-3-
hydroxy-4(1#)-quinolones 1.30, N oxides 1.31 and derivatives with 
unsaturated alkyl side chains 1.32 and 1.33.
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1.4.4.2.1 The Role of PQS in Pseudomonas aeruginosa Quorum Sensing
It has been shown that the synthesis and bioactivity of PQS are controlled by
the 6+% and ,56 QS systems respectively. This suggests that PQS is not involved 
in sensing population density, rather it is synthesised in response to population 
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density as other systems instigate the transcription of the genes required for its 
production and has an influence later in the cell cycle
105
.
It has been shown that PQS production is dependent on the 6+% system, 
and that PQS itself has an integral part in the ,56 system
106
, directly influencing 
the expression of ,56B
105
.
PQS controls the expression of 6+%<
100
which is responsible for 
producing LasB elastase, a major virulence factor for $2 +&,'-.")%+. It may 
have a role in the adherence of $2 +&,'-.")%+ and the formation of biofilms
106
with regards to infection in the lungs of CF patients although the mechanisms 
through which it does this are not yet known.
1.4.5 Quorum sensing signal molecules as immune modulators
It was hypothesised that since bacteria such as $2 +&,'-.")%+ were using 
QSSM, small molecules able to readily diffuse across cell membranes
107
, to 
coordinate their virulence, it may be possible that the signalling molecules 
themselves have a direct effect on the immune system of the host
56
. It can be 
seen that this ability for the bacterial population to remain undetected by the 
host until the population was of a required size as evidence of this. 
Additionally, it has been shown that OdDHL was able to stimulate dose-
dependent interleukin 8 (IL-8) production by lung epithelial cells
108
, showing 
the possibility of these molecules to have a direct effect on biological systems.
This provided preliminary evidence that there is a possible direct effect from 
QSSM on the immune response.
1.4.5.1 Immune modulation by N-Acylhomoserine lactones (AHLs)
Two of the AHLs produced by $2 +&,'-.")%+, OdDHL and OHHL, have been
tested ." E.E) in a range of assays in order to determine whether these 
molecules are capable of modulating the immune system.
OdDHL and OHHL were chosen in order to compare the difference 
effects of a long chain AHL compared to that with a short chain. OdDHL was 
found to exert a significant immune modulating activity ." E./,), without 
38
exhibiting any cytotoxicity. OHHL was not found to have any significant 
effects
56
.
It has also been shown that OdDHL also has a direct effect on 
fibroblasts
109,110
, respiratory epithelial cells
108,109,111
, arterial smooth muscle 
cells
112,113
, and that its effects on the immune system include specific effects on 
monocytes
110
, neutrophils
110
and lymphocytes
114,115
.
1.4.5.1.1 SAR study on OdDHL
A structure activity relationship (SAR) has been undertaken using OdDHL as 
the lead molecule in which the areas altered were the side chain A, the 3-oxo-
acyl moiety B and the hetero ring C 
114
Fig. 1.5.
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Figure 1.5 Areas altered in SAR study of OdDHL
In the course of this study, twenty-four analogues of OdDHL were synthesised 
and evaluated in a range of biological assays to ascertain their ability to 
modulate murine and human leukocyte proliferation and TNF-α secretion.
The SAR study found the following structural attributes that are were 
important in exerting its immune modulatory action. A C12 side chain is
optimal, although C13 and C14 chains retained similar activities and a branched 
chain is slightly less active. A reduction in activity when the chain is
unsaturated close to the 3-oxo-acyl moiety shows that flexibility in the side 
chain is important. Polar groups on the side chain reduce the activity 
significantly, suggesting that the lipophilic nature of the molecule is important, 
probably due to its solubility and its ability to enter cells. Analogues in which 
the 3-oxo was replaced with 3-hydroxyl retained activity but replacing the 
homoserine lactone ring with other heterocyclic ring systems produced inactive 
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molecules. It was noted, however, that OdDHL had inferior potency than 
ciclosporin or dexamethasone in cell proliferation assays.
The exact target and mode of action for OdDHL is not yet known, 
although some work in this area has been carried out. Dr. Christopher Harty, in 
his research thesis, used affinity chromatography in attempting to identify the 
immunophilin bound by OdDHL. Affinity chromatography involves loading 
the drug molecule onto a solid support, such as an Affi-Gel, allowing the 
screening of biological products. This technique has been used to identify the 
binding proteins for a range of drug molecules. Terminal 1.34 and mid-chain
linked 1.35 matrices were prepared, treated with murine splenocytes and bound 
proteins identified using tricene sodium dodeylsulfate polyacrylamide gel 
electrophoresis (SDS-PAGE).
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This identified two bound proteins that showed homology with murine 
calgranulin A and B. Further work confirmed calprotectin as a putative 
molecular target for OdDHL
116
, although there is some doubt as too whether 
calgranulin is the specific immunological target for OdDHL due to its lack of 
specificity in binding.
Ritchie &/ +6. found that the effect that OdDHL has on T cells is a 
combination of factors. These include OdDHL affecting early events in T cell 
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activation, acting on intracellular targets and it does not induce death in T-
lymphocytes at concentrations needed to suppress T cell proliferation
117
.
1.4.5.2 Immune modulation by PQS
PQS was found to modulate the immune system and when compared in a range 
of immunological assays by Hooi &/ +6, OdDHL and PQS were found to 
modulate the immune response in distinctly different ways
118
. PQS was more 
potent in suppressing lymphocyte response to ConA (IC50 0.98 μM compared 
to 18.24 μM for OdDHL) in the absence of cytotoxicity. Also, PQS was shown 
to be more potent than OdDHL in suppressing T cell proliferation (IC50 1.73 
and 44.47 μM respectively). PQS exerted its antiproliferative action without 
any effect on cell viability, whereas at higher concentrations OdDHL began to 
affect cell viability
118
. 
Results suggested that OdDHL prevents proliferation by acting 
upstream of IL-2 secretion whereas PQS inhibits proliferation downstream of 
IL-2 production, in a manner similar to rapamycin. Also, in contrast to the 
suppressive effect OdDHL has on TNF-α secretion, PQS has an inhibitory 
effect
118
.
Based on these results Hooi &/ +62 concluded that the abilities of these 
compounds to modulate the immune response could possibly be harnessed to 
treat immunological disease
118
. The different modes of action exhibited by 
PQS and OdDHL also raise the possibility of the compounds having a 
synergistic relationship with regards to immune modulation.
1.4.5.2.1 Structure activity relationship study of PQS
No SAR data is available for PQS. The only information known prior to this
project has come from the testing of the precursors in the existing PQS 
synthesis. This showed that 2-"-heptyl-4(M#)-quinolone 1.36 and 3-formyl-2-
"-heptyl-4(M#)-quinolone 1.37 do not possess any activity in the
immunological assays.
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The areas in which alteration could be made in the first stages of a SAR are 
shown in Fig. 1.6. The alkyl chain (A), substitution at the 3-position (B), the 
substitution on the nitrogen (C) and the possible introduction of substitution
onto the aromatic ring (R) are all possible areas of exploitation in an SAR
study.
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Figure 1.6 Potential areas of alteration in SAR study of PQS
Through these alterations it may be possible to identify the essential
pharmacophores that need to be present within the PQS structure, to exert 
optimum immune modulatory activity.
Examples of alteration would take the form of finding the optimum
chain length, shown by the change in activity of lengthening or shortening the 
chain. Differing functionality at the 3-position may show the importance of 
having hydrogen bonding capability at this position, or the possible steric 
effects of certain groups. Substitution on the nitrogen, such as a methyl group,
would investigate the importance of hydrogen bonding in this part of the 
molecule. For example, if the N-methyl PQS analogue showed reduced 
activity, it may be postulated that the hydrogen atom present on the nitrogen is 
an important structural component in the PQS activity on the immune system.
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1.5 Synthesis of PQS
While PQS has been synthesised previously
100
the synthesis reported is not 
satisfactory for the purposes of carrying out a SAR study. The existing 
synthesis is shown in scheme 1.7.
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1.431.45 1.441.28
A&+-&"/% +"( 8)"(./.)"%: (i) DCCI, DMAP, DCM; (ii) EtOH, Δ; (iii) Aniline, 
34TSA, C6H6, Δ; (iv) Diphenyl ether, 240 °C; (v) Hexamine, TFA, Δ; (vi) 
H2O2, EtOH, NaOHaq
Scheme 1.7 Existing synthesis of PQS
Meldrum’s acid 1.38 is acylated using octanoic acid 1.39 in the presence of 
1,3-dicyclohexylcarbodiimide (DCCI) and catalytic 4-dimethylaminopyridine 
(DMAP). This 5-acyl Meldrum’s acid 1.40 is then heated at reflux in ethanol to 
form a β-keto ester 1.41. Acid-catalysed condensation of the β-keto ester with 
aniline forms the imine 1.42. The imine isomerises to the thermodynamically 
more stable enamine 1.43, which undergoes a cyclo-condensation when heated 
in a high boiling solvent, such as diphenyl ether, forming 2-heptyl-4(1#)-
quinolone 1.44. A formyl group is introduced at the 3-position using 
hexamethylenetetramine (hexamine) in the presence of trifluoroacetic acid 
(TFA), giving 1.45. The formyl group is then transformed to a hydroxyl group
via a Baeyer Villiger oxidation, using hydrogen peroxide, forming PQS 1.28.
This synthesis is unsuitable due to the large number of steps involved, 
coupled with low yields at certain steps, most noticeably in the thermal 
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cyclisation of the enamine 1.43 and formylation of the 2-alkyl-4(1#)-quinolone
1.44, shown in scheme 1.8 (yields of 20 % and 44 % respectively).
1.43 1.451.44
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A&+-&"/% +"( 8)"(./.)"%: (i) Diphenyl ether, 240 °C; (ii) Hexamine, TFA, Δ
Scheme 1.8 Low yielding steps in existing PQS synthesis
The synthetic route also affords little opportunity to quickly and simply
introduce any variation in the course of the synthesis following the first couple 
of steps, and no option of producing a synthon. A synthon is a molecule with a 
basic structure which can be altered readily, thereby enabling the creation of a 
number of analogues in a short time. If it is not possible to produce a synthon 
molecule, another preferable option could be to have a synthetic route that 
involves fewer steps to achieve a final molecule and be able to introduce 
variation in those steps. Therefore, in order to undertake an effective SAR 
study, there needs to be the development of a new suitable synthetic method for 
producing PQS and its related analogues.
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1.6 Aims of the thesis
• The main aim of the research programme is to use PQS as the lead 
molecule in a structure activity relationship study in order to determine
the essential structural features required for biological activity. The 
effect of alterations to the structure will be assessed using 
immunological assays
• Development of a new facile route for the synthesis of PQS and other 
structurally related molecules and use these methods to produce a 
library of compounds.
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Chapter 2
Synthesis of 4-Quinolone Based Analogues of 2-Heptyl-
3-Hydroxy-4(1H)-Quinolone (PQS)
The ability for bacterial quorum sensing molecules to suppress the immune 
system was first identified in !-(3-oxododecanoyl-)-L-homoserine lactone 
(OdDHL)
56
2.1. 
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This molecule is produced by $%&'()*)"+% +&,'-.")%+ and is one of a range 
of similarly structured homoserine lactone based signal molecules, although 
this was the only one to display an ability to modulate the immune system. It 
was shown that OdDHL can exert a significant effect on the immune response 
of mammalian cells in vitro
56
. In a murine splenocyte assay OdDHL 
significantly reduces the ability of lymphocytes to respond to the stimulant 
concanavalin A (ConA). This assay gives a good indication with regards to 
immune suppression capability in humans.
Lately, another quorum sensing signal molecule produced by $2 
+&,'-.")%+, 2-heptyl-3-hydroxy-4(1#)-quinolone (PQS) 2.2 was identified by 
Pesci et al
100
.
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PQS was also found to possess an immune modulatory capability
118
. When 
compared in a range of immunological assays OdDHL and PQS were found to 
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modulate the immune response in a distinctly different ways. Most importantly, 
PQS was more potent in suppressing T-cell proliferation (IC50 0.98 μM
compared to 18.24 μM for OdDHL)
118
. PQS exerted its antiproliferative effect 
without any effect on cell viability, whereas at higher concentrations OdDHL 
began to affect cell viability. Results suggested that OdDHL prevents 
proliferation by acting upstream of IL-2 secretion whereas PQS is preventing 
proliferation downstream of IL-2 production, in a manner similar to rapamycin. 
Also, whereas OdDHL has a suppressive effect on TNF-α secretion, PQS has a 
contrasting inhibitory effect
118
.
An initial structure activity relationship (SAR) study, using OdDHL as 
the lead molecule has been undertaken
114
. Twenty four alterations were made 
to the structure and the compounds were assayed for their ability to suppress 
leukocyte proliferation in both murine and human cells as well as TNF-α 
secretion by lipopolysaccharide (LPS) stimulated human leucocytes. The areas 
altered were the side chain (A), the 3-oxoacyl moiety (B) and the hetero-ring 
(C) as shown in Fig. 2.1.
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Figure 2.1 Areas of OdDHL altered in SAR study
It was found that the optimal compounds were those with alkyl chain length 
between C11 – C13 and either a 3-oxo or 3-hydroxy group. Analogues with 
monosaturation and a terminal nonpolar substituent on the side chain were also 
potent immune suppressive agents. Those compounds that lacked the 
homoserine lactone ring did not have L-configuration at the chiral centre and 
those with polar substituents did not have significant activity. The successful 
compounds that were taken on to testing of TNF-α secretion indicated the 
suitability of these compounds for further investigation
114
.
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In this way the SAR study was important in establishing the 
pharmcophores within the structure, that is the areas essential for its biological 
activity.
The evidence that PQS has immune modulating activity, allied to the 
supporting evidence from the SAR study of OdDHL, heavily suggested that it 
would be valuable to investigate further the immune modulatory activity of this 
quorum sensing signal molecule.
The structural components of the molecule that can be altered are 
shown below in Fig 2.2. These areas are the 2-alkyl chain (A), the 3-hydroxy 
(B) and substitution on the nitrogen (C). In addition to this there could be 
substitution introduced onto the carbocyclic ring 
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Figure 2.2 Structural components of PQS that can be altered for SAR study
Results from the SAR study would provide information regarding the 
important structural elements present in the molecule for optimum activity, 
thereby identifying the pharmacophore, and eventually it may be possible to 
produce a molecule that has improved immune activity than the original PQS.
The only information relating to structure and activity is that the two 
precursors of PQS in the synthetic pathway, 2-heptyl-4(1#)-quinolone 2.3 and 
3-formyl-2-heptyl-4(1#)-quinolone 2.4, had no activity.
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An issue to consider in future development of these compounds would be their 
quorum sensing ability. The ideal molecule would potently suppress the 
48
immune system but have no effect with regards the activation of quorum 
sensing pathways.
The target immunophilins for PQS are not known and hopefully the 
SAR may also provide some insight into the nature of the interactions between 
the target receptor and PQS and its analogues. This information will be far 
from conclusive, in terms of target, but can be used as the initial steps towards 
understanding the receptor-molecule interaction.
Due to the disadvantages of existing immune modulators, outlined in 
chapter 1, new and novel molecules are of importance in this field. The ability 
of the PQS quorum sensing molecule to modulate the immune system warrants 
further research in developing facile syntheses of this type of molecule.
2.1 Synthesis of Pseudomonas Quinolone Signal and its analogues
The existing quinolone based drug molecules have already been reviewed in 
Chapter 1. This review will deal with the synthetic methods reported in 
literature to elaborate the 4-quinolone core structure present in PQS.
Though a number of examples of 2-methyl and 2-phenyl substituted 4-
quinolones are reported in the literature, there is little information on 2-alkyl 
substituted analogues apart from 2-methyl derivatives.
2.1.1 Review of literature methods of 4-quinolone synthesis
The simplest method reported in the literature for the production of 2-methyl-
4(1#)-quinolone 2.5 is the condensation of methyl anthranilate with acetic 
anhydride, scheme 2.1, producing 2-methyl-4(1#)-quinolone in one step,
though an amide ester of the methyl anthranilate 2.6 is also produced as a side 
product.
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Scheme 2.1 Synthesis of 2-methyl-4(1#)-quinolone using methyl anthranilate
The production of the 2-methyl compound to the SAR study is important as the
2-methyl substituent can be elongated to a longer alkyl chain, for example via 
the use of "-octyl bromide in the presence of sodium amide
119
, scheme 2.2.
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A&+-&"/% +"( 8)"(./.)"%N (i) NaNH2, NH3 in H2O, "-octyl bromide
Scheme 2.2 Conversion of 2-methyl-4(1#)-quinolone to 2-nonyl-4(1#)-
quinolone
In this example the chain is lengthened to a nonyl chain to give 2.7 but this 
could easily be used to set the desired length of the alkyl chain after the 
quinolone ring system was formed. It is more convenient though, if possible, to 
have the desired alkyl chain in place when the quinolone is initially formed.
The paper in which the quorum sensing attribute of PQS was described 
used a synthetic route based on that published by Somanathan &/ +6
MCO
. They 
synthesised a number of 2-alkyl-4(1#)-quinolones 2.9 by the condensation of 
β-keto esters 2.8 with aniline, scheme 2.3.
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Scheme 2.3 Condensation of aniline with a β-keto ester to produce 2-alkyl-
4(1#)-quinolone
In this case the requisite β-keto esters were produced by the acylation of ethyl 
acetoacetate 2.10 with an acid chloride in the presence of sodium hydride, 
followed by treatment with sodium ethoxide, causing deacetylation
121-123
, 
allowing the alkyl chain to be incorporated as required, as shown in scheme 
2.4.
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A&+-&"/% +"( 8)"(./.)"%: (i) NaH, RCOCl; (ii) NaOEt in EtOH
Scheme 2.4 Production of β-keto ester using an acid chloride
A limitation with this method of quinolone production, with regards to the 
demands of this project, is the absence of the hydroxy, or indeed any suitable 
substitution, at the 3-position meaning that it needs to be introduced onto the 
already formed quinolone product. 
The condensation of a β-keto ester with aniline, seen in scheme 2.3, is 
also used in the Conrad-Limpach synthesis, the difference being that the 
enamine product of the condensation 2.11 is isolated and heated in diphenyl 
ether, a high boiling point solvent, to produce the 4-quinolone. The quinolone 
is recovered by the addition of petroleum ether, due to differential solubility. 
This has been used to produce 2-methyl-4-quinolone
124
.
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A&+-&"/% +"( 8)"(./.)"%N (i) Glacial AcOH, C6H6; (ii) Diphenyl ether, 200 °C
Scheme 2.4 Formation of 2-methyl-4(1#)-quinolone
A similar method has been used to produce 2-ester functionalised substitution 
on the resulting 4-quinolone
125
. In this case the β-keto ester is replaced by 
diethyl 3-oxoglutarate 2.12 and this is heated in chloroform under Dean-Stark 
conditions and the intermediate enamine product 2.13 is then heated in excess
Polyphosphoric acid (PPA) to form the 4-quinolone 2.14.
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Scheme 2.6 Synthesis of 2-ester functionalised 4-quinolones
This use of PPA to allow ring closure was initially reported in 1961
126
and 
concentrated on the conversion of a number of esters 2.15 into the quinolone 
by heating in PPA at 170 °C.
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Scheme 2.7 Formation of a 2,3-disubstituted 4-quinolone using PPA
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Another method for the production of 2-methyl-4(1#)-quinolone involves the 
initial synthesis of 5-(tributylstannyl)isooxazoles 2.18 using 
tributylethynylstannane 2.16 and !-acetonitrile oxide 2.17. This forms a 
bicyclic structure 2.20 when reacted with 3-bromonitrobenzene 2.19 using a 
palladium catalyst, which is then catalytically hydrogenated over Raney nickel 
at pressure to obtain 2-methyl-4(1#)-quinolone
127
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Scheme 2.8 Formation of 2-methyl-4(1#)-quinolone
Quinolone based molecules have also been investigated in relation to inhibition 
of inosine 5’-monophosphate dehydrogenase (IMPDH)
128
, seeking to find 
specific IMPDH type II selectivity. This study produced 4-quinolones with 
substitution at the 2, 6 and 7-positions. Two synthetic routes were detailed, 
both taking 3-methoxy-4-(oxazol-5-yl)benzenamine 2.21 as the starting point, 
leading to the substitution in the final quinolone molecule as described above.
The first step involves the iodination of the aromatic nucleus followed by 
53
reaction with a suitable alkyne 2.22 in the presence of a palladium 
chloride/triphenyl phosphine catalyst to form the desired quinolone 2.23
128
, 
scheme 2.9.
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Scheme 2.9 Formation of highly substituted 4-quinolone structure
An alternative method has also been reported for the production of 2.23 and is 
similar to that mentioned previously. It uses either a β-keto ester 2.24 (Route 
A) in refluxing toluene in the presence of toluene-3-sulphonic  acid (34TSA) or
3-(dimethylamino)but-2-enoate 2.25 in refluxing dichloromethane (Route B), 
in the presence of pyridine 3-toluenesulphonate (PPTS). Both of these routes
produce the same enamine product 2.26. This enamine is then heated in xylene 
to close the ring and give the 7-methoxy-6-(oxazol-5-yl)-2-alkyl-4(1#)-
quinolone 2.23, scheme 2.10.
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Scheme 2.10 Two different routes to the formation of a substituted 4-quinolone
A 4-quinolone without 2-substitution was also produced by a third method, 
again using 3-methoxy-4-(oxazol-5-yl)benzenamine 2.21 as the starting point, 
reacting it with 5-(methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione
2.27 and then heating the resulting product in diphenyl ether
128
, scheme 2.11.
This differs to the other methods described, as there is no substitution of the 
heterocyclic ring on the molecule produced 2.28.
#$! &")
!
& ! !
! !
#$!
#$! &
"
!
&
!
!
!
!
&
"
!!
&
#$!
4 44
2.21 2.27 2.28
A&+-&"/% +"( 8)"(./.)"%: (i) MeOH, rt, 15 min; (ii) Ph2O, 200 °C, 2.5 h
Scheme 2.11 Formation of 6,7-disubstituted 4-quinolone
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Another method to produce quinolones possessing ester, or nitro, functionality 
at the 3-position has been reported. Here aniline is reacted, neat, with diethyl 
ethoxymethylenemalonate 2.29, forming an arylaminomethylenemalonate 2.30. 
This can then be heated in Dowtherm A, a high boiling solvent, to around 250 
°C to form ethyl 1,4-dihydro-4-oxo-3-carboxylate 2.31, as seen in scheme 2.12, 
which then precipitates out of solution on cooling.
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Scheme 2.12 Formation of ethyl 1,4-dihydro-4-oxo-3-carboxylate
This introduces functionality at the 3-position in a short number of steps, but 
there is no substitution at the 2-position and this means that an alkyl chain 
would need to be introduced via metallation for it to be useful for this SAR 
study.
As described above, most commonly the ring closure to a 4-quinolone
is reported via thermal methods, that is the use of a high boiling solvent. There 
is evidence that the ring closure can be carried out using a combination of 
acetic anhydride and concentrated sulphuric acid. A number of acetoacetate 
anils 3.35 have been cyclised in this way, producing 3-substituted-4-quinolones
2.36, scheme 2.14.
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Scheme 2.14 Cyclisation using sulphuric acid and acetic anhydride
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As well as using aniline derivatives to produce quinolones, )-amino carbonyl 
compounds have also been used. In one method, an anthranilamide 2.37 is 
combined with a ketone 2.38 to produce the intermediate imine 2.39, which is 
then treated with lithium diisopropylamide (LDA) in THF, producing a 4-
quinolone with 2- and 3-substitution
129
2.40, scheme 2.15. The substitution, in 
this example, consisted of alkyl chain, ethyl ester and phenyl substitution.
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Scheme 2.15 Formation of 2,3-disubstituted-4(1#)-quinolone
This is a modification of the von Niementowski synthesis, which itself is 
similar to both the Friedländer and Pfitzínger methods. The nature of the A 
group, in the molecule 2.41, changes in relation to the method being shown
129
in scheme 2.16.
&")
F
!
&
F
+)
+C
+7 +
7
+)
+C!
2.41
Scheme 2.16 Synthesis of 4-quinolone and derivatives. Methods distinguished 
by nature of A group; A = H, R (Friedländer); A = CO2Na (Pfitzínger); A = 
OH, OR (von Niementowski)
A method similar, in some ways, to those discussed before is where a 
nitrobenzoic acid 2.42, produced by using a benzoic acid, is used. The acid is 
the converted into an acid chloride and is condensed with a β-keto ester 2.43 to 
give the compound 2.44. This diketo ester can then be converted to an !-
hydroxy-2-substituted-4-quinolone 2.45, possessing ester functionality at the 3 
position, by mild catalytic hydrogenation
130
, scheme 2.17.
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Scheme2.17 Formation of !-hydroxy-2-substituted quinolone
The Heck-Stille coupling has been utilised in the production of substituted 4-
quinolones
131
. The reaction involves the palladium catalysed coupling of a 
stannyl compound 2.47 with methyl 2-iodoacetanilide 2.46, or similar 
iodobenzene, followed by a catalytic reduction to open the oxazole ring. 
Depending on the substitution present in the system, the intermediate could 
either be cyclised directly to the quinolone 2.48 or undergo a transformation 
before cyclisation, scheme 2.18. 
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°C
Scheme 2.18 Formation of 4-quinolones using Heck-Stille coupling
A 4-quinolone was formed from 2.49 (R = Me) by either treating with acidic 
aqueous ethanol or refluxing in acetic acid in the presence of sodium acetate. If 
the R = Ph the reflux in acetic acid merely converted the amino group into a 
hydroxyl 2.50, which then required to be heated to around 140 °C to form the 
4-quinolone. There was a mixture of compounds produced, one with the R 
group at the 2-position 2.48, which would be preferred in the case of this 
project, or the R group as a component of an ester at the 3-position 2.51, which
59
unfortunately constitutes the higher percentage of product formed in the 
reaction.
Quinolones with 2-substitiution and a hydroxyl group at the 3-position
2.54, ideal for our SAR study, have also been reported and are synthesised by 
the method shown in scheme 2.19
132
. Anthranilic acids are used as starting 
materials and are esterified using either chloroketones or bromoketones, in the 
presence of potassium bromide, indicating that the potassium salt 2.52 is 
involved in the reaction. These anthranilate derivatives 2.53 are then heated 
either in !-methylpyrrolidone (NMP) or polyphosphoric acid (PPA), for times 
ranging from 10 min to 15 h. The length of time was dependent on the nature 
of the substitution present in the system. It was found that using NMP as the 
reaction solvent is more suitable than PPA, in terms of yield and purity. The 
substitution present on the molecules produced was altered at the 2-position 
and the nitrogen but was limited to methyl and phenyl substitution, no alkyl 
chain substitution was included. It was also revealed that increased size of 
substituents at the 1- and 2-positions, would cause a decrease in the yield of the 
final quinolone.
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Scheme 2.19 Formation of !-substituted-2-substituted-3-hydroxy-4(1#)-
quinolone
4-Quinolones disubstituted in the 6- and 8-positions 2.55 have been produced 
using solid phase synthetic methods
133
. A polymer-supported cyclic ester was 
reacted with an aniline derivative and then heated to 240 °C to give the 4-
quinolone 2.55 and return a polymer bound ketone 2.56, which can then be 
recycled in another reaction. The quinolones produced from this method do not 
have any substitution at the 2 and 3 positions.
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Scheme 2.20 Solid phase synthesis of disubstituted 4-(1#)-quinolone
2.1.2 Retrosynthetic analysis of PQS
The synthesis reported by Pesci &/ +6
100
can be rationalised if a retrosynthetic 
approach to PQS is considered and this can be seen in scheme 2.21.
PQS has a 4-quinolone structure with a heptyl side chain and a 
hydroxyl group at the 3-position. It would be possible to have this hydroxyl 
introduced via a Baeyer Villiger oxidation on a formylated quinolone 2.56, 
produced from the 2-heptyl-4(1#)-quinolone 2.57. A disconnection at the C-C 
bond shown affords an enamine intermediate 2.58, which will also exist in the 
less stable imine form 2.59.  Considering the imine form of this intermediate, it 
becomes obvious that a condensation reaction between aniline and a suitable β-
keto ester 2.60 would provide a suitable synthetic route. β-Keto esters may be 
61
formed by the acylation of Meldrum’s acid 2.61 with a carboxylic acid, 
followed by alcoholysis of the acylated derivative.
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Scheme 2.21 Retrosynthetic approach of PQS
2.2 Synthesis of PQS via Existing Method
The existing method was evaluated in the lab to identify problems and issues 
that arise at each step of the synthetic route.
2.2.1 Formation of β-keto esters by acylation of 2,2-dimethyl-1,3-dioxane-
4,6-dione (Meldrum’s acid)
Meldrum’s acid is initially acylated using the appropriate carboxylic acid 2.62.  
The acid determines the length of the final carbon side chain at the 2-position 
of the quinolone.  An acid containing one more carbon than required in the side 
chain needs to be used e.g. for a pentyl side chain, hexanoic acid is used.  The 
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carbonyl in the acid needs to be activated to make it more electrophilic. The 
method involves 1,3-dicyclohexylcarbodiimide (DCCI) 2.63 with a catalytic 
amount 4-dimethylaminopyridine (DMAP) 2.64.  The mechanism for the 5-
acyl derivative formation is shown in scheme 2.22.
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Scheme 2.22 Acylation of Meldrum’s acid
Initially the condensation of the carboxylic acid with DCCI affords )-
acylisourea 2.65, which is intercepted by the nucleophilic attack of DMAP to 
give the highly reactive !-acyl pyridinium species 2.66.  The latter is the 
effective acylating agent and delivers the desired product by regenerating 
DMAP.  As the DMAP is continually being regenerated it needs to be added in 
only catalytic amounts. The product 2.67 exists in its H-bonded enolic form 
2.68.
2.2.1.1 Alternative method for acylation of Meldrum’s acid using 1,1’-
carbonyldimidazole (CDI)
Alternatively the acylation may be achieved using 1,1’-carbonyldimidazole 
(CDI) as shown in schemes 2.23 and 2.24.
The carboxylic acid is activated in a similar manner by the use of 1,1’-
carbonyldimidazole (CDI) 2.69, shown in scheme 2.23. There is electrophilic 
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attack on the carbonyl of the CDI, liberating an imidazole ring 2.70 and starts a 
process that produces an acylated imidazole species 2.71 with an activated 
carbon in the carbonyl.
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Scheme 2.23 The activation of carbon by the production of an imidazole 
species
The imidazole species makes the carbon more electrophilic and is therefore 
open to attack by the enolised form of Meldrum’s acid, forming 5-acyl 
Meldrum’s acid 2.67, scheme 2.24.
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Scheme2.24 Formation of 5-acyl Meldrum’s acid from imidazole
2.2.2 Formation of β-keto ester
The alcoholysis of Meldrum’s acid with ethanol at reflux gives the 
corresponding β-keto ester 2.72.  The mechanism involves the nucleophilic 
attack of ethanol on one of the endocyclic carbonyls, liberating acetone and 
carbon dioxide, and producing the β-keto ester, as shown in scheme 2.25.  The 
ring carbonyl is much more electrophilic than the exocyclic carbonyl due to the 
latter being deactivated due to the positive inductive effect of R.
64
!
!
!
!
+
!
@9!"
+ !@9
! !
. 8V$90;$
. '!)
2.72
Scheme 2.25 Formation of β-keto ester
Care was taken to use anhydrous ethanol as if there is water present in the 
system there will be some β-keto acid formed 2.73, which will then convert to 
the corresponding methyl ketone 2.74, as shown in scheme 2.26.  However, if 
formed, this can be removed using column chromatography.
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Scheme 2.26 Formation of a methyl ketone
2.2.3 Formation of 4-quinolone
When reacted with aniline at low temperatures the β-keto ester gives the kinetic 
product 2.58, which when cyclised, gives the 4-quinolone 2.57.  When higher 
temperatures are used, the thermodynamic product 2.75 is given, producing a 
2-quinolone 2.76 when cyclised, scheme 2.27.  The literature value for the 
difference in temperature is stated to be approximately 140 °C, but in our 
hands there appears to be a difference in the proportions of 4- and 2-quinolone 
produced even with the relatively small difference in temperature such as 
provided by using benzene instead of toluene. 
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Scheme 2.27 Formation of thermodynamic (2-quinolones) and kinetic product 
(4-quinolones)
The low temperature directs the attack by the nitrogen lone pair to the more 
electrophilic ketone carbonyl rather that the ester carbonyl.  The product has 
two resonance forms, the imine and enamine (scheme 2.28).  The imine form is 
unstable and the product is stabilised by the enamine form.
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Scheme 2.28 Resonance forms of product 2.58
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The imine is also liable to attack from water, thereby reversing the reaction, 
scheme 2.29.  For this reason, Dean Stark apparatus is used to remove any 
water formed during the reaction, thereby reducing the chances of this 
hydrolysis.
& +
"
!
@9!
"
!
"
Scheme 2.29 Hydrolysis of imine
Heating at reflux in diphenyl ether (b.p. 250 
o
C) provides the energy required 
to close the ring, forming the 4-quinolone 2.57, scheme 2.30.  The reaction 
proceeds by the nucleophilic attack of the aromatic ring on the ester carbonyl.  
This is a high-energy process, as it requires the disruption of the aromaticity of 
the ring hence the high temperature needed to accomplish the reaction.
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Scheme 2.30 Mechanism of thermal ring closure
To complete the synthesis of PQS, a hydroxy group needs to be introduced at 
the 3-position. For this, initially a 3-formyl group was introduced as discussed 
below.
2.2.4 Formylation of 4-quinolone
A method for formylation found in the literature, the Duff Reaction
134
, involves 
hexamine 2.77 in the presence of trifluroacetic acid (TFA)
100,135
. The 
mechanism of the reaction is shown in scheme 2.31. The protonation of the 
hexamine leads to the eventual release of the reactive species 2.78.
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Scheme 2.31 Formation of ammonium ion from hexamine
The species 2.78 then reacts with the quinolone 2.57, at the 3-position on the 
ring, to give the formylated product 2.56 following aqueous work-up, scheme 
2.32.  This step only produces a 44 % yield of the formylated 4-quinolone.
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Scheme 2.32 Formylation of 4-quinolone by hexamine in presence of TFA
2.2.5 Conversion of Formyl Group to Hydroxyl via Baeyer Villiger 
Oxidation
The conversion of the formyl group to the required hydroxyl is via a Baeyer 
Villiger oxidation and involves the use of hydrogen peroxide. This attacks the 
protonated carbonyl of the formyl group forming intermediate 2.79 which 
rearranges to form the bond between the 3-position carbon of the quinolone 
and the oxygen, replacing the C-C bond with a C-O bond, and producing the 
formate 2.80. This formate is then hydrolysed in the presence of water to yield 
the hydroxyl group and the product PQS.
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Scheme 2.33 Conversion of formyl to hydroxyl via Baeyer Villiger oxidation
Although this method delivers the final product, it does so only in small yield. 
The problems with this synthetic route include a large number of steps, some of 
which are low yielding. If adopted, this method will require synthesis of each 
different analogue from scratch, as there is no room to alter a core molecule to 
produce a number of analogues quickly.
2.3 Exploration of alternative synthetic routes to PQS and its analogues
The problems that need to be addressed with regard to a new method for the 
synthesis of PQS and related 4-quinolone analogues are as follows:
• Large number of steps in synthetic route. It would be advantageous to 
reduce these, if possible.
• Steps that are low yielding
• Formylation step that does not work effectively and is low yielding
• An intermediate synthon that could deliver analogues with fewer steps
Examining the synthesis of PQS that has been described above certain 
problems can be identified and possible improvements that could be suggested.
2.3.1 Alternative Methods for Formylation
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The formylation step was critical but low yielding and a difficult reaction in 
practice. Two possible approaches could be considered. One would be to
investigate different methods of introducing the formyl, or acyl, group onto the 
quinolone structure. Another option would be to devise a synthetic route which 
delivers a suitable group at the 3-position that can be later transformed into an 
OH group. In both cases ideally, for the synthesis of PQS, the group present at 
the 3-position would be a hydroxyl group, thereby negating the need for further 
synthetic steps to convert the group into the hydroxyl but there may be 
advantages gained, with regards to the structure activity relationship study, if 
the functional group was one that would allow conversion into a number of 
different groups and thus allow swift analogue production.
A method of doing this is by the use of the Elbs oxidation, shown in 
scheme 2.34, in which a peroxodisufate ion reacts with the quinolone anion, 
forming a sulfate ester 2.81. This ester can be hydrolysed using an acid 
catalysed hydrolysis, forming a quinolone with the desired hydroxyl 
functionality
136
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Scheme 2.34 Introduction of hydroxyl group via Elbs oxidation
2.3.1.1 Vilsmeier Reaction
A commonly used method for formylation is the Vilsmeier reaction; therefore 
the suitability of this method was investigated.  The mechanism is shown in 
schemes 2.34 and 2.35.  There is the initial formation of the Vilsmeier iminium 
cation 2.84 via the reaction between phosphorus oxychloride (POCl3) 2.82 and 
the solvent, dimethylformamide (DMF) 2.83.
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Scheme 2.34 Formation of Vilsmeier cation
This iminium cation 2.84 could then react with the quinolone at the 3-position 
to form a more stable iminium salt 2.85, due to the conjugation between the 
heterocyclic nitrogen and the iminium group. A work up involving aqueous 
Na2CO3 would hydrolyse the imine salt, giving the formylated product 2.56.
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Scheme 2.35 Vilsmeier reaction followed by hydrolysis
Two different methods of the Vilsmeier reaction were attempted
137,138
but 
unfortunately did not yield the desired formylated product.  Spectroscopy of 
the product suggests that, instead of formylating at the 3-position, there was
chlorination at the 4-position, producing 2.86.
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If there had been formylation at the 3-position there should be a proton 
observable for both the formyl group and that attached to the nitrogen, these 
were not present. Additionally, in the mass of the compound produced did not 
match that of the expected product. Having an additional CHO, the mass of the 
formylated product should have been 271 but MS showed that it had the 
characteristic pattern to show the relative occurrences of Cl mass prominent
around 261. The formation 2.86 was not totally unexpected as POCl3 is often
used as a chlorinating agent, although this is mostly when it is used on its own 
as a primary reactant.
Initially it was thought that the method chosen did not give sufficient 
opportunity for the Vilsmeier complex to form in the reaction vessel and 
therefore the reaction proceeded as though the quinolone was reacting with 
POCl3 (scheme 2.36).  
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Scheme 2.36 Chlorination of quinolone
An alteration to the method, allowing prior mixing of POCl3 and DMF, thereby 
giving an adequate opportunity for the complex to form, was attempted but the 
chlorinated product was again produced. It is possible that the Vilsmeier 
reaction would exclusively form 3-formyl product from !-methyl quinolone as 
the proton is missing to provide the 4-chloro derivative.
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2.3.2 Exploring alternative methods for cyclisation
In the existing method used to produce PQS, in the cyclisation step, the 
aromaticity of the carbocyclic ring needs to be disrupted to allow the ring 
closure that forms the bicyclic quinolone structure. An aromatic structure is 
very stable and therefore a large amount of energy needs to be introduced to 
the system to allow it to be overcome, hence the use of a solvent with a high 
boiling point. Diphenyl ether was used in this case. If reactive functional 
groups were present on the required positions of the benzene ring and allowed 
cyclisation without disrupting the aromatic system of the benzene ring, the ring 
closure would theoretically require less energy, proceed more readily and may 
prove preferential in terms of ease of execution and yields. 
Another issue of concern with the use of diphenyl ether is the recovery 
of the quinolone compound following the reaction. This is achieved via 
differential solubility of the quinolone between diphenyl ether and petroleum 
ether (60 – 80 °C) and recovery is low. When the process is scaled up it 
becomes problematic in relation to the volume of petroleum ether required.
Considering these issues, alternative methods were attempted to form a 
quinolone ring system without the need for thermal methods of cyclisation.
2.3.2.1 Synthesis of 2-alkyl-3-hydroxy-4(1H)-quinolone via 3-Acetyl-4(1H)-
quinolone
Literature shows a method for the synthesis of an ester substituted quinolone 
that may be able to be altered to produce an acylated 4-quinolone. The 
synthesis involves a ring closure via the use of concentrated sulphuric acid and 
acetic anhydride. In addition this quinolone may be used as a synthon molecule 
that will allow the introduction of a variety of side chains at the 2-position. In 
order to ensure the addition of the alkyl chain is directed specifically to the 2-
position the nitrogen would need to be protected using a suitable group.
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Scheme 2.37 Proposed synthesis of PQS and its analogues via acylated 4-
quinolone synthon
Aniline is reacted with ethyl 2-(ethoxymethylene)-3-oxobutanoate 2.87, 
forming 2.88, which undergoes a ring closure to the 3-acetyl-4(1#)-quinolone 
2.89. This 4-quinolone can then be protected, using the benzyloxycarbonyl 
protecting group, to furnish 2.90 followed by the conversion of the 3-acetyl 
group to the 3-hydroxy derivative 2.91 via a Baeyer Villiger oxidation.  
Protection of both the 3- and 4-hydroxy groups using triisopropylsilyl triflate 
allows the introduction of the alkyl side chain at the 2-position via the use of an 
appropriate Grignard reagent
139
.  Hydrogenolysis removes all the protecting 
groups in one step, affording the desired 2-alkyl-3-hydroxy-4(1#)-quinolone.
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2.3.2.1.1 Synthesis of ethyl 2-(ethoxymethylene)-3-oxobutanoate
The first step in this synthesis is the production of the ethyl 2-
(ethoxymethylene)-3-oxobutanoate 2.87 and this is done by the condensation 
of ethyl acetoacetate 2.92 with triethyl orthoformate 2.93 in the presence of 
acetic anhydride, scheme 2.38.
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Scheme 2.38 Formation of ethyl 2-(ethoxymethylene)-3-oxobutanoate
The reactants are mixed and heated to 140 °C. As the reaction proceeds, 
ethanol is produced as the by product and reacts with the acetic anhydride, 
forming ethyl acetate. It is thus easy to monitor the reaction, the reaction 
having stopped when no more ethyl acetate is produced. As well as this, if the 
ethyl acetate is distilled off as it is produced it will drive the reaction forward.
The reaction proceeds via the mechanism shown in scheme 2.39. The 
reaction is initiated via the enolic form of the ethyl acetoacetate, leading to a 
Michael type attack on the triethyl orthoformate. The product was then purified 
using vacuum distillation, producing a straw coloured, viscous liquid.
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Scheme 2.39 Mechanism of formation of ethyl 2-(ethoxymethylene)-3-
oxobutanoate
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2.3.2.1.2 Synthesis of the arylaminomethylenemalonate
As discussed earlier, aniline is mixed with ethyl 2-(ethoxymethylene)-3-
oxobutanoate 2.87 and heated to 130 °C for 3 h, forming an 
arylaminomethylenemalonate 2.88, scheme 2.40. After the allotted time the 
reaction mixture is cooled to room temperature and then further cooled, 
allowing the malonate to solidify as an amber solid. The appearance of the 
solid suggests an amorphous nature, rather than crystalline.
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Scheme 2.40 Formation of arylaminomethylene malonate
Also, it is obvious that there will be two isomers of the arylaminomethylene
malonate due to the presence of the double bond. The NMR confirmed this, 
with two separate signals showing for each expected proton that integrates to 
the expected value.
2.3.2.1.3 Synthesis of 3-acyl-4(1H)-quinolone
It was stated in the literature that the ring closure to the quinolone could be 
achieved by means of a reaction involving cH2SO4 and acetic anhydride
140
. 
This would proceed through the mechanism shown in scheme 2.41 and start 
with the acid protonating one of the carbonyls, leading to electrophilic attack 
by the aromatic electrons.
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Scheme 2.41 Proposed mechanism of acid catalysed 3-acetyl-4(1#)-quinolone 
ring closure
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Disappointingly this was not achieved. After the initial reaction, the solution is 
neutralised and chilled, prompting a white solid to precipitate. This white solid 
was shown to be, in the main, returned starting material by NMR. 
However, refluxing in diphenyl ether as used in the original method 
produced the desired compound 2.89 using petroleum ether to precipitate the 
solid out of solution gave a better recovery in this example, most likely due to 
the absence of an alkyl chain aiding the molecule’s solubility in polar solvents.
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Scheme 2.42 Comparing methods of ring closure
Another method reported in literature proposed a different route to produce 3-
acetyl-4(1#)-quinolone without using a thermal method to effect ring closure. 
Also, the route dealt with another issue with the original synthesis in relation to 
the ring closure step. As mentioned before for the ring closure to take place 
with a mono-substituted benzene derivative the aromaticity of the benzene ring 
has to be overcome as shown in 2.94. If there is an additional ester substituent 
at the ortho-position on the benzene ring, this would be a lower energy process.
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Scheme 2.43 Differences between mechanisms of 4-quinolone ring closure
with and without ortho-substituents
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To this end, structure 2.95 was synthesised as follows. The commercially 
available 3-butyn-2-ol 2.96 was oxidised using chromic acid to form 3-butyn-
2-one 2.97. The NMR showed the loss of the hydroxyl and other proton, as 
well as a shift in the alkyne proton.
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Scheme 2.44 Formation of 3-butyn-2-one by oxidation of 3-butyn-2-ol
The oxidation proceeds according to the mechanism shown in scheme 2.45. 
The reaction starts with the formation of HCrO4
-
ions, Cr(VI). In the presence 
of acid this forms a chromate ester with the alcohol. This ester decomposes by 
elimination of the HCrO3
-
, (CrIV), yielding the ketone product.
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Scheme 2.45 Chromic acid oxidation of 3-butyn-2-ol
The Cr(IV) subsequently reacts with a Cr(VI) species to yield two Cr(V). 
These Cr(V) species can oxidise alcohols in the same way and are therefore 
reduced to Cr(III). Due to this there is an observable colour change as the 
reaction proceeds caused by orange Cr(VI) being converted into green Cr(III).
When 3-butyn-2-one is reacted with methyl anthranilate in methanol 
and left to stand, it forms an enamine 2.99
141
, scheme 2.46. This molecule 
would be able to undergo ring closure without having to disrupt the aromaticity 
of the benzene ring.
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Scheme 2.46 Formation of methyl 2-(3-oxobut-1-enylamino)benzoate
The literature described a method forming the 3-acetyl-4(1#)-quinolone in the 
presence of base, specifically sodium methoxide
141
. 
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Scheme 2.47 Proposed ring closure of methyl 2-(3-oxobut-1-
enylamino)benzoate
The reaction was carried out but the product was not sufficiently recovered, 
partly due to the low solubility of the quinolone causing difficulty in the 
purification by column chromatography. The reaction was attempted using 
sodium hydride, a stronger base, to see if this would cause the reaction to 
proceed more smoothly, but this proved equally unsuccessful. However, we 
were able to produce sufficient quantities of 2.89 by the method detailed in the 
scheme.
2.3.2.1.4 N-Protection of 3-Acetyl-4(1H)-quinolone
As mentioned before it was thought that this quinolone could be used as a 
synthon, allowing the manipulation of the 2-position and altering of the side 
chain. To enable the 2-position to be selectively targeted in any reaction the 
nitrogen would have to be suitably protected. This protecting group could then 
be removed at a later stage to afford the NH. 
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The use of protecting groups is used widely within peptide and other 
synthetic chemistry areas. The protecting group chosen in this case was the 
carboxybenzyl (Z) group. This is used for the protection of amines and is 
introduced using benzyl chloroformate 2.100.
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Literature shows that this group can be used to protect the nitrogen of 4-
quinolones with ethyl esters and nitro groups
142
present at the 3-position and it 
was decided to investigate its possible use in this example.
A suitable base should theoretically be able to remove the proton 
attached to the nitrogen, followed by the addition of benzyl chloroformate 
2.100. The negative charge on the nitrogen, caused by the removal of the 
proton, would attack the carbonyl on the benzyl chloroformate and chlorine 
would leave. This would then deliver !-protected 3-acetyl-4(1#)-quinolone 
2.101, scheme 2.48.
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Scheme 2.48 !-Z protection of 3-acetyl-4(1#)-quinolone
Three bases with varying strengths were tried in this reaction, in an attempt to 
introduce the Z group. Sodium hydride was used initially, diisopropylamine 
(DIPEA) in the second attempt and then sodium methoxide in the third attempt. 
Unfortunately none of these were able to cause the reaction to complete 
satisfactorily. A reason that the reaction does not proceed is due to the acetyl 
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group allowing the negative charge from the nitrogen to delocalise and 
therefore become less reactive. This delocalisation of charge is not as apparent 
with 4-hydroxyquinolone, hence its ability to be !-Z protected.
This was disappointing and consequently the rest of the route could not 
be attempted. Due to this, alternative syntheses towards the target structure, via 
3-ester substituted 4-quinolones were sought.
2.3.3 Synthesis of 2-Alkyl-3-methoxycarbonyl-4(1H)-quinolone
It was reported that the reaction of isatoic anhydride 2.102 and ethyl 
acetoacetate 2.103 yielded 2-methyl-3-ethoxycarbonyl-4(M#)-quinolone 2.104, 
as shown in scheme 2.49.
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Scheme 2.49 Formation of 2-methyl-3-ethoxycarbonyl-4(1#)-quinolone
It was originally thought that the production of this molecule would take two 
steps as shown in scheme 2.50, the first involving the nucleophilic opening of 
the heterocyclic ring of the isatoic anhydride, using sodium hydride to abstract
a methylene proton, followed by a refluxing in ethanol to cause the ring closure 
to the quinolone.
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Scheme 2.50 Mechanism of 2-methyl-3-ethoxycarbonyl-4(1#)-quinolone 
formation
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In reality the reaction went in one step and did not require the isolation of the 
ring opened intermediate 2.105. This was rather encouraging as using 
appropriate β-keto ester the desired alkyl chain can be installed at the 2-
position. Indeed, when methyl 3-oxodecanoate was used 2.106, instead of the
ethyl acetoacetate, to give 4-quinolone with C7 side chain 2.107, present in 
PQS, was the result. 
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Scheme 2.51 Formation of methyl 2-heptyl-1,4-dihydro-4-oxo-3-carboxylate
using isatoic anhydride
Although this molecule still has a group at the 3-position that would need to be 
transformed to an OH group to afford PQS, the quinolone core structure is 
assembled in only one step. This is a clear advantage over the original method, 
requiring four steps in order to produce the similar formylated quinolone.
2.3.3.1 Transformation of 3-Methyl Ester Functionality to Deliver Other 
Derivatives
The methyl ester at the 3-position could be altered to give other functional 
groups at that position. These new analogues with different functional groups 
could then be assessed to see their effect on the activity of the molecules in 
biological assay.
2.3.3.1.1 Formation of 3-carboxamide
Conversion of the methyl ester into a carboxamide 2.108 with the use of 
ammonia solution was attempted.
82
&
"
!
!
!
&
"
!
&")
!
&"CH8]I
2.108
Scheme 2.52 Conversion of methyl ester to carboxamide
This was not successful, largely due to solubility problems associated with the 
quinolone. Initially the compound was placed in 33 % ammonia solution and 
stirred overnight but the solid never sufficiently dissolved to allow it to react 
with the ammonia and therefore there was a return of the starting material. In 
the second attempt a small amount of methanol was added to the solution, in 
order to allow the solid methyl ester to dissolve. This again was stirred 
overnight and then the solvent removed under vacuum to leave a white solid. 
This solid was shown to be the starting material, due to the presence of the 
methyl singlet in the NMR at δ 3.76.
2.3.3.1.2 Formation of Carboxylic Acid
This ester can be used to produce 2-heptyl-1,4-dihydro-4-oxo-3-carboxylic 
acid 2.109. This can be achieved either by acid or base hydrolysis. The use of a 
base such as sodium hydroxide would theoretically be able to saponify the 
ester. This method was attempted, using aqueous sodium hydroxide but the 
reaction did not produce the carboxylic acid. An explanation for the failure for 
this reaction to work may be that the use of the base may cause N-negative 
charge to feed into the carbonyl and therefore will prevent attack by the 
hydroxide ion which is required for the saponification to occur.
This was eventually achieved by heating the methyl ester in 2M HCl
solution, causing the hydrolysis of the ester and forming the desired carboxylic 
acid functionality. 
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Scheme 2.53 Conversion of methyl ester to carboxylic acid
The mechanism for this reaction is shown in scheme 2.54 and begins with the 
protonation of the carbonyl leading to an attack by water leading to the 
formation of the carboxylic acid and methanol.
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Scheme 2.54 Mechanism of acid catalysed hydrolysis
The product was obtained without the need for purification via a column, as is 
the method involving the chloroketones. This is highly desirable, as the 
quinolones with substituents at the 3 position become very insoluble, making it 
extremely difficult to carry out chromatography. Therefore if other methods of 
purification are available, this is desirable.
It is theoretically possible to transform the 3-CO2Me to 3-OH via a 
conversion route of ester to carboxamide 2.108, then to amino 2.110, then 
diazo 2.111 and finally OH. This would also be valuable in the fact that it 
produces a number of other analogues for testing in biological assays. Of main 
interest would be 2-heptyl-3-amino-4(1#)-quinolone 2.110, as NH2 is an 
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isostere of OH, possessing similar hydrogen bonding properties and also 
similar in size.
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Scheme 2.55 Conversion of methyl ester to hydroxyl via other potentially 
useful functional groups
Considering the number of steps involved and the solubility of quinolone, this 
approach was abandoned and alternative methods for the synthesis of PQS and 
its analogues were explored.
2.4 Alternative Method for Synthesis of PQS and its Analogues
2.4.1 Synthesis of 2-methyl-3-hydroxy-4(1H)-quinolone
The literature records a facile two step synthetic route to 2-methyl-3-hydroxy-
4-(1#)-quinolone starting from anthranilic acid
132,143
.
Esterification of anthranilic acid with a α-chloroketone in DMF, in the 
presence of a base, furnishes 2.112, as seen in scheme 2.56
132
.
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Scheme 2.56 Esterification of anthranilic acid
This can then be heated in !-methylpyrrolidinone, a high boiling dipolar 
aprotic solvent, to produce 2-methyl-3-hydroxy-4(M#)-quinolone 2.113, 
scheme 2.57.
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Scheme 2.57 Formation of 2-methyl-3-hydroxy-4(1#)-quinolone
The mechanism for this step, as shown in scheme 2.58, involves a seven 
membered ring intermediate 2.114 formation initially, which then undergoes a 
rearrangement to yield the 4-quinolone 2.113.
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Scheme 2.58 Mechanism of 2-methyl-3-hydroxy-4(1#)-quinolone formation
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This shows there is still the need for a high boiling point solvent but the 
method allows the recovery of the material in a more convenient and clean
manner. Polyphosphoric acid (PPA), literature boiling point 300 °C, may also 
be used to effect ring closure. PPA is less convenient to use in practice, in 
terms of product recovery.
The production of 2-methyl-3-hydroxy-4(1#)-quinolone was carried 
out as a pilot synthesis, to evaluate the literature method. The reaction 
proceeded well, in desirable yields at both steps and with ease of recovery of 
the product. Chloroacetone was a commercially available starting material. 
However other α-chloroketones, with longer alkyl chains are not commercially 
available.
2.4.2 Introduction of Halogen on Alkyl side chain
It was thought if dichloroacetone 2.115 was used in the place of chloroacetone, 
this would give a quinolone product with CH2Cl substituent at 2-position 
2.116. This would allow the manipulation of the side chain via a phosphonium 
derivative 2.117 produced using triphenylphosphine, which in turn can react 
with an aldehyde of suitable length to afford the desired alkyl chain, via Wittig 
olefination, albeit unsaturated 2.118. The latter can be hydrogenated to achieve 
the saturated chain 2.119.
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Scheme 2.59 Introduction of an alkyl chain via Wittig olefination
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The reaction did not proceed as desired, using the same conditions as that for 
the chloroacetone product. Due to the reactivity of the chloride substituents, 
dimeric product 2.120 was formed. This dimer could not be easily identified by 
using proton NMR, due to its symmetry causing the protons to be equivalent 
and therefore only producing one set of signals. The main distinguishing 
feature was no signal present for the CH2 next to the chlorine. The structure 
was finally confirmed with the use of MS, the mass being 328, rather than 227.
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The reaction was repeated without heating and with an excess of the 
dichloroacetone, in an attempt to ensure that esterification was the most 
prevalent reaction that could take place in the reaction. The reaction was also 
repeated by reacting anthranilic acid with DIPEA, a weaker base than sodium 
hydride, and adding this dropwise to a solution of dichloroacetone, thereby 
allowing the deprotonated acid to react with the dichloroacetone and 
minimising the levels of free anthranilic acid available to react with the 
acylated product. Despite these attempts to control aspects of the reaction, the 
dimer was still the only product formed instead of the desired material. 
2.4.3 Extension of the Method Using Other α-Chloroketones
2.4.3.1 General synthesis of PQS analogues
As the only derivative reported in literature produced by the method shown 
above in schemes 2.56 and 2.57 was 2-methyl-3-hydroxy-4(1#)-quinolone
132
it 
was decided to investigate the possible extension of this reaction, with the use 
of longer chain α-chloroketones, or other halogenated ketones. The use of 
derivatives of anthranilic acid would allow the substitution on the carbocyclic 
ring, as detailed in scheme 2.60.
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Scheme 2.60 General method for producing substituted 4-quinolones using α-
chloroketones
Thus the method had great scope and would allow production of analogues 
with choice of substitution on the carbocyclic ring, at the 2-position and also on 
the heterocyclic nitrogen.
2.4.3.2 Esterification of Anthranilic Acids with α-Haloketones
The range of α-chloroketones available commercially is unfortunately small. 
Bromoketones were investigated to give substitution at the 2 position but these 
compounds gave much less satisfactory products than the chloroketones, in 
terms of ease of purification and quality of the material. Bromoketones are 
likely to be more reactive than the corresponding chloroketones. This may 
prove a problem with forming these O-alkylated intermediates cleanly due to 
the increased potential for side reactions. Products produced with the use of α-
chloroketones did not require any purification after the initial reaction and 
simply precipitated out of solution upon dilution with cold water.
2.4.3.2.1 Reaction With 4-Chloroacetoacetate
Commercially available chloroketone ethyl 4-chloroacetoacetate 2.121 was 
expected to deliver the ester 2.122.
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Scheme 2.61 Reaction of ethyl 4-chloroacetoacetate with anthranilic acid
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The reaction proceeded satisfactory and produced 2.122 as a colourless solid. 
The product was identified due to having the protons present in the aromatic 
region of the NMR spectra, allied with 2 singlets produced by the CH2 protons 
present at the 4 and 5-positions on the ester side chain.
2.4.3.2.2 Formation of side product
Besides 2.122, a second product was also produced. This was isolated by 
recrystalisation from ethyl acetate/hexane and identified, using NMR and mass 
spectrometry as diethyl 2,5-dioxocyclohexane-1,4-dicarboxylate
144
2.123 and 
possibly via the mechanism shown scheme 2.62.
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Scheme 2.62 Formation of dicarboxylate side product
The base, potassium carbonate removes the proton to generate an anion 2.124, 
leading to a nucleophilic attack on one of the chloroketone displacing chlorine. 
This intermolecular reaction is then followed by an intramolecular one, similar 
in nature, leading again to a nucleophilic attack and the displacement of the 
second chlorine remaining on the molecule and forming 2.123.
2.4.3.2.3 Ring closure of ester product 2.122
When the ester 2.122 was heated in NMP to effect ring closure, the expected 
material, with the ethyl ester at the 2-position, was not formed. The NMR 
spectrum showed no signals for the ethyl protons. The material produced was 
actually 2-methyl-3-hydroxy-4(1#)-quinolone 2.113. The production of this 
material can be rationalised as shown in scheme 2.63. If there was any water 
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present in the NMP there is the potential for the ester to be hydrolysed, forming 
a β-keto acid 2.125. The latter, in the high boiling solvent, was decarboxylated, 
yielding ethyl 2-aminobenzoate. This will then obviously yield 2-methyl-3-
hydroxy-4(1#)-quinolone, as seen before, after undergoing ring closure.
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Scheme 2.63 Hydrolysis and decarboxylation occurring during heating
2.4.3.3 Synthesis of α-Chloroketones
Due to the high reactivity of the α-bromoketones, seen in reactions attempted 
with this type of compounds, it was decided to use α-chloroketones 
exclusively.
Though these α-chloroketones are known to be important as staring 
materials in a range of synthetic methods but convenient methods for their 
production have not always been forthcoming. α-Chloromethyl ketone has 
been formed via the chlorination of methyl ketone or the reaction of an acyl 
chloride with diazomethane
145
. Shono &/ +6
146
proposed what they referred to as 
a simple, straight forward method but this involved the formation of a 
trichloroether type of molecule, followed by an electroreductive reaction to 
furnish a dichloro species, which then had to be converted to a mono chloro 
ketone via an additional two steps.
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Scheme Formation of α-chloroketone using electroreduction
2.4.3.3.1 Synthetic Methods for α-Chloroketones
Two methods were investigated in order to produce α-chloroketones with the 
required side chains. The first of these involved acylating Meldrum’s acid 2.61
with an appropriate carboxylic acid in the presence of DMAP and DCCI. This 
5-acylated Meldrum’s acid 2.67 is then treated by heating at reflux in sulfuryl 
chloride scheme 2.64. The excess sulfuryl chloride was removed under vacuum 
to yield 5-chloro-5-acyl Meldrum’s acid 2.126. Hydrolysis with 1M HCl, 
liberated the chloroketone
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2.127.
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2.66 2.126 2.127
A&+-&"/% +"( 8)"(./.)"%: (i) DMAP, DCCI, DCM; (ii) SO2Cl2; (iii) 1 M HCl, 
heat
Scheme 2.64 Formation of α-chloroketone using Meldrum’s acid
This is unsatisfactory method for the production of α-chloroketones, as 
acylated Meldrum’s acids were difficult to purify or store for periods of time, 
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due to the instability of the ring structure. A preferable method, involving the 
use of β-keto esters as the starting material, was used. While the β-keto esters 
are produced using some of the above methods, namely acylation of 
Meldrum’s acid, they are easier to purify and store for longer periods of time.
Thus α-chloroketones with varying chain length were produced by
using sulfuryl chloride and β-keto esters of appropriate chain lengths. This is 
shown in scheme 2.65.
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2.128 2.127
A&+-&"/% +"( 8)"(./.)"%: (i) SO2Cl2 (ii) cH2SO4, H2O, Δ
Scheme 2.65 Synthesis of α-chloroketones using β-keto esters
The sulfuryl chloride was added to the relevant β-keto esters neat, stirring at 
0°C, then left to stir overnight at room temperature. After this the remaining 
sulfuryl chloride was removed under vacuum yielding the chlorinated β-keto 
ester 2.128 as a yellow oil, in a quantative yield. The oil was used without 
purification in the next step. There was an observable colour change in the 
course of the reaction, as the original solution was colourless and clear, 
whereas the product was yellow. The product was readily identified by NMR, 
which showed a loss of proton, with a singlet for the CH in the chlorinated 
product being evident in the 
1
H NMR spectrum. The signal for this proton 
occurs at a high PPM because it is between two carbonyls and chlorine. The 
chlorine is an electron withdrawing group and will therefore cause the proton 
to be less shielded. Additionally, the electrons will be able to delocalise into 
the π electron system.
In the final step, the α-chloroketone 2.127 is produced from this 
chlorinated β-keto ester by hydrolysis of the methyl ester with concomitant 
decarboxylation of the carboxylic acid produced 2.129.
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Scheme 2.66 Hydrolysis and decarboxylation of chlorinated β-keto ester
This transformation was attempted in two different ways. The first method 
attempted was the heating at reflux in a mixture of tetrahydrofuran (THF),
water and concentrated sulphuric acid but this required a significant time for 
the reaction to take place (approx. 40 h).The alternative was a method in which 
the compound was heated at reflux in 50 % concentrated sulphuric acid/water 
mixture and the desired chloroketone was afforded after approximately 2 h and 
could be extracted into a suitable organic solvent. The two methods are 
comparable in terms of yield but the reduced reaction time of the latter meant it 
was more convenient as a routine method.
A number of α-chloroketones were thus produced using this method 
and are listed in Table 2.1. All compounds were obtained essentially in 
quantative yield.
Table 2.1 α-Chloroketones produced
;)*3)'"( F/,'8/',&
2.130
'(
!
2.131
'(
!
2.132
'(
!
It was found that methyl esters were better for producing the α-chloroketones 
than ethyl esters, in terms of yields and the nature of the product recovered.
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2.4.3.4 Esterification of Anthranilic Acid Derivatives with α-
Chloroketones
The α-chloroketones was then used to react with a range of substituted
anthranilic acid, or substituted anthranilic acid to obtain a variety of PQS 
analogues in the same way that was shown for the production of the methyl 
compound.
A number of substituted anthranilic acids are commercially available 
and one named either anthranilic acid derivatives or 2-aminobenzoic acid 
derivatives. Those derivatives allow production of a number of structures with 
different substitution in various the positions on the carbocyclic ring.
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A&+-&"/% +"( 8)"(./.)"%N (i) Potassium carbonate, DMF, heat
Scheme 2.67 General synthesis of P-alkylated anthranilic acid derivatives
The α-chloroketone was added to a mixture of the anthranilic acid derivative
2.133 that had been stirred with potassium carbonate in DMF. The potassium 
carbonate removes the acidic proton, allowing the chloroketone to P-alkylate
the anthranilic acid forming compounds of general structure 2.134. The initial 
reaction to remove the proton is carried out at 90 °C and the following reaction 
involving the chloroketone is initially at room temperature but is then heated to 
50 °C to complete the reaction. The product is simple to recover as it 
precipitates out after dilution with ice water that is roughly 10 times the 
volume.
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Table 2.2 P-alkylated anthranilic acids produced
;)*3)'"( A
M
A
C
A
Q
R.&6(
2.112 H CH3 H 61
2.135 H C5H11 H 36
2.136 H C7H15 H 75
2.137 H C7H15 6-Cl 70
2.122 H CH2CO2C2H5 H 31
2.138 CH3 C7H15 H 28
In addition to the compounds shown in the table above, 2-aminopyridine-3-
carboxylic acid was also used to produce 2-oxononyl 2-aminopyridine-3-
carboxylate 2.139.
&
!
!
&")
!
2.139
This compound provides the opportunity to introduce a heterocyclic atom into 
the carbocyclic ring, bringing potential changes to the molecule’s properties
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which are further discussed below.
2.4.3.5 Cyclisation of Anthranilates
The anthranilates produced are cyclised to form the 3-hydroxy-4(1#)-
quinolone structure 2.140 by heating for varying times in the high boiling point 
solvent, NMP. As previously mentioned this method still requires the use of a 
high boiling point solvent but the recovery and quality of the compounds 
produced are preferable to the original method, where diphenyl ether was used.
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Scheme 2.68 General synthesis of substituted 3-hydroxy-4(1#)-quinolones 
(PQS analogues)
In terms of reaction times required for ring closure, it was found that as the 
length of the side chain increased, the reaction time required increased. This is 
due to the electron donating effect of the straight alkyl chain substituents 
feeding into the carbonyls and making them less electrophilic and therefore 
less reactive, meaning that the reaction will proceed at a slower rate. There 
may also be some steric effects of the chain, as the chain increases in length it 
becomes more flexible and more likely to cause steric hindrance in the 
intramolecular reaction process required for ring closure.
Again, a main advantage of this method is the convenience of 
purification of the product. The quinolone precipitates out of solution on
addition of ethyl acetate and the cooling in ice. Due to the problems that are 
involved with solubility of the quinolone, the purification of these compounds 
is difficult. The use of column chromatography is not suitable for quinolone 
compounds that have substitution in the 3-position, as these are sparingly 
soluble in traditional organic solvents.
2.4.4 PQS analogues synthesised
The method outlined in schemes 2.67 and 2.68 proved to be very valuable in 
the production of a number of PQS analogues 2.140, with alterations not only 
in the length of alkyl chain at the 2-position but also in the substitutions at the 
N and in the carbocyclic ring. The analogues produced are shown in the table 
below. 
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Table 2.3 PQS analogues produced
;)*3)'"( A
M
A
C
A
Q
R.&6( S
2.141 H C1H3 H 73
2.142 H C5H11 H 78
2.143 H C7H15 H 59
2.144 H C7H15 6-Cl 47
2.145 Me C7H15 H 28
2.4.5 Variations in General Method
Some of the compounds produced by this new method differed in their ease of 
synthesis slightly. These are discussed below.
2.4.5.1 N-Methyl PQS
The !-methyl compound, 2-heptyl-3-hydroxy-1-methyl-4(M#)-quinolone 2.146
was not as convenient to produce as the other compounds. The yield of the P-
alkylated !-methyl anthranilic acid derivative was lower then the other results, 
as seen in table 2.2, as was the yield obtained after heating in NMP. This was 
largely due to it not precipitating out of solution on the addition of ethyl 
acetate, as the other compounds had. This meant the recovery of the product 
from the high boiling solvent had to be attempted in an alternative manner.
&
!
!"
'"C
2.146
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In order to obtain the product the ethyl acetate was removed under vacuum and 
as much of the NMP was removed as possible, through a combination of high 
vac evaporation and by a stream of nitrogen gas, leaving a thick, viscous liquid. 
A small amount of ethyl acetate was added to this liquid and the solution was 
chilled, causing the product to form off-white crystals. This affected the yield 
and caused it to be lower than that of the other analogues produced using this 
method.
2.4.5.2 Naphthyridinone Based Analogue
This problem of the product not precipitating upon the addition of ethyl acetate
also occurred with the synthesis of 2-heptyl-3-hydroxy-1,8-naphthyridin-
4(1#)-one 2.147, containing an extra nitrogen in the 8-position. There is 
evidence to suggest that the introduction of extra heterocyclic atoms in a 
molecule is potentially better for increased bioactivity. The additional nitrogen 
could lower the pKa of the molecule, meaning that it would be more available 
at physiological pH
148
. This would be possible without increasing the bulk of 
the molecule and thereby having little effect on the receptor interaction. An 
attempt was made to recrystalise the compound using ethyl acetate in a manner 
similar to that of the !-methyl compound 2.146 but this did not produce 
satisfactory results.
& &
"
!
!"
2.147
2.5 Extended Use of New Method
Subsequent to the completion of this project the method outlined above has 
been utilised to produce a further number of compounds in the School of 
Pharmacy, Nottingham, including further chain length alterations, including a 
C2 and C3 chain, as well as methyl substitution on the carbocyclic ring.
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Table 2.4 Additional substituted 4-quinolones produced
;)*3)'"( A
M
A
C
A
Q
R.&6( S
2.148 H C2H5 H 77
2.149 H C3H7 H 59
2.150 H C7H15 6-Me 57
As well as advantages in the production of a wide range of analogues, there is 
also the advantage in the fact that there is no purification required to obtain 
material in terms of column chromatography. This is important if the SAR 
identifies a suitable molecule for further investigation in the way of biological 
assays, formulation or production. Column chromatography can be convenient 
in a lab setting when dealing with up to a few gram scale but becomes a 
problem when the reaction is scaled up, in terms of size of column and 
subsequent volumes of solvent required. 
2.6 Summary of Results
A facile synthetic route to PQS and its analogues has been developed along 
with a facile, one step synthesis to produce a 3-substituted-4(1#)-quinolone
This project has demonstrated how the synthesis of analogues of PQS may be 
achieved in a number facile synthetic routes, allowing the manipulation of the 
required areas of the molecule, namely:
• The 2-alkyl chain
• The 3-position substitution
• !-substitution
• Substitution on the carbocyclic ring
• Introduction of additional heterocyclic atoms into the molecule
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2-Alkyl-4(1#)-quinolones with ester functionality at the 3-position can be 
synthesised from isatoic anhydride and a β-keto ester in one step. There is the 
ability to alter both the 2-alkyl chain and the ester by changing the β-keto ester. 
This reaction produces the quinolone without the need for purification. 
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Scheme 2.69 Formation of 2-alkyl-3-ester-4(1#)-quinolones
The ester at the 3-position has the potential to be transformed into other groups, 
such as carboxylic acid and carboxamide. The conversion to carboxylic acid 
was achieved by refluxing in 2M HCl, thereby hydrolysing the ester.
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Scheme 2.70 Conversion of ester into carboxamide
PQS can be synthesised by the alkylation of anthranilic acid and cyclisation 
with NMP in a facile, two step synthesis.
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Scheme 2.71 Facile two step synthesis of PQS
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The method allows quick, simple synthesis of a number of analogues by simply 
employing appropriate starting materials. Diversity can be introduced, at the 2-
position, on the nitrogen and also in the carboxylic ring.
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Scheme 2.72 General synthesis of PQS analogues
This method was used to produce a range of analogues in a short period of 
time. These analogues included an example of each of the 3 areas shown above 
being altered, as well as the introduction of a heterocyclic atom into the 
carbocyclic ring.
These synthetic routes have enabled the production of 4-quinolone 
molecules with alterations made at each of the areas targeted in the original 
aims and objectives of the project.
The method established in this work is more convenient and better than 
that reported previously. These 4-quinolone based analogues of PQS that have 
been subsequently tested in a range of biological assays to establish their 
immune modulatory activity, discussed further in Chapter 4.
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Chapter 3
Quinazolinone Based Analogues of PQS
3.1 Quinazolinone based immune modulatory agents
As discussed in the previous chapter, there is evidence to suggest that the 
introduction of extra heterocyclic atoms in a molecule is potentially better for 
increased bioactivity along with altering physiochemical factors, such as 
solubility
148
. They also may allow a more simple method of synthesis and these 
changes would be possible without increasing the bulk of the molecule and 
thereby minimising effect on the receptor interaction. Analogues were 
synthesised and evaluated with an additional nitrogen at the 8-position in the 
carbocyclic ring. This concept was further extended by incorporating an extra 
nitrogen at the 3-position in the hetero ring of the 4-quinolone structure 3.1, 
giving rise to the well known quinazolinone ring structure 3.2. Quinazolinones 
were chosen as they possess a closely related structure and had previously been 
exploited as drug molecules
149-153
.
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3.1 3.2
Using quinazolinones it would be possible to introduce a variety of substitution 
in the core structure in the areas shown in figure 1.1. It would be possible to 
alter the length and nature of the 2-alkyl chain (R
1
), change the functionality at 
the 3-position (R
2
) and to introduce substitution into the carbocyclic ring (R
3
).
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Figure 1.1 Structural areas of quinazolinones that can be altered for SAR study
These alterations could be achieved individually or in combination and their 
effects assessed within biological assays. This structure activity relationship 
(SAR) study would thus provide a number of new molecules that can be 
assayed for their immune modulatory properties.
It was also intended to use the quinazolinone structure as a surrogate 
structure, expecting that alterations will mimic the relative equivalents in the 
original 4-quinolone system. 
An example of this would be observing the effect of altering the length 
of the side chain and seeing if the activity rises or falls. It would be of interest 
to see if the change in activity parallels the 4-quinolone analogues.
3.1.1 Quinazolinones as Quinolone Surrogate systems
Quinazolinones have been used previously as a suitable replacement for the 4-
quinolone structure.
Xia &/ +62
154
investigated fluorinated 2-phenyl-4-quinolone derivatives 
with regards their antimitotic antitumour activity. The lead molecule for the 
study was 2’-fluoro-6,7-methylenedioxy-2-phenyl-4-quinolone 3.3, a potent 
antimitotic antitumour agent.
&
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3.3
In the course of this study, three quinazolinone structures, 3.4, 3.5 and 3.6, 
were compared with the lead molecule.
104
&
&"
!
&
"
&"
!
&
&"
!
3.4 3.5 3.6
These molecules were assayed for their antitubulin activity and were compared 
with compounds bearing the 4-quinolone structure 3.7. This was undertaken to 
provide an insight into the important structural elements required for 
antitubulin activity. Specifically these areas were the presence of an N 
hydrogen and the nature of the substitution at the 2-position.
&
"
!
3.7
In this case, it was found that the presence of a hydrogen on the 1-N was 
important for the retention of activity and that 2-styryl group showed enhanced 
activity when compared with the 2-phenyl.
3.2 Literature Review
A number of quinazolinones of varying complexity in structure have been 
reported to have a range of medicinal properties. 
For example, methaqualone 3.8 has sedative effects, 2-alkyl/aryl-3-
arylhydrazino-4(3#)-quinazolinones 3.9 possess antibacterial activity
152,153
, as 
well as central nervous system (CNS) effects similar to that of monoamine-
oxidase inhibitors
153
. Quinazolinylpyrimidinediones have been found to have 
anti-inflammatory activity
151,155,156
. Derivatives of 2,3-dihydro-2-(aryl)-
quinazolinone (DHQZ) 3.10 show some antitumour effects
150,157
and various 2-
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methyl quinazolinone analogues have been synthesised that possess antifolate 
properties
158
.
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Quinazolinone alkaloids are present in nature and a number of these have been 
isolated and identified. Some of these naturally occurring quinazolinones are 
known to have medicinal properties, including luotonin A
159
3.11, which has 
cytotoxic properties
160,161
, and tryptanthrin
162
3.12, which has been shown to 
have antibacterial properties
163
, inhibit nitric oxide and prostaglandin E2
synthesis
164
.
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It was thus encouraging to notice that a number of quinazolinone based 
structures have been exploited as drug candidates. In order to elaborate 
quinazolinone structures that mimic PQS molecule it was imperative to review 
the literature to exploit the synthetic routes for their preparation.
3.2.1 Synthesis of Quinazolinones
There are a number of different methods for producing this class of molecules 
in the literature. However, this review will only concentrate on the synthesis of 
3-substituted 2-alkyl-4(Q#)-quinazolinones as these are the molecules that are 
closely related to PQS.
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3.2.1.1 Review of literature methods of quinazolinone synthesis
A simple, unsubstituted quinazolinone 3.13 can be synthesised using isatoic 
anhydride 3.14 by treating it with formamidine acetate
165
, scheme 3.1. More 
complex quinazolinones can be formed by introducing substitution onto the 
isatoic anhydride
166
.
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3.14 3.13
A&+-&"/% +"( 8)"(./.)"%: (i) Formamidine acetate
Scheme 3.1 Formation of quinazolin-4(3#)-one using isatoic anhydride
4-Quinazolinones with 2-substution can be produced simply and quickly. 
Carboxylic acid quinazolinone derivatives 3.15 can be conveniently 
synthesised by reacting anthranilamide 3.16 with a range of anhydrides and 
oxalates, including benzoic anhydride, succinic anhydride, glutaric anhydride 
and diethyl oxalate, followed by a cyclisation using aqueous sodium 
hydroxide
167,168
, as shown in scheme 3.2.
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3.15 3.16
R = Ph, (CH2)2COOH, CO2Et
A&+-&"/% +"( 8)"(./.)"%: (i) various anhydrides or oxalate; (ii) aq NaOH
Scheme 3.2 Formation of quinazolinone carboxylic acid derivatives
A further simple way to form substituted quinazolin-4(3#)-ones 3.17 is by 
oxidative hydration of )-aminobenzonitriles 3.18 using urea-hydrogen peroxide 
(UHP) that will cyclise in the same step
169,170
, scheme 3.3.
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3.18 3.17
A&+-&"/% +"( 8)"(./.)"%: (i) UHP, cat. K2CO3, acetone: water, Δ
Scheme 3.3 Synthesis of quinazolin-4(3#)-ones using )-aminobenzonitriles
The reaction of anthranilic acid 3.19 with a variety of pre-formed imidates 3.20
in methanol, scheme 3.4, is an additional method for the production of simple 
2-substituted quinazolinones 3.21.
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3.19 3.20 3.21
Scheme 3.4 Formation of simple 2-substituted quinolone from anthranilic acid 
and an imidate
A number of quinazolinones with a functionalised 2-alkyl substituted are also 
reported. It is possible to synthesise a 6,7-disubstituted quinazolinone with a 
chloromethyl present at the 2-position 3.22 by cyclising a substituted 
anthranilic acid derivative 3.23 with chloroacetonitrile in methanol in the 
presence of catalytic sodium methoxide, scheme 3.5.
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3.22 3.23
A&+-&"/% +"( 8)"(./.)"%: (i) ClCH2CN, MeONa, MeOH
Scheme 3.5 Formation of 2-chloromethyl quinazolinone
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For the purpose of this project, the production of 2, 3-disubstituted-4-
quinazolinones is important. The predominant method for the production of 2, 
3-disubstituted-4-quinazolinones in literature is the acylation of anthranilic acid 
3.19, or one of its derivatives
171,172
, followed by cyclisation, frequently forming 
a benzoxazinone intermediate
173
3.24. This also allows he introduction of 
substitution at the 3-position
174
, via the use of nitrogen dinucleophiles. In this 
example, shown in scheme 3.6, hydrazine is used to produce 3.25.
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3.19 3.24 3.25
A&+-&"/% +"( 8)"(./.)"%: (i) Ac2O, reflux; (ii) NH2NH2
Scheme 3.6 Production of 2-methyl-3-amino-4-quinazolinone
This simple reaction can be extended to alter the nature of substitution at the 2-
position through lithiation of the molecule. The example below shows this 
being carried out on 3-(pivaloylamino)-2-methyl-4(3#)-quinazolinone 3.26 (R 
= /Bu) or 3-(acetylamino)-2-methyl-4(3#)-quinazolinone 3.26 (R = Me)
174
, 
synthesised as shown in scheme 3.7.
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3.26
A&+-&"/% +"( 8)"(./.)"%: (i) Ac2O, reflux; (ii) NH2NH2; (iii) acylating agent 
(pivaloyl chloride or Ac2O)
Scheme 3.7 Formation of 3-acylamino quinazolinones
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The derivative 3.26 is then treated twice with butyl lithium (BuLi) as shown in 
scheme 3.8. The BuLi first lithiates the amide carbonyl and then causes 
lithiation at the 2-methyl. Following this, it is then possible to insert an 
electrophile at the 2-position forming 3.27.
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3.26
3.27
A&+-&"/% +"( 8)"(./.)"%: (i) BuLi, THF, - 78 °C; (ii) BuLi, THF, - 78 °C; (iii) 
electrophile, - 78 °C
Scheme 3.8 Introduction of an electrophile to substituted 4-quinazolinone via 
lithiation
The acylated quinazolinone can also be easily converted back to a 3-amino 
substituent by refluxing in aqueous sodium hydroxide
174
, scheme 3.9.
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A&+-&"/% +"( 8)"(./.)"%: (i) NaOH, MeOH, H2O, reflux
Scheme 3.9 Deacylation of substituted quinazolinone
In this example, the pivaloyl group is being used as a protecting group, thus 
allowing the aforementioned lithiation to introduce variation into the molecule 
at the 2-position.
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This type of reaction can also be carried out on a quinazolinone 3.28 
unsubstituted at the 2-position, as shown in scheme 3.10. Again it involves the 
use of BuLi at low temperature
175
, having first protected the 3-N with a group 
such as /-butoxycarbonyl 3.29. An electrophile can then be introduced at the 2-
position, forming 3.30, and the quinazolinone subsequently deprotected
176
to 
leave 2-substituted molecule 3.31.
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3.303.31
A&+-&"/% +"( 8)"(./.)"%: (i) BuLi, THF, - 78 °C; (ii) Electrophile, H3O
+
; (iii) 
TFA, CH2Cl2
Scheme 3.10 Addition of electrophile to protected quinazolinone
Atkinson &/ +6
177
state that the production of 2-alkyl-3-amino-quinazolinone 
3.32 allows insertion of a double bond into the alkyl side chain when the 
quinazolinone ring is constructed in the way shown in scheme 3.11. It begins 
with the production of an acid chloride from a carboxylic acid 3.33, using 
thionyl chloride, which is then reacted with methyl anthranilate to form the 
product 3.34. This can then be cyclised in ethanol, with hydrazine allowing the 
insertion of the amino functionality at the 3-position.
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3.33 3.34 3.32
A&+-&"/% +"( 8)"(./.)"%: (i) SOCl2; (ii) methyl anthranilate; (iii) NH2NH2, 
EtOH
Scheme 3.11 Production of 2-alkenyl-3amino-4-quinazolinone
3-Aryl substituted quinazolinones 3.35 can be formed, as shown in scheme 
3.12, by premixing an anthranilate 3.36 and an ortho ester, followed by reflux 
and addition of the anthranilate ester to the refluxing ortho ester
178
. This will 
cause the production of a side product of formimidate 3.37 in cases where there 
is an alkyl chain present as the R group. The yield of quinazolinone can be 
increased by varying the ratio of orthoformate/anthranilate, a smaller ratio 
giving a better yield.
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Scheme 3.12 Formation of 3-phenyl substituted quinazolinone from ortho ester
3.2.1.1.1 3-Hydroxy and 3-amino-4-quinazolinones
Suitable derivatives of anthranilic acid may be used to form quinazolinones. 
Reddy &/ +6
179
found that 2-methyl-3-hydroxy-4-quinazolinone 3.38 was 
formed when an equimolar mixture of P-(2-aminobenzoyl) hydroxylamine 
3.39 and triethyl orthoformate, was heated with triethyl orthoacetate, scheme 
3.13. They also produced a number of quinazolinone molecules by reacting 
aoryl derivatives of P-(2-aminobenzoyl)-!-aroylhydroxylamines in decalin or 
polyphenyl ether (PPE). The molecules produced were largely limited to those 
with substituted aromatic groups at the 2 position and the details relating to 2-
alkyl substituted derivatives, more relevant to this study, were not investigated.
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A&+-&"/% +"( 8)"(./.)"%: i) HC(OEt)3/benzene; ii) CH3C(OEt)3/decalin; iii) 
PPE
Scheme 3.13 Formation of 2-substituted-3-hydroxy-4-quinazolinone
It has also been noted that 2-substituted 3-amino-4-quinazolinones 3.40 have 
been formed by refluxing anthranoyl hydrazine 3.41 with orthoesters
180
3.42, 
as shown in scheme 3.14. This also produces the two side products, a 
benzotriazepinone 3.43 and an oxadiazole 3.44. This method came about as an 
observation that quinazolinones were produced in the attempted synthesis of 
benzotriazepinones.
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Scheme 3.14 Production of 2-substituted-3-amino-4-quinazolinones as a by 
product in the production of benzotriazepinones
They also observed that the ring closure was dependent on the temperature of 
reflux. The quinazolinone is the thermodynamic product and is formed at 
higher temperatures. In ethanol the 4-quinazolinone 3.45 was formed, whereas 
in benzene only the imidate 3.46 was produced, which could then be cyclised 
113
by heating in a suitable solvent, such as ethanol or higher boiling point solvent, 
scheme 3.15. These reactions do not occur if aprotic solvents are used.
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A&+-&"/% +"( 8)"(./.)"%N  (i) EtOH, heat; (ii) C6H6, heat; (iii) EtOH or high 
boiling solvent, heat
Scheme 3.15 Formation of the thermodynamic and kinetic products of 2-
aminobenzohydrazide
3-Amino-4-quinazolinone 3.47 was shown to form in one step when 2-
aminobenzoylhydrazine 3.48 was treated at reflux with formic acid
181
. When 
acetic acid was substituted for the formic acid, firstly 1-(2-
acetylaminobenzoyl)-2-acetlyhydrazine 3.49 is formed, which can be directly 
converted to 3-aminoquinazolin-4-one in one step upon treatment with 
concentrated sulphuric acid or in two steps via 3-acetamido-2-
methylquinazolinone intermediate 3.50. 
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A&+-&"/% +"( 8)"(./.)"%N (i) HCOOH; (ii) RCOOH; (iii) cH2SO4; (iv) xylene, 
3-toluene sulphonic acid
Scheme 3.16 Products when 2-aminobenzohydrazide is reacted with different 
carboxylic acids
It was also shown that similar reactions to those outlined above, using aromatic 
acids there was not any formation of a quinazolinone molecule, rather a 
benzotriazepinone 3.51 was the main product formed, accompanied by two 
other minor products
181
3.52 and 3.53, scheme 3.17.
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Scheme 3.17 Reaction of 2-aminobenzoylhydrazine with aromatic acids
There thus exists a large amount of literature relating to the production of 
quinazolinones and there is the potential to provide a number of useful 
molecules in this series within a short period of time.
3.3 Synthesis of quinazolinones
The aim of the general synthetic route was to produce a number of analogues 
that have structural similarity to PQS in a simple fashion but with the ability to 
introduce diversity in a straightforward manner.
3.3.1 General synthetic route
The general route that was used for the elaboration of the PQS based 
quinazolinone structure is shown below in scheme 3.18. 
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3.573.58
A&+-&"/% +"( 8)"(./.)"%N (i) NaOH, H2O; (ii) Ac2O, Δ; (iii) R
3
NH2, EtOH, Δ
Scheme 3.18 General method for the production of 4-quinazolinone molecules
An anthranilic acid derivative 3.54 is initially acylated using an acid chloride 
3.55, forming 3.56. This can then be cyclised to form a benzoxazinone 3.57, 
which when reacted with a hydrazine derivative forms a 2,3-substituted 
quinazolinone 3.58.
This general method was used to produce a number of analogues. The 
formation of 2-"-heptyl-3-amino-4(3#)-quinazolinone 3.59 is discussed in 
detail and any modifications to the method will be described in relation to other 
derivatives.
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The decision to produce 2-"-heptyl-3-amino-4(3#)-quinazolinone 3.59 was 
taken as NH2 is an isostere of OH. This means that NH2 has the same valency 
as OH and allows the character of the molecule to be changed in a controlled 
way
182
. 
Also, the NH2 group will allow the retention of any hydrogen bonding 
possible at this position. This is potentially important as the two immediate 
precursors of PQS, 2-"-heptyl-4(1#)-quinolone and 2-"-heptyl-3-formyl-
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4(1#)-quinolone, lack functional groups capable of hydrogen bonding and 
have been shown to be inactive in the relevant biological assays. 
3.3.2 Formation of 4-Quinazolinones via benzoxazinone
The initial step required in the scheme was the formation of the benzoxazinone 
intermediate, which has been extensively used in the production of 4-
quinazolinones. Interestingly, they have also been used in the synthesis of 2-
quinolones
183
.
These heterocycles have their own therapeutic effects, including the 
inactivation of chymotrypsin
184,185
and inhibition of serine protease
149
. These 
molecules can be synthesised in a number of ways. 
The best established method is described by Errede &/ +6
186,187
, based on 
work done by Bogert and Seil
188
, delivering 2-methylbenzoxazinone 3.14, by 
refluxing anthranilic acid 3.13 in acetic anhydride, is shown below. 
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A&+-&"/% +"( 8)"(./.)"%N (i) Ac2O, Δ
Scheme 3.19 Production of 2-methyl-benzoxazinone
This synthesis of the benzoxazinones can also tolerate substitution on the 
carbocyclic ring, as demonstrated by the production of a 6,8-dibromo-2-
methyl-4-quinazolinone
152
3.60 is produced if the reaction in scheme 3.20 is 
undertaken.
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A&+-&"/% +"( 8)"(./.)"%: (i) Ac2O, Δ
Scheme 3.20 Synthesis of substituted benzoxazinone using acetic anhydride
In another example the acetic anhydride was replaced by dichloroacetyl 
chloride, thereby giving the 2-dichloromethylbenzoxazinone. An 8-
triflouromethyl compound 3.62 was produced from the corresponding 
anthranilic acid
189
3.61 using this method.
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A&+-&"/% +"( 8)"(./.)"%: (i) Dichloroacetyl chloride, Δ
Scheme 3.21 Synthesis of substituted benzoxazinone using dichloroacetyl 
chloride
There are alternatives for the production of the benzoxazinones, such as the use 
of isatoic anhydride 3.63 instead of anthranilic acid, which is heated at reflux 
in pyridine. An anhydride is used to supply the substitution at the 2-position, in 
the example shown in scheme 3.22 a trifluoroacetic anhydride is used to form 
3.64.
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A&+-&"/% +"( 8)"(./.)"%N (i) (CF3CO)2O, pyridine, Δ
Scheme 3.22 Formation of 2-(trifluoromethyl)-4#-benzoxazinone
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In the second step, attack by nitrogen nucleophiles, such as hydrazines, 
aniline
190
and amines
191
, on the 4-carbonyl of the benzoxazinone produces the 
desired 4-quinazolinone. This allows substitution to be introduced at the 3-
position of the resulting quinazolinone 3.65.
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Scheme 3.23 Attack of nitrogen nucleophile on benzoxazinone
The substituents will have a dominant bearing on how reactive the 
benzoxazinone carbonyl is and it appears to be the electronic contribution in 
particular of the ring substituents that dominate. The order of reactivity was 
seen to follow the trend of the electronic contribution of the substituents 
through either induction, resonance or a combination of the two
187
. 
Conversely, if there is an N-N type molecule acting as the nucleophile, 
the factor that determines which nitrogen attacks seems to be the steric effects, 
rather than nucleophilicity. The least hindered nitrogen attacks the carbonyl, 
rather than the most nucleophilic.
This information is valuable if a range of nitrogen nucleophiles are used 
in the formation of quinazolinones and may go towards explaining differing 
yields of final product.
Thus the benzoxazinone molecule was very useful as there was 
potential to introduce diversity into the system at specific points by simply 
changing the nature of the starting materials. It has been shown that they will 
undergo ring opening with different nucleophiles
192-194
allowing incorporation 
of substitution at the 3-position. This in turn will generate a number of 
molecules for the SAR study.
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3.3.3 Acylation of anthranilic acid
Substituted anthranilic acid 3.54 can allow substitution on the carbocyclic ring 
in 3.56, whereas changing the acid chloride 3.55 provides the alteration in the 
side chain.
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A&+-&"/% +"( 8)"(./.)"%: (i) NaOH, H2O
Scheme 3.24 General method for !-acylation of anthranilic acid derivatives
3.3.3.1 Alteration of alkyl chains
It was decided to alter the side chain early in the process, so that it would be in 
place when the ring closure was complete, rather than attempting to alter its 
nature following the ring closure. The latter is possible using an aldehyde with 
zinc chloride to convert an ethyl side chain 3.66 to that with an unsaturated or 
aromatic nature
190
3.67. This method would allow more complex substitution if 
required later on in the SAR study.
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A&+-&"/% +"( 8)"(./.)"%: (i) RCHO, ZnCl2
Scheme 3.25 Alteration of benzoxazinone side chain using zinc chloride
3.3.3.2 Formation of N-octanoylanthranilic acid
In order to introduce C7-side chain at the 2-position, mimicking that present in 
PQS, anthranilic acid is acylated in a Schotten-Bauman type reaction, with 
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octanoyl chloride 3.68 that is added dropwise to a solution of anthranilic acid 
in aqueous NaOH, scheme 3.26. 
This solution is extracted with ethyl acetate and following removal of 
the solvent and trituration with petroleum ether, allows the !-
octanoylanthranilic acid 3.69 to be collected as a white solid in a 65 % yield. 
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A&+-&"/% +"( 8)"(./.)"%N (i) NaOH, H2O
Scheme 3.26 Formation of !-octanoyl anthranilic acid
The mechanism for the reaction proceeds as shown in scheme 3.27, lone pair 
on the nitrogen attacks the electrophilic carbonyl on the octanoyl chloride 3.68, 
forming !-octanoylanthranilic acid. The H
1
NMR shows the expected broad 
peak for NH, present at δ 11.03.
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Scheme 3.27 Acylation of anthranilic acid with octanoyl chloride
It is also possible to produce this molecule in a reaction using pyridine at 0 
°C
187
but the use of sodium hydroxide compared to pyridine is preferable due 
to toxicity considerations. The method using pyridine was attempted but 
produced a product that was extremely inferior to that produced by the method 
explained above.
When commercially available, acid chlorides were used to give alkyl 
chain substitution. The method can be extended to other substitutions with the 
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required acid chlorides 3.71 being prepared by treating carboxylic acids 3.70
with thionyl chloride at reflux temperature for 2 h
187
.
3.3.3.3 N-Acylated Anthranilic acids produced
A number of molecules, containing differing substituents both in terms of 
length of side chain and on the benzene ring, were synthesised in this way.
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Table 3.1 !4Acylated anthranilic acids produced
;)*3)'"( A
M
A
C
R.&6( TSU
3.74 H C5H11 63
3.69 H C7H15 65
3.75 H C9H19 67
3.76 4-Cl C5H11 70
3.77 4-Cl C7H15 69
3.78 4-Cl C9H19 68
3.3.4 Formation of 2-alkyl benzoxazinone
The next step in the synthesis involves cyclisation of the anthranilate 3.69, via 
dehydration, forming a benzoxazinone 3.79 intermediate.  
Two dehydrating agents, acetic anhydride
174,187,194
and thionyl 
chloride
187
, were assessed with acetic anhydride yielding a substantially cleaner 
more satisfactory product.
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Scheme 3.28 Formation of 2-heptyl benzoxazin-4-one
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The reaction proceeds according to the mechanism shown in scheme 3.29. The 
carboxylate anion on the anthranilate 3.69 attacks a carbonyl on the acetic 
anhydride.  The intramolecular cyclisation is driven by the lone pair on the 
nitrogen and the proximity of the mixed anhydride functional group. These two 
steps occur in the course of the reaction, with the product 3.79 being afforded 
after the removal of the acetic anhydride.
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Scheme 3.29 Benzoxazinone ring closure
3.3.4.1 Benzoxazinones produced
A number of substituted benzoxazinones were synthesised using this general 
route. They were all produced in quantitative yield and used without further 
purification in the next step.
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Table 3.2 Benzoxazinones produced
;)*3)'"( A
M
A
C
3.80 H C5H11
3.79 H C7H15
3.81 H C9H19
3.82 6-Cl C5H11
3.83 6-Cl C7H15
3.84 6-Cl C9H19
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3.3.4.2 Instability of benzoxazinones
One of the main reasons that these molecules were not purified due to their 
potential to degrade when exposed to water.
It is a report that the benzoxazinones are liable to hydrolysis by water 
and that 2-alkylbenzoxazinones increase in stability relating to the length of the 
side chain
194
. The actual extent to which this hydrolysis occurs varies greatly 
across a range of molecules. A molecule of water would be able to open the 
benzoxazinone ring by attacking the intracyclic carbonyl and effectively 
hydrolysing the cyclic ester, as shown in scheme 3.30. Care was therefore 
taken in storage and utilisation of these molecules.
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Scheme 3.30 Hydrolysis of benzoxazinone
As mentioned before, it has also been suggested that the nature of the 
substitution on the benzoxazinone can modulate the reactivity of the carbonyl, 
in that electron donating groups cause the carbonyl to be less electrophilic and 
reduce the reactivity of the benzoxazinone carbonyl to nucleophilic attack
185
. 
This is desirable in terms of stability on storage, or if they are to be final 
molecules themselves, but may be a factor when these molecules are altered for 
further analogue production.
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+I effect
An alkyl chain will act as an electron donor (+I effect), as shown above, which 
suggests that the longer the chain gets, the more difficult a reaction and 
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insertion of the group that will constitute substitution at the 3-position of the 
corresponding quinazolinone. This did not present a problem with the 
molecules that were produced in this study but may have a bearing on further 
investigations to extend the number of analogues in this series.
3.3.5 Formation of 2-n-heptyl-3-amino-4(3H)-quinazolinone
The next stage in the synthesis requires the substitution to be introduced to the 
molecule to provide a suitable quinazolinone molecule.
When the benzoxazinone 3.79 reacts with hydrazine at room 
temperature, in tetrahydrofuran (THF), scheme 3.31, it yields an uncyclised 
form of the desired product, 2-(octanamido)benzohydrazide 3.84, along with a 
highly coloured, fluorescent material, which could not be satisfactorily 
characterised.
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Scheme 3.31 Formation of 2-(octanamido)benzohydrazide
Even though the quinazolinone was not produced, this method would have had 
value if the uncyclised form could be recovered in a suitable quantity and then 
further reacted to form the quinazolinone. Unfortunately, the uncyclised form 
of the compound was produced in an 8 % yield, meaning that the method was 
not suitable for use.
This implied that there required to be more energy put into the system 
to allow the ring closure to occur. Another contributing factor is that it is 
desirable to keep the number of steps to achieve the desired final molecule to a 
minimum.
Fortunately, refluxing the benzoxazinone 3.79 in anhydrous ethanol in 
the presence of excess hydrazine, as shown in scheme 3.32, produced the 
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required molecule
152,178,195
, 2-"-heptyl-3-amino-4(3#)-quinazolinone 3.85. It is 
also possible to carry out this reaction using pyridine
153
.
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Scheme 3.32 Formation of 2-"-heptyl-3-amino-4(3#)-quinazolinone
The production of 2-"-heptyl-3-amino-4(3#)-quinazolinone was supported by 
a signal for the NH2 protons at δ 4.91 in the H
1
NMR spectrum and by it 
showing *01 260.2 in positive electrospray MS. The NH2 signal disappeared 
when the 
1
H NMR was recorded in the presence of deuterium oxide (D2O).
The mechanism for the reaction is as shown below in scheme 3.33. It 
begins with an intermolecular reaction between the hydrazine 3.86 and the 
benzoxazinone 3.79, and then proceeds with an intramolecular step, causing 
the ring closure. Firstly, the lone pair on the hydrazine nitrogen attacks at the 
carbonyl on the ring, causing the ring to open.  The lone pair of the newly 
produced hydrazide nitrogen then instigates an intramolecular attack towards 
the amide carbonyl, causing the ring to close again.  A loss of the water 
molecule, forming 2-"-heptyl-3-amino-4(3#)-quinazolinone 3.85, is driven by 
extension to conjugation. The solid obtained was triturated with hexane and 
purified using column chromatography.
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Scheme 3.33 Formation of 2-"-heptyl-3-amino-4(3#)-quinazolinone
There is evidence reported that temperatures of 150 °C – 250 °C are required to 
afford ring closure to the quinazolinone, although the temperature seems to 
vary in terms of what substitution is present in both starting materials. To 
illustrate this with some examples, the relative reactivities, in relation to 
substitution at R in the scheme above would be, (R = CF3) > (R = H) > (R = 
CH3) > (R = NH2) ≈ (R = Ph)
187
.
An alternative mechanism where hydrazine attacks the 2-position
178,187
is hindered by the +I effect of the 2-alkyl substituent.
There is also the possibility that this molecule may be formed by first 
reacting the anthranilate with hydrazine, then causing ring closure by refluxing 
in acetic acid
195
but this is probably more relevant for a reaction that does not 
proceed to completion in one step and would require further ring closure.
3.3.6 Use of general method
Initially the compounds 2-"-heptyl-3-amino-4(3#)-quinazolinone and 2-"-
heptyl-3-hydroxy-4(3#)-quinazolinone were synthesised and their biological 
activity assessed. This was done to ascertain whether this route was a fruitful 
one to pursue.
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The compounds showed initial activity that, while below that of PQS, 
was comparable to OdDHL, discussed further in chapter 4. These results were 
encouraging enough to continue with the synthesis of a number more 
compounds in this series.
3.3.6.1 4-Quinazolinones produced
This general method was used to produce a number of molecules with little 
alteration to that outlined above. Molecules that included chlorine substitution 
on the carbocyclic ring produced very clean products following 
recrystalisation.
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Table 2.3 Substituted 4-quinazolinones synthesised
Compound R
1
R
2
R
3
Yield (%)
3.87 H C7H15 OH 29
3.85 H C7H15 NH2 38
3.88 H C5H11 NH2 47
3.89 H C9H19 NH2 46
3.90 6 - Cl C7H15 NH2 78
3.3.6.1.1 Formation of 2-methyl-4-quinazolinone as a side product
There was a formation of a 2-methyl derivative 3.91 as a side product during 
the formation of the longer alkyl chain molecules These occurred due to there 
being some of the anthranilic acid, or derivative, not being acylated during the 
course of the first step of the reaction, thereby meaning that a 2-
methylbenzoxazinone 3.92 was formed in the following step and this was not 
removed. As these were not purified, these were carried on to the next step and 
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the hydrazine would react in the same way to form the 2-methyl derivative 
3.91, which would then be isolated as part of purification.
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A&+-&"/% +"( 8)"(./.)"%: (i) NaOH, H2O; (ii) Ac2O, Δ; (iii) NH2NH2, EtOH, Δ
Scheme 3.34 Formation of 2-methyl-3-amino-3#-quinazolin-4-one analogue 
side product
The compounds, however, are useful in the SAR study, as they provide 
molecules with a minimal alkyl side chain and can be valuable in showing the 
role that an alkyl side chain plays.
3.3.6.2 Formation of 2-n-heptyl-3-hydroxy-4(3H)-quinazolinone
The production of 2-"-heptyl-3-hydroxy-4(3#)-quinazolinone 3.87 is 
obviously of value in this study and the investigation of the surrogate system 
offered by the quinazolinones as this most closely resembles PQS.
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The production of 2-"-heptyl-3-hydroxy-4(3#)-quinazolinone differed from 
the established route for the addition of the hydroxy group as there is not a 
commercially available hydrazine derivative (NH2OH or hydroxylamine) 
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suitable to do the straight reaction. The hydrochloride salt is available, which 
requires the free base to be liberated prior to the reaction. This was done by 
using sodium ethoxide by dissolving sodium metal in ethanol. This caused the 
formation of sodium chloride that needed to be removed by filtration prior to 
the addition of 2-heptyl-4-benzoxazinone. 
Although the reaction did take place it did not proceed as successfully 
as the previously described examples and the desired product was obtained in a 
low yield of 29 %. 
After the liberation of the free base, the mechanism is very similar to 
that for the previously described for 2-"-heptyl-3-hydroxy-4(3#)-
quinazolinone and is shown in scheme 3.35.
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Scheme 3.35 Mechanism for formation of 2-"-heptyl-3-hydroxy-3#-
quinazolin-4-one
The lower yield is possibly due to a reduction of the amount of free 
hydroxylamine in the reaction mixture, caused by inevitable losses during the 
treatment with sodium methoxide and subsequent filtration. There is also the 
possible reduction in the reactivity of the nitrogen lone pair in the 
hydroxylamine, due to the relative higher electronegativity of the oxygen (α 
effect), compared to the nitrogen present in hydrazine. This would cause the 
lone pair to be less nucleophilic.
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3.3.6.2.1 Alternative method for production of 2-n-heptyl-3-hydroxy-
4(3H)-quinazolinone 
An alternative method, that was not attempted, that potentially could allow 
easier purification and increased recovery of the product is shown in scheme 
3.36. This method would involve the use of )-benzylhydroxylamine to produce 
3.93. The benzyl group could then be removed, via hydrogenolysis, to obtain 
the desired hydroxyl group at the 3-position.
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A&+-&"/% +"( 8)"(./.)"%N (i) Pd/C, H2, EtOH
Scheme 3.36 Proposed alternative method for the production of 2-alkyl-3-
hydroxy-4#-quinazolinone
3.3.7 1, 2-Dihydro derivatives of 4-quinolones
Reduced activity of 2-"-heptyl-3-hydroxy-4(3#)-quinazolinone as compared to 
PQS may be, in part, to the absence of hydrogen on the !
1
. The presence of the 
hydrogen on the nitrogen is potentially significant. Having the nitrogen 
unsubstituted retains the aromaticity, and therefore the rigidity, of the molecule 
but evidence suggests that the presence of a proton on the nitrogen significantly 
affects the activity. 
Quinazolinones have been previously investigated in relation to their 
potential antitumour activity. In the course of this investigation the molecules 
3.94 and 3.95 were produced
154
and assayed for their inhibition of tubulin 
polymerization
150
. The molecule with the hydrogen present on the nitrogen was 
significantly more active than that which did not (IC50 14 µM compared with > 
40)
154
.
132
3.953.94
&
&"
!
&
"
&"
!
This change in activity is obviously dependent on the nature of the active site 
interaction with the molecule and whether hydrogen bonding is significant in 
this.
3.3.7.1 Method of reduction
The introduction of the hydrogen onto the nitrogen requires a reduction across 
the 1, 2-double bond present in the heterocyclic ring. Similar reactions have 
been carried out using the reducing agents including sodium borohydride and 
sodium cyanoborohydride
196
.
Theoretically there are three main alternatives:
• Hydrogenation of the double bond, using a palladium catalyst. In this 
method the hydrogen is absorbed onto the palladium surface and the π 
electrons of the nitrogen-carbon double bond are able to bind and each 
atom to take on a hydrogen.
• Sodium borohydride can be used in methanol. This allows the 
formation of sodium methoxide, creating basic conditions and causing a 
hydride ion to attack the carbon and reducing the double bond onto the 
nitrogen.
• Using sodium cyanoborohydride
196
in acidic conditions causes a 
protonation of the nitrogen. The pH of the reaction must be maintained 
at pH 3-4 to ensure success in the reaction. The hydride from the 
cyanoborohydride attacks the carbon and the charge is equalised onto 
the nitrogen, causing the reduction of the double bond. Potential 
cleavage of the carbon-nitrogen bond has been reported when using this 
method
197
but has also shown success in similar systems
196
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It would be of value to investigate this type of structural change in the 
quinazolinone series and its effect on immune modulatory activity. It would 
provide an insight into the importance of hydrogen bonding at this point if the 
molecule. Additionally, there is the removal of the aromaticity of the system, 
reducing rigidity and allowing greater movement of the ring, which may be 
important in its binding interactions with the target immunophilin.
3.4 Summary of Results
A number of substituted 2-alkyl-3-substituted quinazolinones were produced 
using a facile three step synthetic route.
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Scheme 3.37 Facile three step synthesis of 2-alkyl-3-substituted 
quinazolinones
This method allows the introduction of a variety of substituents into the core 
structure of the quinazolinone, in the areas shown above, in a quick and simple 
way. This has allowed the synthesis of a number of analogues in the system 
that acts as a surrogate system for the 4-quinolone based compounds. This 
system was significantly more convenient with regards to production of 
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molecules than that of the 4-quinolone. The quinazolinone series of molecules 
can be quickly and simply produced, using inexpensive starting materials.
This series of molecules has allowed the number of analogues in the 
SAR study to be increased in number in a short period of time. It may also 
provide information with regards to similar alterations in the 4-quinolone 
series. The immune modulatory properties of these new 4-quinazolinone based 
derivatives were investigated as detailed and discussed in chapter 4.
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Chapter 4
Immune Modulatory Activity of PQS Analogues: 
Structure Activity Relationship Studies
4.1 Natural products in immune therapy
Immune modulation is the alteration of the body’s immune response via the use 
of external stimuli. This is important in the range of diseases and conditions 
that occur due to an inappropriate immune response initiated by the host. This 
can take the form of the rejection of a transplanted organ, hypersensitivity to 
allergens or autoimmunity, where the host mounts an immune response to its 
own tissues. In these cases it is imperative to suppress the immune response to 
obtain a favourable outcome and the agents currently in use in this area have 
been reviewed in Chapter 1. A number of these compounds have been directly 
or indirectly derived from natural products e.g. Tacrolimus, also known as 
FK506, a macrolide produced by the bacteria F/,&3/)*?8&% /%'@'G+&"%.%
39
and 
Sirolimus first isolated from a strain of F/,&3/)*?8&% 5?-,)%8)3.8'%
46
. The 
discovery that signal molecules involved in the bacterial communication 
process, known as quorum sensing, possessed immune modulating capability
56
has led to the possible exploitation of these molecules with the view of 
developing immune therapies
114
.
The quorum sensing signal molecules (QSSMs), !-(3-oxododecanoyl)-
L-homoserine lactone (OdDHL) 4.1 and 2-"-heptyl-3-hydroxy-4(1#)-
quinolone (PQS) 4.2, produced by the opportunistic human pathogen 
$%&'()*)"+% +&,'-.")%+, have been found to modulate the immune system in 
distinctly different ways
118
. 
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4.2
While an initial structure activity relationship (SAR) study has been undertaken 
using OdDHL as a lead molecule
114
, no such information regarding PQS is 
known. Its ability to potently inhibit the immune response warrants this area 
being investigated.
4.2 Structure activity relationship studies
The aim of a structure activity relationship (SAR) study is to establish which 
parts of the molecule are important to biological activity. In order to carry out 
an SAR study a lead molecule is first identified and then a number of 
analogues that vary slightly from the lead molecule are synthesised. These can 
then be assessed with regards to their biological activity and compared to the 
lead molecule.
Drug molecules will interact with their target receptor through binding 
interactions such as ionic bonding, van der Waals interactions, hydrogen 
bonding and dipole-dipole interactions. The functional groups present on the 
molecule can possibly engage in these types of interactions but these may not 
occur in practice. A method for establishing the importance of the potential 
interactions is to alter the structure e.g. by converting a hydroxyl into either an 
ether or ester. If the activity remains similar to the lead molecule, the group 
altered does not play a large role in the interactions but if the activity is 
reduced then it can be concluded that the group has a major influence.
In order to ascertain what functional units within the PQS structure 
were important for its binding to immunophilin targets it is essential to carry 
137
out a SAR study. The areas that might be considered to have potential for 
binding to a receptor in PQS are highlighted in Fig. 4.1. The alkyl chain (A), 
substitution at the 3-position (B), the substitution on the nitrogen (C) and the 
possible introduction of substitution onto the carbocyclic ring (R) are all 
possible areas of exploitation in an SAR study.
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Figure 4.1 Potential areas of alteration in SAR study of PQS
A number of the PQS analogues produced were assayed to ascertain their 
activity in relation to the inhibition of T cell proliferation. In order to gain an 
accurate appreciation of this effect it was important to also ascertain their 
cytotoxicity. These assays are outlined below. Through these assays it is 
possible to gain an idea of what areas of the PQS molecule are important for its 
action as an immune modulator and begin to optimise the structure. The results 
obtained from the murine splenocyte proliferation assay do not correlate 
directly with the compounds’ cellular physiological activity; rather it is an 
indicator of pharmacological activity. The term EC50 represents the plasma 
concentration required for obtaining 50% of a maximum effect ." E.E).
4.2.1 Proliferation Assay
The concanavalin A (ConA) mitogen-stimulated proliferation of murine spleen 
cells was used to assess the effect of the PQS analogues on T cell activation 
and proliferation. Proliferation was assessed by the incorporation of 
[
3
H]thymidine into DNA. Eight-week-old female mice were obtained from 
Harlan (Biscester, Oxon, United Kingdom) and given food and water ad 
libitum. Spleen cell suspensions were prepared by removing the spleens and 
placing them into Hanks’ balanced salt solution (HBSS). The spleens were 
chopped with scissors and forced through a Falcon 70μm pore size nylon cell 
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strainer (2350; Beeton Dickinson, Franklin Lakes, N.J.) with the plunger from 
a 5 ml syringe to produce a single cell suspension. Pellets of the cells were 
produced by centrifugation and erythrocytes were lysed using 0.017 M Tris-
0.144 M ammonium chloride, pH 7.2. Leukocytes were washed with HBSS 
twice and resuspended in complete cell culture medium (CTCM). The cell 
suspension was incubated for 48 h at 37°C in 5% CO2/air in the presence of the 
PQS analogues and ConA, which stimulates the proliferation of the cells. 
Following this time, 20 μl of [
3
H]thymidine in CTCM was added and the 
mixture incubated for a further 24 h. Cells were harvested onto fibreglass 
filters with a Packard filtermate 196 harvester. The [
3
H]thymidine is 
incorporated into any proliferating leukocytes and, following harvesting and 
the addition of 20 μl scintillation fluid (Microscint-O), the proliferation can be 
quantified using a Packard Topcount scintillation counter.
The compounds were tested in duplicate (n = 2) over a concentration 
range of 0.3 to 1000 μM with the EC50 calculated from the resulting dose-
response curves. The dose-response curve for PQS is shown below (figure 4.2). 
Wells containing DMSO alone provided a control and the solvent was found to 
have a negligible effect on inhibition of proliferation.
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Figure 4.2 The effect of PQS and DMSO on the ConA stimulated proliferation 
of murine splenocytes
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4.3 SAR studies
Systematic alterations to the areas indicated in Fig. 4.1 were carried out to 
obtain new analogues of PQS.
4.3.1 Alteration of side chain
It can be seen from evidence reported previously that the length of an alkyl 
chain can influence the pharmacological activity of a molecule. A related 
example to illustrate this is the difference in antiproliferative activity between 
OdDHL 4.1 and OHHL 4.3
56,81
. The only difference between the two 
molecules is alkyl chain length, yet OdDHL possesses a potent antiproliferative 
activity in a murine splenocyte assay, whereas OHHL is inactive. An alkyl 
chain will aid in the lipophilicity of a compound, the longer chain providing 
increased lipophilicity.
4.1
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In relation to altering the alkyl side chain of the original PQS structure, three 
structures were tested. These included 2-methyl-3-hydroxy-4(1#)-quinolone 
and 2-"-pentyl-3-hydroxy-4(1#)-quinolone produced in the course of this 
study, via the synthetic methods discussed in Chapter 2. Additionally, 2-"-
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nonyl-3-hydroxy-4(1#)-quinolone
1
was tested, in order to allow the 
comparison of both shortening and lengthening the alkyl chain. The results are 
summarised in Table 4.1.
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Table 4.1 Immunological data for compounds with alkyl chain length 
alterations
Compound R EC50 (µM)
2.143 (PQS) C7H15 0.082
2.141 CH3 15.5
2.142 C5H11 0.9
4.4 C9H19 0.023
It is clear that the alkyl chain is important, due to the drop in activity with 
2.141. The results show that the molecule can tolerate a shortening or 
lengthening of the alkyl side chain and still retain a useful activity. The 
optimum chain length of those compounds tested appears to be C9.
The dose-response curves shown in figure 4.3 demonstrate the 
similarity in activity of PQS and 2-"-nonyl-3-hydroxy-4(1#)-quinolone 4.4.
  
1
Kindly donated by Mr Alex Truman of the Institute of Infection, Immunity and Inflammation, 
University of Nottingham
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Figure 4.2 Influence of PQS and 2-"-nonyl-3-hydroxy-4(1#)-quinolone 4.4 on
ConA mitogen-driven proliferation of murine spleen cells
4.3.2 N-substitution
When the nitrogen is present on PQS and its derivatives is replaced with a 
methyl group it removes the capability for hydrogen bonding. A similar 
example to this can be seen when considering terbutaline 4.5, where its anti-
asthmatic, β2-agonist activity is lost when the molecule is metabolised to its 
methyl ether
198
4.6, as seen in scheme 4.1.
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Scheme 4.1 Metabolism of noradrenalin to its inactive methyl ether
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Methylation also decreases the polarity of the molecule, thereby making it 
more lipophilic and enabling greater membrane permeability. This is important 
in classes of drugs such as hypnotics and antiepileptics, such as hexabarbitone 
4.7.
4.7
& &"
!
! !
#$
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The hydrogen being replaced by the methyl group will prevent any 
tautomerism occurring in the molecule and will therefore provide clues to 
which tautomer interacts more strongly with the receptor.
The !-methyl derivative shows a drop in activity compared with PQS. This 
decrease is not large and suggests that the hydrogen bonding interaction with 
the target, involving this area of the molecule, while useful, is not key to its 
activity. It also suggests that permeability of the molecule is important for its 
action.
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Table 4.2 Immunological data for !-methyl PQS
Compound R EC50 (µM)
2.143 (PQS) H 0.082
2.145 CH3 0.2
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4.3.3 Alteration of the hydroxyl functional group
A hydroxyl groups present in a drug molecule can be commonly involved in 
hydrogen bonding with the target receptor. A hydroxyl group will act as a 
hydrogen bond donator. Converting a hydroxyl to an ether or an ester will 
change the nature of the bonding. An ester, for example, will act as a hydrogen 
bond acceptor, interacting if a hydrogen is present on the receptor, rather than a 
hydrogen bond donator in the vein of the hydroxyl. It had been seen previously 
that the immediate two precursors in the original synthetic route for PQS, 2-"-
heptyl-4(1#)-quinolone 4.8 and 2-"-heptyl-3-formyl-4(1#)-quinolone 4.9, did 
not have any activity in murine splenocyte antiproliferation assays. This 
suggests that the interaction of the hydroxyl group with the target is important. 
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4.8 4.9
The method chosen for this study was to replace the hydroxyl with an ester 
group at the 3-position. This was achieved in the production of 2.107 and 
2.104, having the ester as a lone alteration to structure and in combination with 
the reduction of the side chain, along with a 3-carboxylic acid derivative 2.109.
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Table 4.3 Immunological data for compounds with altered 3-substitution
Compound R
1
R
2
EC50 (µM)
2.143 (PQS) OH C7H15 0.082
2.107 COCH3 C7H15 2.9
2.104 COC2H5 CH3 199.0
2.109 COOH C7H15 12.4
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While there is the potential for hydrogen bonding with an ester the nature of 
this bond will be different. When a hydroxyl group is present, this acts as a 
hydrogen bond donator, whereas the ester will act as a hydrogen bond acceptor.
The results show that the activity drops when the hydroxyl is replaced with an 
ester 2.107. The activity also drops when a carboxylic acid, another hydrogen 
bond acceptor, is present at the 3-position 2.109. These results suggest that the 
nature of the hydrogen bonding at this position is an important consideration, 
with hydrogen bond donators allowing a stronger interaction between the 
receptor and the molecule. Compound 2.104, where the ester at the 3-position 
is present with a methyl at the 2-position, confirms that the 2-alkyl chain is 
important for activity.
4.3.4 Additions and insertions involving the carbocyclic ring
Lead molecules do not always interact with all possible binding areas of the 
receptor and also may not be chemically optimal in terms of solubility and 
lipophilicity. The addition of extra functional groups can allow the interaction 
with areas of the binding site that are not involved with the lead molecule and 
also the addition of groups to affect the polarity of the molecule will have an 
effect on the solubility. Additional groups may also affect the stability of 
molecules which may take the form of increased resistance to hydrolysis or the 
combating of enzymes that metabolise the drug. This can be seen when 
comparing amoxicillin 4.10 with diphenicillin 4.11. Amoxicillin is susceptible 
to β-lactamase enzymes and the addition of an additional phenyl group 
sterically inhibits the access of these enzymes to the β-lactam ring and 
therefore limiting the enzyme’s hydrolytic activity
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The effect of additions to the carbocyclic ring were investigated initially by the 
addition of a chlorine at the 6-position in the quinolone structure. Chlorine 
substitution has been shown to affect binding and metabolism in drug 
molecules
199
. The activity for the 6-chloro compound is lower than that of PQS 
but is still useful, showing a tolerance for this nature of substitution.
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Table 4.4 Immunological data for compounds with chloro substitution
Compound R
1
R
2
EC50 (µM)
2.143 H C7H15 0.082
2.144 Cl C7H15 0.6
4.3.5 Heterocyclic ring structure
The introduction of additional heteroatoms into a drug molecule can bring 
about changes in its physiochemical properties
148
. The addition of an extra 
heteroatom into the heterocyclic ring was achieved by introducing a nitrogen at 
the 3-position, giving rise to the synthesis of a number of quinazolinone 
structures.
The quinazolinone series demonstrated less activity than that of the 
equivalent quinolone molecules, PQS having an EC50 of 0.98 µM, although the 
activity was better than OdDHL (EC50 of 4.5 µM) in the case of the 3-amino 
derivatives.
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Table 4.5 Immunological data for compounds with additional heterocyclic 
atoms present in the ring system
Compound R
1
R
2
EC50 (µM)
3.85 NH2 C7H15 2.2
3.87 OH C7H15 10.8
3.91 NH2 CH3 400.0
3.88 NH2 C5H11 5.5
3.89 NH2 C9H19 9.3
The alkyl chain length is important, demonstrated by the lack of activity of 
3.91 which possesses a reduced alkyl chain, compared with that of 3.85. A C7
chain shows the best activity with a drop in activity when going to C5 and C9. 
This contrasts with the results for the 4-quinolones, where the activity was 
slightly raised with a longer alkyl chain.
Interestingly, the replacement of OH with NH2 appears to increase 
potency, as shown by comparing 3.87 and 3.85. NH2 is an isostere of OH and 
allows the retention of hydrogen bonding, without changing other factors 
greatly, such as the steric effects. This difference in activity can also be seen in 
comparing the dose response curves from the murine splenocyte assay, figure 
4.3.
147
Q
)QQQ
LQQQ
NQQQ
PQQQ
QK7 7 7Q 7QQ 7QQQ
conc (mM)
P
ro
li
fe
ra
ti
o
n
 (
c
p
m
)
CKPO
CKP-
Figure 4.3 Influence of 3-substituent on the quinazolinone ring system. 2-"-
Heptyl-3-amino-4(3#)quinazolinone 3.87 shows a greater activity than 2-"-
hydroxy-3-amino-4(3#)quinazolinone
If these results transfer over to the quinolone series of molecules it suggests 
that the production of 2-"-heptyl-3-amino-4(1#)-quinolone 4.12 would offer 
promising results.
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The introduction of chlorine onto the carbocyclic ring was also investigated by 
producing 6-chloro-2-heptyl-3-amino-4(3#)-quinazolinone and this can be 
compared to 3.85 to see the effect on biological activity.
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Table 4.5 Immunological data for chloro substituted quinazolinone
Compound R
1
R
2
EC50 (µM)
3.85 H C7H15 2.2
3.90 Cl C7H15 20.3
It can be seen that the introduction of chlorine onto the carbocyclic ring is not 
well tolerated and causes a ten-fold drop in activity. This contrasts with the 4-
quinolone series of molecules, where antiproliferative activity was not 
adversely affected by the introduction of chlorine onto the carbocyclic ring.
4.4 Toxicity Assay
The cytotoxicity of the PQS analogues towards murine spleen cells was 
assessed by dye exclusion after 24h. The murine spleen cells were incubated 
with the compounds for 24 h at 37°C in 5% CO2/air. The cells were then 
stained with 0.4% trypan blue, a dye that is incorporated into dead cells, 
leaving viable cells unstained. The viable cells are then counted. This is an 
improvement over lactate dehydrogenase (LDH) release, a method that has 
been used in this area previously, as the assay can also detect cytostatic 
compounds. The toxicity value relates to the concentration at which toxicity is 
first observed. There is also the possible cytostatic (S) effect observable in the 
compounds too. 
The toxicity data is important to provide an idea of the influence, 
initially, on cell proliferation in the murine splenocyte assay and also in future 
considerations to do with the compounds potential use as a drug molecule. The 
ideal result regarding the toxicity assay is for a compound to be non-toxic (NT) 
but if this is not the case, a large window exists between the EC50 and the 
concentration at which the compound is toxic. This allows the evaluation of the 
potential for assessment of what is known as therapeutic window, if the two 
149
concentrations above are too close there is the increased possibility of toxic 
effects being observed if it was used as a drug molecule. The results of the 
toxicity assay are shown in table 4.6 in comparison to the EC50.
Table 4.6 Toxicity data for PQS analogues. Some compounds are non-toxic 
(NT) while others demonstrated a possible cytostatic (S?) effect
Compound EC50 (μM) Toxicity (μM)
2.141 15.5 NT
2.142 0.9 S
2.144 0.6 40 S?
2.145 0.2 10
2.104 199.0 750 S?
2.107 2.9 70
2.109 12.4 120
3.85 2.2 50
3.87 10.8 3.87
3.88 5.5 100
3.89 9.3 300
3.90 20.3 300
3.91 400.0 NT
4.4 0.13 600 S?
4.5 Summary of results and conclusions
From these results it can be seen that certain areas of the PQS molecule are 
important for biological activity, as well as the introduction of additional 
heteroatoms causing a reduction of activity;
• The alkyl chain present at the 2-position is important for activity, 
shown by the 2-methyl derivative having largely reduced activity. The 
molecule can tolerate changes of chain length by either addition or 
subtraction of two carbons to the chain.
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• The proton on the nitrogen does not appear to have a large influence on 
activity.
• The polarity and lipophilicity of the molecule has an influence on its 
activity.
• The 3-hydroxyl functionality is important, as demonstrated by the 
observation that the precursors in the synthetic route lacking this group 
were inactive. There is the possibility for some alteration of the 
functionality at the 3-positon, such as the use of a methyl ester, while 
retaining a useful amount of activity but the introduction of an acid 
reduces activity even more. The concomitant reduction in size of the 2-
alkyl chain reduces activity greatly.
• The 4-quinazolinone structures are roughly ten times less potent than 
that of the 4-quinolones but still retain a useful level of activity, 
comparable to that of OdDHL
• The production of 2-alkyl-3-amino-4(1#)-quinolones may provide 
potent biologically active molecules.
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Chapter 5
Conclusion and Future Work
5.1 Conclusion
This project has demonstrated how the synthesis of analogues of 2-n-heptyl-3-
hydroxy-4(1#)-quinolone (PQS) may be achieved in a number facile synthetic 
routes, allowing the exploitation certain areas of the molecule. These areas 
include the 2-alkyl chain, 3-position substitution, !-substitution, substitution 
on the carbocyclic ring and the introduction of additional heteroatoms into the 
molecule
2-Alkyl-4(1#)-quinolones with ester functionality at the 3-position can 
be synthesised from isatoic anhydride and a β-keto ester in one step. There is 
the ability to alter both the 2-alkyl chain and the ester by changing the β-keto 
ester. This reaction produces the quinolone without the need for purification. 
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Scheme 5.1 Formation of 2-alkyl-3-ester-4(1#)-quinolones
The ester at the 3-position can be transformed into a carboxylic acid.
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Scheme 5.2 Conversion of ester into carboxamide
PQS can be synthesised by the alkylation of anthranilic acid and cyclisation 
with NMP in a facile, two step synthesis.
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Scheme 5.3 Facile two step synthesis of PQS
The method allows quick and simple synthesis of a number of analogues by 
simply employing appropriate starting materials. Diversity can be introduced, 
at the 2-position, on the nitrogen and also in the carboxylic ring.
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Scheme 5.4 General synthesis of PQS analogues
These synthetic routes have enabled the production of 4-quinolone molecules 
with single or combined systematic alterations made at each of the areas 
targeted in the aims and objectives of the project.
A number of substituted 2-alkyl-3-substituted quinazolinones were 
produced using a facile three step synthetic route.
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Scheme 5.5 Facile three step synthesis of 2-alkyl-3-substituted quinazolinones
This allows the introduction of a variety of substituents into the core structure 
of the quinazolinone in a quick and simple way.
These molecules were assessed for immune modulatory activity in a 
murine splenocyte assay. From this it was seen that certain areas of the PQS 
molecule are important for biological activity and that the introduction of 
additional heteroatoms caused a reduction in activity.
The alkyl chain present at the 2-position is important for activity, 
shown by 2-methyl-3-hydroxy-4(1#)-quinolone having greatly reduced 
activity. The molecule can tolerate changes of chain length by either addition 
or subtraction of two carbons to the chain. The proton on the nitrogen does not 
have a large influence on activity, due to the better activity seen with the !-
methyl derivative. The polarity and lipophilicity of the molecule influences its 
activity. The 3-hydroxy group is important for activity but there is the 
possibility for some alteration of the substitution at the 3-positon, such as the 
use of a methyl ester, while retaining an acceptable amount of activity but the 
introduction of an acid reduces activity further. The 4-quinazolinone structures 
are roughly ten times less potent than that of the 4-quinolones but still retain a 
useful level of activity, comparable to that of OdDHL.
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5.2 Future Work
Future work in this area would include the production of additional analogues 
containing further alteration of the 2-alkyl chain. These alterations would 
include further alterations to length, reduction of flexibility by producing 
unsaturated chains and substitution on and within the alkyl chain. Further 
substitution at the 3-position would include the production of 2-"-heptyl-3-
amino-4(1#)-quinolone 5.1, as the results for the 3-amino quinazolinones 
suggest this would possess potent activity. Substitution of further groups 
around the carbocyclic ring would involve the introduction of both electron 
withdrawing, such as fluorine 5.2, and donating groups, such as a methoxy 5.3, 
in order to assess their effect on activity. These groups would also be rotated 
round the carbocyclic ring.
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5.1 5.2 5.3
Analogues which yielded promising results in the initial murine splenocyte 
assays would be taken on to testing with human PBMC cells in order to more 
fully see the potential effects on human immune response.
The identification of a target immunophilin for PQS, potentially via the 
use of affinity matrices, would be of great value. The identification of a target 
would allow a more targeted approach to analogue design through the use of 
molecular modelling.
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Chapter 6
Experimental Section
6.1 Materials
Starting materials were purchased from Aldrich Chemical Co., Dorset and 
Lancaster Synthesis Ltd., Morecambe.  Deuterated chloroform and deuterated 
dimethylsulfoxide were purchased from Goss International Ltd., England. 
Methanol-d4 was purchased from Cambridge Isotope Laboratories, Andover.  
The solvents used were HPLC grade.  Ethanol was dried by refluxing with 
magnesium turnings and iodine (Mg(OEt)2), redistilled and stored over 
molecular sieves (3 A 1-2 mm beads).
6.2 General analytical procedures
Melting points were determined on a Kofler Hot Stage and are uncorrected. 
1
H 
NMR and 
13
C NMR spectra were recorded on a Bruker AMX-250 
spectrophotometer operating at 250 MHz, using tetramethylsilane as an internal 
standard, and 62.9 MHz respectively.  Chemical shifts are reported relative to 
an internal CDCl3 standard on a broad band decoupled mode, and assignments 
were done using a DEPT pulse sequence.  Infrared spectra through the range 
4000-600 cm
-1
were obtained with KBr discs or as thin films using an Avatar 
360 Nicolet FT-IR spectrophotometer. Elemental analyses were obtained on a 
Perkin-Elmer 240 D elemental analyser.
Thin-layer chromatography (TLC) was preformed using Merck silica gel 60 
GF254 precoated (0.2 mm) alumina plates.  Preparative thin-layer 
chromatography (PLC) was preformed using Merck silica gel 60 GF254 coated 
(1.0mm) glass plates (20 cm x 20 cm).  Column chromatography was 
preformed using Merck Kieselgel 60 (230-400 mesh) silica
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6.3 Chapter 2
2,2-Dimethyl-1,3-dioxane-4,6-dione (Meldrum’s Acid) (2.61)
!
!
!
!
Concentrated H2SO4 (0.4 mL) and acetone (10 mL) were added to a stirred 
solution of malonic acid (13.0 g, 0.125 mol) in acetic anhydride (15 mL).  The 
solution is stirred at room temperature for 1 h Scratching then caused the 
product to precipitate, which was subsequently filtered under suction, washed 
with ice-cold water, and dried under vacuum in a dessicator to yield a white, 
crystalline solid. 
Mp: 90-91 
o
C (Lit: 94-96 
o
C).  
1
H NMR (CDCl3) δ 1.80 (6H, s, CH3), 3.61 (2H, s, COCH2CO)
5-Hexanoyl meldrum’s Acid (2.67)
!
!
!
!
!
N, N’-Dicyclohexylcarbodiimde (0.454 g, 2.2 mmol) was added to a stirred 
solution of hexanoic acid (2.32 g, 2 mmol) and 4-dimethylaminopyridine 
(0.269 g, 2.2 mmol) in dry dichloromethane (30 mL).  The mixture was stirred 
at room temperature for 1 h and Meldrum’s acid (2 mmol) was added.  The 
stirring was continued at room temperature overnight.  The solvent was 
removed under reduced pressure and the residue redissolved in ethyl acetate 
and filtered.  The filtrate was washed with 1 M HCl (2 x 20mL) and dried over 
MgSO4.  The solvent was removed under reduced pressure yielding a yellow 
oil, which was mixed with acetone (3 ml) and chilled in a fridge. The solid 
impurity was then removed by micro filtration and washed with cold acetone. 
The acetone was then evaporated under vacuum to yield the product as a 
yellow oil in 93 % yield.  This was used without purification in the next step.
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Ethyl 3-oxooctanoate (2.72)
!
!!
A solution of 5-hexanoyl Meldrum’s acid (1.09g, 4.24 mmol) in dry ethanol 
(30 ml) was heated under reflux overnight.  The solvent was evaporated under 
vacuum and residue redissolved in ethyl acetate.  The solution was sequentially 
washed with a saturated solution of sodium bicarbonate, 1 M KHSO4 and 
saturated brine solution.  Drying over MgSO4 and concentration under vacuum 
yielded the β-keto ester as an oil. The product was then purified using column 
chromatography, producing a 63 % yield.  
TLC; Rf = 0.25 (10 % ethyl acetate, hexane). 
1
H NMR (CDCl3) δ 0.77 (3H, t, V = 1.97 Hz, 8-H CH3), 1.16 (7H, m, 
OCH2;#Q, 7-H & 6-H), 1.48 (2H, quintet, V W 14.52 Hz, COCH2;#C), 2.42 
(2H, t, V = 7.28 Hz, 4-H), 3.31 (2H, s, COCH2CO), 4.06 (2H, m, O;#CCH3)
13
C NMR (CDCl3) δ 13.87, 14.10 (2 x CH3), 22.39, 23.15, 43.00, 49.33, 53.41, 
61.33 (6 x CH2), 167.28, 202.99 (2 x 4°)
Ethyl 3-oxododecanoate
!
!!
Yield = 79 %.  
TLC; Rf = 0.29 (10 % ethyl acetate, hexane). 
1
H NMR (CDCl3) δ 0.84 (3H, t, V = 6.87 Hz, 12-H), 1.22 (15H, m, OCH2;#Q
& 11-H to 6-H (CH2)6), 1.82 (2H, m, 5-H), 2.49 (2H, t, V = 7.43 Hz, 4-H), 3.40 
(2H, s, 2-H), 4.13 (2H, m, CO;#CCH3)
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Ethyl 3-anilino-2-octanoate (2.58)
&
"
!@9
!
A solution of aniline (0.354 g, 3.8 mmol), ethyl 3-oxooctanoate (0.92 g, 3.8 
mmol) and toluene-3-sulfonic acid (30 mg) in dry benzene (40 mL) was heated 
under reflux for 24 h using Dean-Stark apparatus for the azeotropic removal of 
water. The solution was filtered to remove the toluene-3-sulfonic acid and 
solvent was removed under vacuum.  The product was yielded as an oil, which 
was used without purification in the next step.
2-Pentyl-4(1H)-quinolone (2.57)
&
"
!
The crude product of ethyl 3-anilino-2-octanoate (1.70 g, 6.5 mmol) was added 
drop wise to refluxing diphenyl ether (10 mL) and heated for 30 min.  The 
solution was cooled to room temperature and then diluted with petroleum ether 
(b.p. 60-80 
o
C; 80 ml) until product began to precipitate out as a fine crystalline 
solid.  The petroleum ether was decanted off and the solid was washed with 
further petroleum ether to remove any residual diphenyl ether.  Product was a 
pale orange, crystalline solid in 50 % yield.  
TLC; Rf = 0.46 (5 % methanol, DCM).  
1
H NMR (CDCl3) δ 0.94 (3H, t, V = 6.56 Hz, 5’-H CH3), 1.34 (4H, m, (CH2)2), 
1.86 (2H, m, 2’-H), 2.87 (2H, t, V W 7.74 Hz, 1’-H), 6.43 (1H, s, 3-H), 7.48 
(1H, m, 8-H), 7.74 (1H, t, V W 7.51 Hz, 5-H), 8.05 (1H, d, V = 8.32 Hz, 7-H), 
8.53 (1H, d, V = 8.04 Hz, 6-H), 13.18 (1H, s, NH)
13
C NMR (CDCl3) δ 13.88 (CH3), 22.34, 28.68, 31.28, 34.29 (4 x CH2), 108.12 
(Ar CH), 118.51, 123.59 (Ar 2 x CH), 124.89 (4°), 125.25, 131.79 (Ar 2 x 
CH), 140.56, 155.20, 178.79 (3 x 4°)
(MS-ES) *01 216.12 (MH
+
, C14H17NO requires *01 216.29)
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2-Nonyl-4-(1H)-quinolone
&
"
!
Yield = 76 %.
TLC; Rf = 0.23 (5 % methanol, DCM).
1
H NMR (CDCl3) δ 0.99 (3H, t, V = 6.67 Hz, 9’-H CH3), 1.32 (12H, m, 
(CH2)6), 1.87 (2H, m, 2’-H), 2.87 (2H, t, V = 7.12 Hz, 1’-H), 6.42 (1H, s, 3-H), 
7.48 (1H, t, V = 7.27 Hz, 6-H), 7.74 (1H, t, V = 7.37 Hz, 8-H), 8.02 (1H, d, V = 
8.17 Hz, 7-H), 8.53 (1H, d, V = 7.93 Hz, 5-H), 13.21 (1H, s, NH)
13
C NMR (CDCl3) δ 14.10 (CH3), 22.65, 24.90, 29.16, 29.27, 29.35, 29.46, 
31.84, 34.40 (8 x CH2) 108.09 (Ar CH), 118.66, 123.55 (Ar 2 x CH), 124.97 
(4°), 125.19, 131.75 (Ar 2 x CH), 140.74, 155.48, 178.90 (3 x 4°) 
3-Formyl-2-pentyl-4(1H) quinolone (2.56)
135
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!
"
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A mixture of 2-pentyl-4(1#)-quinolone (0.2 g, 0.93 mmol) and hexamine 
(0.065 g, 0.465 mmol) in trifluroacetic acid (6 mL) was stirred under nitrogen 
at reflux for 27 h.  Methanol (7.5 mL) and water (7.5 mL) were added and 
heating continued for 1 h.  3 M HCl (3 mL) was added and heating continued 
for 30 min.  The mixture was allowed to cool.  The precipitate formed on 
cooling was filtered under suction and washed with water.  Product was then 
purified using column chromatography.  This method proved unsuccessful in 
producing the required molecule.
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3-Formyl-2-heptyl-4(1H) quinolone
137,138
&
"
!
"
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Method A
A solution of 2-heptyl-4(1#)-quinolone (121.5 mg, 0.5 mmol) and 
dimethylformamide (DMF) (46.05 mg, 0.63 mmol) in 1,2-dichloroethane (10 
mL) was cooled to 0 
o
C. Phosphorus oxychloride (92.98 mg, 0.626 mmol) was 
added slowly with stirring. The mixture was then heated under reflux for 2 h. 
The solution was cooled, poured over crushed ice and neutralized with sodium 
acetate. The organic layer was separated and the aqueous layer extracted with 
ether. The organic phases were combined and washed with sodium hydrogen 
carbonate and dried over magnesium sulphate.  The solvent was removed under 
vacuum to yield the product as a brown liquid. TLC; Rf = 0.76 (5 % methanol, 
DCM)
1
H NMR (CDCl3) δ 0.79 (3H, t, V = 6.32 Hz, 7’-H CH3), 1.25 – 1.53 (8H, m, 
(CH2)4), 1.66 – 1.77 (2H, m, 2’-H), 2.85 (2H, t, V = 7.72 Hz, 1’-H), 7.31 (1H, s, 
3-H), 7.37 – 7.48 (1H, m, 7-H), 7.51 – 7.67 (1H, m, 6-H), 7.97 (1H, d, V = 
8.419 Hz, 8-H), 8.08 (1H, d, V = 8.40 Hz, 5-H), 8.26 (1H, s, NH) 
(MS-ES) *01 261.98 & 263.91 (MH
+
, C17H21NO2 requires 272.16)
Method B
DMF (0.88 mmol) was cooled in an ice-salt bath and phosphorus oxychloride 
(0.22 mmol) was added with stirring over a period of approximately 30 min.  
To this a solution of 2-heptyl-4(1#)-quinolone (0.2 mmol) in DMF (0.3 mmol) 
was added over the period of about 1 h, ensuring that the temperature did not 
rise above 10
o
C.  This viscous solution was brought to 35 
o
C and was stirred 
for 1 h.  Crushed ice is then added to the vessel, producing an aqueous solution.  
The solution was transferred to a flask containing crushed ice and to this was 
added an aqueous solution of sodium hydroxide with stirring.  The solution 
was rapidly brought to its boiling point and allowed to cool to room 
temperature, after which it was placed in a refrigerator overnight.  The aqueous 
phase was washed with ether and the solvent removed to yield a yellow oil.  
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Despite a difference in colour this was shown to be the same product as 
produced by first method attempted for the Vilsmeier by 
1
H NMR and TLC.  
TLC; Rf = 0.76 (5 % methanol, DCM)
Ethyl-2-(ethoxymethylene)-3-oxobutanoate (2.87)
!
!
!
!
Ethyl acetoacetate (26.03 g, 0.2 mol), triethyl orthoformate (44.46 g, 0.3 mL) 
and acetic anhydride (60 mL) were mixed together and heated to 140 
o
C. The 
ethyl acetate formed during the reaction was distilled off and the reaction is 
stopped whenever no more ethyl acetate is produced. The product was then 
collected as a straw coloured oil using vacuum distillation, in a 72 % yield 
(26.76 g)
1
H NMR (CDCl3) δ 1.27 – 1.43 (6H, m, 2 x COOCH2;#Q), 2.35 (3H, apparent 
doublet, COCH3), 4.18 – 4.34 (4H, m, 2 x COO;#CCH3), 7.66 (1H, apparent 
doublet, CH)
Arylaminomethylenemalonate (2.88)
&
"
!
!
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Ethyl-2-(ethoxymethylene)-3-oxobutanoate (11.20 g, 60 mmol) was added neat 
to aniline (5.20 g, 60 mmol), causing the evolution of heat. This was fitted with 
an air condenser heated at 130 
o
C for 6 hr. This was allowed to cool to room 
temperature and then further cooled to 0 °C, causing formation of the product, 
as an orange solid, in a 95 % yield (13.38 g).
TLC; Rf = 0.56 (50 % ethyl acetate, hexane).
1
H NMR (CDCl3) δ 1.37 (3H, t, V = 7.12 Hz, COCH2;#Q), 2.58 (3H, s, 
COCH3), 4.29 (2H, q, J = 7.121 Hz, CO;#CCH3), 7.17 – 7.29 (3H, m, Ar), 
7.40 – 7.45 (2H, m, Ar), 8.54 (1H, apparent doublet, CH), 12.79 (1H, apparent 
doublet, NH)
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3-Acetyl-4(1H)-quinolone (2.89)
&
"
! !
Method A
Methanolic sodium methoxide was prepared from sodium (0.29 g) and 
methanol (20 mL). Methyl 2-(3-oxobut-1-enylamino)benzoate (0.548 g, 2.5 
mmol) was added and heated at reflux for 10 min. Following this the reaction 
mixture was poured into cold water (70 mL) and washed with dichloromethane 
(3 x 20 mL)
140
. The aqueous layer was then acidified causing the formation of 
a yellow precipitate. A suitable product was not able to be recovered from this.
Method B
Methyl 2-(3-oxobut-1-enylamino)benzoate (0.377 g, 1.7 mmol) was added to a 
suspension of sodium hydride (0.0413 g, 1.7 mmol) in dimethylformamide, an 
air condenser was fitted, and this was heated at 70 
o
C for 2h. DMF was 
removed and water was added and acidified with 2M HCl and extracted with 
ethyl acetate (2 x 20 mL). On removal of solvent a brown oil was left.
Method C
The arylaminomethylenemalonate 2.88 (1.123 g, 4.8 mmol) was added to 
boiling diphenyl ether (15 mL) and this was heated at reflux for 30 min. The 
solution was allowed to cool and petroleum ether (60 – 80
o
C) added to 
precipitate crude product. This was further washed with petroleum ether (3 x 
50 mL) producing the product as a beige solid in a 54 % yield (0.491 g)
1
H NMR (CDCl3) δ 2.62 (3H, s, COCH3), 7.43 – 7.47 (1H, m, 6-H), 7.63 (1H, 
dd, V = 0.38 & 8.20 Hz, 8-H), 7.71 – 7.75 (1H, m, 7-H), 8.24 (1H, dd, V = 1.17 
& 8.09 Hz, 5-H), 8.52 (1H, s, 2-H), 12.52 (1H,br s, NH)
13
C NMR (CDCl3) δ 36.24 (CH3), 123.02 (4°), 123.40, 129.70, 131.07 (3 x 
aromatic CH), 133.20 (4°), 137.05, 144.02 (2 x CH), 148.78, 181.27, 202.58 (3 
x 4°)
(MS-ES) *01 188.07 (MH
+
, C11H9NO2 requires *01 188.06)
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But-3-yn-2-one (2.97)
!
A solution of CrO3 (10.1 g) in H2SO4/H2O was added slowly over 30 min to a 
stirring solution of  butyn-2-ol (5 ml, 68 mmol) in sulphuric acid/water (5.4 ml/ 
18 ml) at 0
o
C. The solution was stirred for 4 h, ensuring that the temperature 
did not rise above 10 
o
C, then dichloromethane (25 mL) added. The reaction 
mixture was washed with saturated sodium bicarbonate solution extracted with 
dichloromethane (2 x 20 mL) and dried over magnesium sulphate. The 
dichloromethane was distilled off, to leave the product as a clear, colourless 
solution.
1
H NMR (CDCl3) δ 2.41 (3H, s, CH3), 5.73 (1H, s, CH)
IR 1687 (C=O), 2097 (C≡O), 3287 (CH) cm
-1
Methyl 2-(3-oxobut-1-enylamino)benzoate (2.99)
141
&
"
!!#$
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Methyl anthranilate (5.14 g, 34 mmol) and 3-butyn-2-one (2.31 g, 34 mmol) 
were dissolved in methanol, ensuring that the temperature did not rise above 20 
o
C. The solution was allowed to warm to room temperature and left to stand in 
a tightly stoppered flask for 20 h. Water was added dropwise following this 
time, forming an immiscible, brown liquid. When this brown layer was dried 
the product was formed as a crystalline solid in a10 % yield (0.775 g). 
1
H NMR (CDCl3) δ 2.22 (3H, s, CO;#Q), 4.02 (3H, s, COO;#Q), 5.40 (1H, d, 
V = 8.12 Hz, CO;#CHNH), 13.0913 (1H, br d, V = 10.80 Hz, NH)
13
C NMR (CDCl3) δ 29.8 (CH3), 52.31 (COO;#Q), 100.08 (CH), 113.59 
(Aromatic), 115.72 (4°), 121.45, 132.117, 134.17 (3 x aromatic), 139.65 
(NH;#CH), 142.81 (4°), 167.02 (;OOCH3), 198.41 (CO)
(MS-ES) *01 219.98 (MH
+
, C12H13NO3 requires *01 220.09)
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Methyl 2-heptyl-1,4-dihydro-4-oxo-3-carboxylate (2.107)
&
"
!
!
!
Ethyl 3-oxodecanoate (1.13 g, 5 mmol) was added to a suspension of sodium 
hydride (0.12 g, 5mmol) in dry DMF (20 mL), causing the liberation of 
hydrogen gas. To this a solution of isatoic anhydride (0.816 g, 5 mmol) in dry 
DMF was added drop wise and stirred under nitrogen overnight. After this, the 
solvent was removed under vacuum and the remaining solvent triturated with 
1M HCl, yielding the product as a white solid.
Mp. 170 – 171 °C
IR 1725 (Ester C=O), 3272 (NH) cm
-1
1
H NMR (DMSO) δ 0.86 (3H, t, V = 6.98 Hz, 7’-H), 1.25 – 1.31 (8H, m, 
(CH2)4), 1.65 (2H, quintet, V = 7.63 Hz, 2’-H), 2.62 (2H, t, V = 7.99 Hz, 1’-H), 
3.35 (3H, s, COO;#Q), 7.33 – 7.37 (1H, m, 6-H), 7.57 (1H, d br, V = 7.57 Hz, 
8-H), 7.66 – 7.70 (1H, m, 7-H), 8.05 (1H, dd, V = 1.22 & 8.08 Hz, 5-H), 11.80 
(1H, s br, NH)
13
C NMR (DMSO) δ 14.40 (CH3), 22.49, 28.70, 29.09, 29.33, 31.52, 32.36 (6 x 
CH2), 52.20 (COO;#Q), 114.90 (4°), 118.90, 124.18 (2 x aromatic CH), 
124.92 (4°), 125.42, 132.74 (2 x aromatic CH), 139.74, 153.02, 167.89, 174.10 
(4 x 4°)
(MS-ES) *01 302.18 (MH
+
, C18H23NO3 requires *01 302.17)
Anal. calcd. for C18H23ON: C, 71.73; H, 7.69; N, 4.65. Found: C, 70.46; H, 
7.36; N, 4.65.
Ethyl 1,4-dihydro-2-methyl-4-oxoquinoline-3-carboxylate (2.104)
&
"
!
!
!
1
H NMR (CDCl3) δ 1.27 (3H, t, V W 7.09 Hz, COCH2;#Q), 2.39 (3H, s, 
CO;#Q), 4.23 (2H, q, V = 7.15 Hz, CO;#CCH3), 7.33 (1H, td, V = 0.88 & 7.91
165
Hz, Ar), 7.54 (1H, br d, V = 8.33 Hz, Ar), 8.05 (1H, dd, V = 1.23 & 8.06 Hz, 5-
H)
13
C NMR (CDCl3) δ 14.69 (COOCH2;#Q), 21.22 (CH3), 60.09 
(COO;#CCH3), 113.88 (4°), 122.06, 122.65, 125.19 (3 x aromatic CH), 126.09 
(4°), 130.92 (aromatic CH), 168.94, 173.39 (2 x 4°)
(MS-ES) *01 232.11 (MH
+
, C13H13NO3 requires *01 232.09)
2-Heptyl-1,4-dihydro-4-oxo-3-carboxylic acid (2.109)
&
"
!
!"
!
Method A
2-Heptyl-4(1H)-quinolone-3-methyl ester (0.09 g, 3 mmol) was dissolved in 
hot methanol (12 mL), to this 1 M sodium hydroxide (3 mL) was added and 
heated overnight. Removal of some of the solvent caused the precipitation of a 
white solid, which was showed to be starting material by NMR.
Method B
2-Heptyl-4(1H)-quinolone-3-methyl ester was heated at reflux overnight in 2 M
HCl. After the reaction mixture had cooled, the precipitate was collected under 
suction and dried over silica.
TLC; Rf = 0.54 (5 % methanol, DCM)
1
H NMR (DMSO) δ 0.86 (3H, t, V = 6.95 Hz, (CH2)6;#Q), 1.26 – 1.41 (8H, m, 
(CH2)4), 1.66 (2H, m, 2’-H), 2.63 (2H, t, V = 7.63 Hz, 1’-H), 7.57 (1H, m, 6-
H), 7.78 (1H, br d, V = 8.04 Hz, 8-H),  7.88 (1H, m, 7-H), 8.25 (1H, dd, V = 
1.29 & 8.17 Hz, 5-H), 13.04 (1H, s, NH)
13
C NMR (DMSO) δ 14.40 (CH3), 22.52, 28.84, 29.60, 29.75, 31.61, 33.91 (6 
x CH2), 106.17 (4°), 119.22 (Ar CH), 123.42 (4°), 125.60, 126.30, 134.44 (3 x 
Ar CH), 138.62, 162.92, 166.76, 179.52 (3 x 4°)
(MS-ES) *01 286.14 (MH
-
, C17H21NO3 requires *01 286.15)
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5-Chloro-5-Hexanoyl Meldrum’s acid (2.126) 
147
!
!
!
!
!
'(
5-hexanoyl meldrum’s acid (0.750 g, 3.1 mmol) was heated at reflux in excess 
sulfuryl chloride (15 mL) for 2 h.  The sulfuryl chloride was removed under 
vacuum to yield the product as a pale yellow oil.
1
H NMR (CDCl3) δ 0.92 (3H, t, V = 6.80 Hz, (CH2)5;#Q), 1.35 (4H, m, 
(CH2)2), 1.67 (2H, m, ;#CCH2CO), 1.85, 1.90 (6H, 2 x s, 2 x CH3), 2.96 (2H, 
t, V = 7.20 Hz, CH2;#CCO)
Methyl 2-chloro-3-oxodecanoate (2.128)
!
!!
'(
Sulfuryl chloride (0.615 mL) was added neat to methyl 3-oxodecanoate (1.5 g, 
7.5 mmol) at 0 °C. This was then stirred at room temperature overnight. On 
removal of solvent the product was afforded as a yellow oil in a 95 % yield 
(1.68 g)
Yield: 95 %
Rf – 0.75 EtOAc/hexane 50/50
13
C NMR (CDCl3) δ 14.07 (CH3), 22.59, 23.48, 28.83, 28.95, 31.62, 38.99 (6 x 
CH2), 53.73 (COO;#Q), 60.74 (CO;(Cl)CO), 165.63(;OOCH3), 199.07 
(;OC(Cl))
Methyl 2-chloro-3-oxododecanoate
!
!!
'(
1
H NMR (CDCl3) δ 0.90 (3H, t, V = 6.6 Hz, CH3), 1.28 – 1.32 (12H, m, 
(CH2)6), 1.62 – 1.72 (2H, m, 5-H), 2.85 (2H, t, V = 7.20 Hz, 4-H), 3.94 (1H, s, 
2-H)
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1-Chlorononan-2-one (2.131)
'(
!
Method A
5-chloro-5-octanoyl-Meldrum’s acid was heated at reflux in water for 2 h. 
Following this, there was extraction of the reaction mixture with ethyl 
acetate
147
. This method proved unsuccessful in producing the product in 
desired quality
Method B
Methyl 2-chloro-3-oxodecanoate (1.06 g, 6 mmol) was heated at reflux in a 
mixture of concentrated sulphuric acid (10 mL) and water (10 mL) for 2 h. The 
reaction mixture was extracted with dichloromethane and solvent removed 
under vacuum. This yielded the product as a yellow oil that was used without 
purification in the next step.
1
H NMR (CDCl3) δ 0.90 (3H, t, V = 6.74 Hz, CH3), 1.30 – 1.33 (8H, m, 
(CH2)4), 1.60 – 1.67 (2H, m, 4-H), 2.60 (2H, t, V = 7.36 Hz, 3-H), 4.01 (2H, s, 
2-H)
1-Chloroheptan-2-one (2.130)
'(
!
1
H NMR (CDCl3) δ 0.95 (3H, t, V = 6.81 Hz, CH3), 1.30 – 1.40 (4H, m, 
(CH2)2), 1.63 – 1.75 (2H, m, 4-H), 2.83 (2H, t, V = 7.43 Hz, 3-H), 4.38 (2H, s, 
2-H)
1-Chloroundecan-2-one (2.132)
'(
!
1
H NMR (CDCl3) δ 0.90 (3H, t, V = 6.60 Hz, CH3), 1.28 – 1.32 (12H, m, 
(CH2)6), 1.64 – 1.71 (2H, m, 4-H), 2.85 (2H, t, V = 7.27 Hz, 3-H), 3.94 (2H, s, 
2-H)
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2-Oxopropyl 2-aminobenzoate (2.112)
132
!
!
!
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To a solution of anthranilic acid (1.646 g, 12 mmol) in DMF (40 mL) was 
added potassium carbonate (1.176 g, 8.6 mmol) and this heated at 90 °C, with 
stirring for 1 h. After this time the solution was cooled to 20 °C, chloroacetone 
(0.924 g, 10 mmol) added, stirred at room temperature for 30 min and then at 
50 °C for 30 min. The mixture was poured into iced water (approx. 100 mL), 
forming the product as a yellow solid (1.17 g, 61 %)
Mp. 77 – 78 °C
1
H NMR (CDCl3) δ 2.26 (3H, s, CO;#Q), 4.85 (2H, s, COO;#CCO), 5.72 (2H, 
s br, NH2), 6.67 – 6.71 (2H, m, 4-H and 6-H), 7.28 – 7.34 (1H, m, 5-H), 7.96 
(1H, dd, V = 1.73 & 8.35 Hz, 3-H)
13
C NMR (CDCl3) δ 26.28 (COOCH2CO;#Q), 68.33 (COO;#CCOCH3), 
109.66 (4°), 116.43, 116.74, 134.69 (3 x aromatic) 150.83(4°), 
167.19(COOCH2COCH3), 202.56(COOCH2;OCH3) 
(MS-ES) *01 194.03 (MH
+
, C10H11NO3 requires *01 194.07)
2-Oxononyl-2-aminobenzoate (2.136)
!
!
!
&")
Mp. 59 °C
Yield – 75 %
Rf – 0.65 EtOAc/hexane 50/50
1
H NMR (CDCl3) δ 0.90 (3H, t, V = 6.74 Hz, CH3), 1.25 – 1.34 (8H, m, 
(CH2)4), 1.62 – 1.70 (2H, m, COCH2;#C), 2.52 (2H, t, V = 7.49 Hz, 
CO;#CCH2), 4.85 (2H, s, COO;#CCO), 5.71 (2H, s br, NH2), 6.67 – 6.71 (2H, 
m, 4-H & 6-H), 7.29 – 7.34 (1H, m, 5-H), 7.96 (1H, dd, V = 1.71 & 8.33 Hz, 3-
H)
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13
C NMR (CDCl3) δ 14.08 (CH3), 22.60, 23.31, 29.03, 29.14, 31.68, 38.93 (6 x 
CH2), 67.98 (COO;#CCO), 109.81, 115.65 (2 x 4°), 116.41, 116.72, 131.41, 
134.61 (4 x aromatic CH), 150.77 (4°), 167.20 (;OOCH2CO), 204.86 
(COOCH2;O)
(MS-ES) *01 278.17 (MH
+
, C16H23NO3 requires *01 278.17)
2-Oxoheptyl-2-aminobenzoate (2.135)
!
!
!
&")
TLC; Rf = 0.61 (50 % ethyl acetate, hexane)
1
H NMR (CDCl3) δ 0.92 (3H, t, V = 6.86 Hz, CH3), 1.34 (4H, m, (CH2)2), 1.67 
(2H, m, COCH2;#C), 2.52 (2H, t, V = 7.34 Hz, CO;#CCH2), 4.85 (2H, s, 
COO;#CCO), 5.74 (2H, br s, NH2), 6.69 (2H, m, Ar), 7.32 (1H, m, Ar), 7.96 
(1H, dd, V = 1.62 & 8.32 Hz, 3-H)
13
C NMR (CDCl3) δ 13.92 (CH3), 22.44, 22.98, 31.34, 38.89 (6 x CH2), 67.99 
(COO;#CCO), 109.08 (4°), 116.41, 116.73, 131.41, 134.62 (4 x aromatic CH), 
150.77 (4°), 167.21, 204.87 (2 x CO)
(MS-ES) *01 249.82 (MH
+
, C14H17NO2 requires *01 250.14)
2-Oxononyl-2-amino-5-chlorobenzoate (2.137)
!
!
!
&")
'(
Mp. 91-93 °C
Yield – 69.7 %
TLC; Rf = 0.64 (50 % ethyl acetate, hexane)
1
H NMR (CDCl3) δ 0.89 (3H, t, V = 7.01 Hz, (CH2)6;#Q), 1.29 – 1.32 (8H, m, 
(CH2)4), 1.65 (2H, m, ;#CCH2CO), 2.50 (2H, t, V = 7.47 Hz, CH2;#CCO), 
4.86 (2H, s, COO;#CCO), 5.74 (2H, s br, NH2), 7.25 (1H, dd, V = 2.55 & 8.82 
Hz, 5-H), 7.92 (1H, d, V = 2.53 Hz, 6-H), 7.96 (1H, br d, V = 2.52 Hz, 3-H)
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13
C NMR (CDCl3) δ 14.08 (CH3), 22.60, 23.35, 29.02, 29.13, 31.63, 38.89 (6 x 
CH2), 68.10 (COO;#CCO), 110.54 (4°), 118.11 (Ar CH), 120.82 (4°), 130.55, 
134.62 (Ar CH), 149.27, 166.26, 204.26 (3 x 4°)
(MS-ES) *01 312.13 & 314.13 (MH
+
, C16H22NO3 requires *01 312.13 & 
314.13)
2-Oxononyl-2-(methylamino)benzoate (2.138)
!
!
!
&"
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Mp. 39 – 41 °C
Yield – 27.7 %
TLC; Rf = 0.7 (50 % ethyl acetate, hexane)
1
H NMR (CDCl3) δ 0.89 (3H, t, V = 7.00 Hz, (CH2)6;#Q), 1.29 – 1.31 (8H, m, 
(CH2)4), 1.65 (2H, m, ;#CCH2CO), 2.51 (2H, t, V = 7.38 Hz, CH2;#CCO), 
2.51 (2H, t, V = 7.38 Hz, CH2;#CCO), 2.93 (3H, d, V = 5.04 Hz, NH;#Q), 4.82 
(2H, s, COO;#CCO), 6.62 – 6.66 (1H, m, 4-H), 6.70 (1H, d, V = 8.3 Hz, 6-H), 
7.41 – 7.45 (1H, m, 5-H), 7.55 (1H, s br, !#CH3), 8.00 (1H, dd, V = 1.59 & 
8.03 Hz, 3-H)
13
C NMR (CDCl3) δ 14.08 (CH3), 22.61, 23.30, 29.04 (3 x CH2), 29.14 
(NH;#Q), 29.57, 31.64, 38.91 (3 x CH2), 67.96 (COO;#CCO), 108.85 (4°), 
110.82, 114.48, 131.78, 135.18 (3x aromatic CH), 152.29, 167.72, 205.06 (3 x 
4°)
(MS-ES) *01 292.19 (MH
+
, C17H25NO3 requires *01 292.18)
2-Oxononyl-2-aminopyridine-3-carboxylate (2.139)
&
!
!
!
&")
Mp. 82 – 83 °C
Yield – 49.7 %
TLC; Rf = 0.45 (50 % ethyl acetate, hexane)
171
1
H NMR (CDCl3): δ 0.89 (3H, t, V = 7.03, (CH2)6;#Q), 1.29 – 1.31 (8H, m, 
(CH2)4), 1.66 (2H, m, ;#CCH2CO), 2.50 (2H, t, V = 7.38 Hz, CH2;#CCO), 
4.88 (2H, s, COO;#CCO), 6.67 (1H, dd, V = 4.76 & 7.80 Hz, 5-H), 8.24 (1H, 
dd, V = 1.8 & 7.82 Hz, 4-H), 8.27 (1H, m, 3-H)
13
C NMR (CDCl3) δ 14.08 (CH3), 22.60, 23.34, 29.02, 29.12, 31.62, 38.90 (6 x 
CH2), 68.17 (COO;#CCO), 105.43 (aromatic CH), 112.87 (4°), 140.46, 154.16 
(2 x aromatic CH), 159.52, 166.15, 203.99 (3 x 4°)
(MS-ES) *01 279.16 (MH
+
, C15H22N2O3 requires 279.16)
3-(Ethoxycarbonyl)-2-oxopropyl-2-aminobenzoate (2.122)
!
!
!
&")
!
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Yield – 31 %
1
H NMR (CDCl3) δ 1.29 (3H, t, V = 7.14 Hz, COCH2;#Q), 3.60 (2H, s, 
CO;#CCO), 4.22 (2H, q, V = 7.13 Hz, CO;#CCH3), 4.97 (2H, s, 
COO;#CCO), 5.72 (2H, s br, NH2), 6.67 – 6.71 (2H, m, 4-H & 6-H), 7.30 –
7.34 (1H, m, 5-H), 7.93 (1H, dd, V = 1.69 & 8.46 Hz, 3-H)
13
C NMR (CDCl3) δ 14.04 (CH3), 46.22, 61.73, 67.81 (3 x CH2), 116.43, 
116.74, 131.31, 134.81 (3 x Ar CH), 150.92, 166.98, 167.50, 197.54, 206.00 (5 
x 4°)
Diethyl 2,5-dioxocyclohexane-1,4-dicarboxylate (2.123)
! !
!
!
!
!
1
H NMR (CDCl3) δ 1.34 (6H, t, V = 7.13 Hz, 2 x COOCH2;#Q), 3.21 (4H, s, 2 
x CH2), 4.27 (4H, q, V = 7.14 Hz, 2 x COO;#CCH3), 12.22 (2H, s, 2 x CH)
13
C NMR (CDCl3) δ 14.23 (2 x COOCH2;#Q), 28.54 (2 x CH2), 60.73 (2 x 
CH), 93.26 (2 x COO;#CCH3), 168.45, 171.30 (4 x 4°)
(MS-ES) *01 255.08 (MH
-
, C12H16O6 requires *01 255.25)
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2-Methyl-3-hydroxy-4(1H)-quinolone (2.141)
132
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A solution of anthranilate (0.386 g, 2 mmol) in 1-methyl-2-pyrrolidinone 
(NMP) (2mL) was heated at reflux for 10 min. The reaction was then cooled, 
ethyl acetate (8 mL) added and stirred at 0 °C for 30 min. The product formed 
as a beige precipitate and was collected by filtration in a 73 % yield (0.255 g)
Mp. 296 – 299 °C (decomp)
TLC; Rf = 0.19 (5 % methanol, DCM)
IR (KBr) 1639 (C=O), 2920 (NH), 3252 (OH) cm
-1
1
H NMR (DMSO) δ 2.37 (3H, s, CH3), 7.22 (1H, m, 6-H), 7.50 – 7.56 (2H, m, 
7-H & 8-H), 8.10 (1H, dd, V = 1.00 & 8.25 Hz, 5-H), 11.53 (1H, s, NH)
13
C NMR (DMSO) δ 14.52 (CH3), 118.08, 121.96 (2 x aromatic CH), 122.77 
(4°), 124.99, 130.43 (2 x aromatic CH), 132.12, 137.73, 138.55 (4°), 169.08 
(CO)
(MS-ES) *01 176.08 (MH
+
, C10H9NO2 requires *01 176.06)
2-n-heptyl-3-hydroxy-4(1H)-quinolone (PQS) (2.143)
&
"
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Yield – 59 %
(MS-ES) *01 260.15 (MH
+
, C16H21NO2 requires *01 260.16
1
H NMR (DMSO) δ 0.84 (3H, t, V = 6.99 Hz, (CH2)6;#Q), 1.23 – 1.33 (8H, m, 
(CH2)4), 1.67 (2H, m, 2’-H), 2.73 (2H, t, V = 7.85 Hz, 1’-H), 7.22, (1H, m, Ar), 
7.53 (2H, m, Ar), 8.09 (1H, d,  V = 8.12 Hz, Ar) 11.43 (1H, br s, NH)
13
C NMR (DMSO) δ 14.39 (CH3), 22.53, 28.29, 28.59, 8.95, 29.25, 31.64 (6 x 
CH2), 118.27, 121.99 (2 x aromatic CH) 122.65 (4°), 124.97, 130.36 (2 x 
aromatic CH), 135.99, 137.81, 138.31 (3 x 4°), 169.28 (CO)
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6-Chloro-2-heptyl-3-hydroxy-4(1H)-quinolone (2.144)
&
"
!
!"'(
Mp. 250 – 252 °C
Yield – 47 %
TLC; Rf = 0.59 (5 % methanol, DCM)
1
H NMR (DMSO) δ 0.84 (3H, t, V = 6.93 Hz, 7’-H), 1.28 (8H, m, 3’-H – 6’-H), 
1.64 (2H, m, 2’-H), 2.72 (2H, t, V = 7.87 Hz, 1’-H), 7.56 (2H, m, 7-H & 8-H), 
8.03 (1H, br d, V = 2.04 Hz, 5-H), 11.64 (1H, s, NH)
13
C NMR (DMSO) δ 14.40 (CH3), 22.52, 28.21, 28.62, 28.92, 29.24, 31.64 (6 x 
CH2) 120.73, 123.63 (4°) 123.66 (Ar CH), 126.64 (4°) 130.55 (Ar CH), 
136.21, 136.81, 138.74 (3 x 4°), 168.19 (CO)
(MS-ES) *01 292.11 & 294.11 (MH
-
, C16H20ClNO2 requires 292.12 & 294.12)
2-n-Pentyl-3-hydroxy-4(1H)-quinolone (2.142)
&
"
!
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Mp. 214 – 216 °C
TLC; Rf = 0.37 (5 % methanol, DCM)
1
H NMR (DMSO) δ 0.87 (3H, t, V = 4.79 Hz, 5’-H), 1.33 (4H, m, 3’-H & 4’-
H), 1.68 (2H, m, 2’-H), 2.73 (2H, t, V = 7.55 Hz, 1’-H), 7.22 (1H, m, 7-H), 7.53 
(2H, m, 6-H & 8-H), 8.10 (1H, br d, V = 8.11 Hz, 5-H), 11.44 (1H, s, NH)
13
C NMR (DMSO) δ 14.36 (CH3), 22.36, 27.95, 28.53, 31.47 (CH2), 118.23, 
121.97 (Ar CH), 122.67 (4°), 124.95, 130.44 (Ar CH), 135.99, 137.82, 138.31 
(3 x 4°) 169.33 (CO)
(MS-ES) *01 230.11 (MH
-
, C14H17NO2 requires *01 230.13)
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2-Heptyl-3-hydroxy-1-methyl-4(1H)-quinolone (2.145)
&
!
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2-Oxononyl-2-(methylamino)benzoate (1.455 g, 0.5 mmol) was dissolved in 
NMP (0.4 mL) and heated at reflux for 1 h 15 min. This was cooled to room 
temperature and ethyl acetate added. This was placed in an ice bath and stirred 
for 30 min. Ethyl acetate and as much of NMP as possible was removed under 
vacuum. Ethyl acetate (0.2 mL) was added and the solution chilled in a fridge, 
forming the product as off-white crystals in a 28 % yield.
Mp. 106 – 107 °C
1
H NMR (DMSO) δ 0.86 (3H, t, V = 6.78 Hz, 7’-H), 1.34 (8H, m, 3’-H – 6’-H), 
1.57 (2H, m, 2’-H), 2.97 (2H, t, V = 7.78 Hz, 1’-H), 3.82 (3H, s, N;#Q), 7.32 
(1H, m, 7-H), 7.66 (1H, m, 6-H), 7.78 (1H, br d, V = 8.80 Hz, Ar), 8.23 (1H, 
dd, V = 1.49 & 8.10 Hz, 5-H)
13
C 14.44 (CH3), 22.55, 26.88, 28.13, 28.93, 29.40, 31.70 (6 x CH2), 35.00 
(NCH3), 117.08, 122.30 (2 x Ar CH), 123.51 (4°), 125.49, 131.17 (2 x aromatic 
CH), 138.63, 139.12, 139.25 (3 x 4°), 168.43 (C=O)
(MS-ES) *01 259.14 (MH
-
, C15H20N2O2 requires *01 259.33)
6.4 Chapter 3
N-Octanoyl Anthranilic Acid (3.69)
&
"
!
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Method A
A solution of anthranilic acid (0.6857g, 5 mmol) in pyridine (50 mL) was well 
stirred and cooled to 0 
o
C in an ice-salt bath.  A solution of octanoyl chloride 
(0.895g, 5.5 mmol) in pyridine was added drop wise and the solution was 
stirred for 2 h.  Pyridine was removed under vacuum leaving a mixture of solid 
175
and liquid. This was triturated with a mixture of ethyl acetate/ether, giving 
pyridine hydrochloride as a solid, which was removed by filtration.  The filtrate 
was washed with 2M HCl and saturated brine solution, then dried over MgSO4.  
Removal of solvent produced an orange syrup that was unsuitable for further 
work.
Method B
Anthranilic acid (6.875g, 50 mmol) was added to a solution of sodium 
hydroxide (2 g, 50 mmol) in water and was well stirred at 0 
o
C.  To this 
octanoyl chloride (8.95 g, 55 mmol) and sodium hydroxide solution (2 g, 50 
mmol) were added drop wise over 30 min, with stirring.  The solution was 
stirred for 30 min, removed from the ice bath and stirred for a further 30 min.  
A precipitate formed during this time.  Ethyl acetate was added to the flask and 
the solution was acidified with conc. HCl, with stirring, until the aqueous layer 
appeared clear. The aqueous layer was removed.  The organic layer was dried 
over MgSO4 and solvent removed to yield a waxy solid.  This was triturated 
with petroleum ether (b.p. 60-80 
o
C), yielding a crystalline solid, in 66 % yield, 
which was collected under suction and dried in a dessicator, under vacuum.  
Product is a beige, crystalline solid
Mpt = 91 – 92 
o
C
TLC; Rf = 0.68 (50 % ethyl acetate, hexane). 
IR (KBr) 1673 (amide C=O), 1692 (amide C=O), 3334 (NH2) cm
-1
1
H NMR (CDCl3) δ 1.01 (3H, t, V = 1.70 Hz, 8’-H CH3), 1.44 (8H, q, V = 6.64
Hz, (CH2)4), 1.83 (2H, m, 3’-H), 2.54 (2H, m, 2’-H CO;#C), 7.24 (1H, m, 4-
H), 7.72 (1H, m, 6-H), 8.25 (1H, dd,  V = 1.54 & 8.02 Hz, 5-H), 8.88 (1H, dd, V
= 0.74 & 8.49 Hz, 3-H), 10.91 (1H, s, COOH), 11.05 (1H, s, NH)
13
C NMR (CDCl3) δ 14.08 (CH3), 22.63, 25.56, 29.02, 29.16, 31.67, 38.74 (6 x 
CH2), 114.05 (4°), 120.60, 122.64, 131.74, 135.58 (4 x Ar CH), 142.07, 
172.10, 172.86 (3 x 4°)
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N-Hexanoyl Anthranilic Acid (3.74)
&
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Yield: 70 %
TLC; Rf = 0.31 (50 % ethyl acetate, hexane)
1
H NMR (CDCl3): δ 0.95 (3H, t, V = 2.25 Hz, CH3), 1.36 – 1.45 (4H, m, 
(CH2)2), 1.76 – 1.83 (2H, m, COCH2;#C), 2.50 (2H, t, V = 7.46 Hz, 
COCH2CH2), 6.69 – 6.73 (1H, m, Ar H), 7.13 – 7.17  (1H, m, Ar H), 7.61 –
7.65 (1H, m, Ar H), 8.80 (1H, dd, V = 0.88 & 8.53 Hz, Ar H), 10.97 (1H, br s, 
NH)
4-Chloro-N-Octanoyl Anthranilic Acid (3.77)
&
"
!
'!!"'(
Yield: 68 %
TLC; Rf = 0.28 (50 % ethyl acetate, hexane)
1
H NMR (CDCl3): δ 0.90 (3H, t, V = 6.44 Hz, CH3), 1.31 – 1.41 (8H, m, 
(CH2)4), 1.74 – 1.86 (2H, m, COCH2;#C), 2.52 (2H, t, V = 7.42 Hz, 
CO;#CCH2), 7.58 (1H, dd, V = 2.63 & 9.08 Hz, 5-H), 8.12 (1H, d, V = 2.60 Hz, 
3-H), 8.77 (1H, dd, V = 3.44 & 9.09, 6-H), 11.06 (1H, s, NH)
13
C NMR (CDCl3) δ 14.11 (CH3), 22.67, 25.45, 29.35, 29.42, 31.87, 38.67 (6 x 
CH2), 118.27 (4°), 121.98 (aromatic CH), 127.59 (4°), 131.18, 135.35 (2 x 
aromatic CH), 140.67, 171.08, 172.64 (3 x 4°)
(MS-ES) *01 295.74 & 297.64 (MH
-
, C15H20ClNO3 requires 297.78)
4-Chloro-N-hexanoyl anthranilic acid (3.76)
&
"
!
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Yield: 63 %
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1
H NMR (CDCl3) δ 0.92 (3H, t, ), 1.13 – 1.18 (4H, m, (CH2)2), 1.51 – 1.55 
(2H, m, COCH2;#C), 2.21(2H, t, V = 7.45, CO;#CCH2), 7.25 (1H, dd, V = 2.63 
& 9.05 Hz, 5-H), 7.83 (1H, d, V = 2.60 Hz, 6-H), 8.50 (1H, d, V = 9.05 Hz, 5-
H), 11.11 (1H, br s, NH)
13
C NMR (CDCl3) δ 13.80 (CH3), 22.19, 24.92, 31.11, 38.37 (4 x CH2), 117.89 
(4°), 119.52 (aromatic CH), 130.67 (4°), 130.74, 133.49 (2 x aromatic CH), 
140.30, 149.49, 169.13 (3 x 4°)
2-n-Heptyl-benzo [d] [1,3]-oxazin-4-one (3.79)
&
!
!
Method A
A solution of n-octanoyl anthranilic acid (1 g, 3.8 mmol) in thionyl chloride 
(20 mL) was heated under reflux for 2 h.  Thionyl chloride was removed under 
vacuum yielding a viscous, brown oil that was unsatisfactory to take on in the 
synthesis.
Method B
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A solution of !-octanoyl anthranilic acid (1 g, 3.8 mmol) in acetic anhydride 
(20 mL) was heated under reflux for 2 h. Acetic anhydride was evaporated 
under high vacuum to yield the product as a yellow oil in 93 % yield.  Residual 
acetic acid was removed by placing in a dessicator, under vacuum, with KOH.
Rf – 0.68 EtOAc/hexane 50/50
1
H NMR (CDCl3) δ 0.86 (3H, t, V = 6.80 Hz, 7’-H CH3), 1.34 (8H, m, (CH2)4), 
1.81 (2H, m, 2’-H), 2.66 (2H, t, V = 7.88 Hz, 1’-H), 7.50 (2H, m, 6-H & 8-H), 
7.77 (1H, m, 7-H), 8.16 (1H, dd, V = 1.23 & 7.86 Hz, 5-H)
13
C NMR (CDCl3) δ 14.41 (CH3), 22.95, 26.51, 29.69, 29.41, 31.99, 35.22 (6 x 
CH2), 117.19 (4°), 126.89, 128.43, 128.73, 136.78 (3 x aromatic CH), 146.82, 
160.18, 163.64 (3 x 4°) 
(MS-ES) *01 246.26 (MH
+
, C15H19NO2 requires *01 246.32)
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2-Nonyl-4H-benzo[d][1,3]oxazin-4-one (3.81)
&
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1
H NMR (CDCl3) δ 0.88 (3H, t, V = 6.23 Hz, 9’-H CH3), 1.27 – 1.37 (12H, m, 
(CH2)6), 1.77 – 1.89 (2H, m, 2’-H), 2.69 (2H, t, V = 7.46 Hz, 1’-H), 7.46 – 7.58 
(2H, m, 6-H & 8-H), 7.76 – 7.83 (1H, m, 7-H), 8.18 (1H, dd, V = 1.13 & 7.86 
Hz, 5-H)
13
C NMR (CDCl3) δ 14.11 (CH3), 21.33, 22.67, 26.16, 29.11, 29.26, 29.26, 
29.41, 31.86, 34.87 (8 x CH2), 116.85 (4°), 126.54, 128.08, 128.39, 136.51 (3 x 
aromatic CH), 146.48, 159.83, 163.32 (3 x 4°)
6-Chloro-2-heptyl-4H-benzo[d][1,3]oxazin-4-one (3.83)
&
!
!
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13
C NMR (CDCl3) δ 14.45 (CH3), 22.98, 26.45, 29.28, 29.42, 32.01, 35.20 (6 
x CH2), 118.37 (4°), 128.14, 128.57 (2 x aromatic), 134.11 (4°), 137.11 
(aromatic), 145.34, 159.18, 164.00 (3 x 4°)
6-Chloro-2-nonyl-4H-benzo[d][1,3]oxazin-4-one (3.84)
&
!
!
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Mp. 51-53 °C
TLC; Rf = 0.51 (50 % ethyl acetate, hexane)
1
H NMR (CDCl3) δ 0.89 (3H, t, V = 6.23 Hz, 9’-H CH3), 1.25 – 1.43 (12H, m, 
(CH2)6), 1.80 – 1.85 (2H, m, 2’-H), 2.70 (2H, t, V = 7.55 Hz, 1’-H), 7.51 – 7.55 
(1H, m, 5-H), 7.73 – 7.67 (1H, m, 7-H), 8.17 (1H, br d, V = 2.43 Hz, 8-H)
13
C NMR (CDCl3) δ 14.11 (CH3), 21.35, 22.67, 26.07, 29.23, 29.38, 31.85, 
34.82 (8 x CH2), 117.79 (4°), 127.76, 128.02 (2 x CH), 133.73 (4°), 136.75 
(CH), 144.88, 158.57, 163.61 (3 x 4°)
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2-n-Heptyl-3-amino-4(3H)quinazolinone (3.85)
&
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Method A
A solution of 2-!-heptyl-benzo[(][1,3]-oxazin-4-one (1.31 g, 5.35 mmol) and 
hydrazine monohydrate (0.268 g, 5.35 mmol) in tetrahydrofuran (THF) (15 
mL) was stirred at room temperature for 2 h.  The solvent was removed under 
vacuum to yield a bright pink oil that solidified on cooling to form a crystalline 
solid.  The solid was triturated with ether, giving a white precipitate that was 
collected by filtration.  The white precipitate was found to be the uncyclised 
form of the desired product.
Method B
A solution of 2-!-heptyl-benzo[(][1,3]-oxazin-4-one (0.494 g, 2 mmol) and 
hydrazine monohydrate (0.4 ml) in ethanol (20 mL) was stirred at reflux 
overnight.  The solvent was removed under reduced pressure, yielding a 
yellow, crystalline solid.  This was triturated with hexane and the resulting 
solid was recrystallised from EtOH/water to give beige, needle crystals in 38 % 
yield.  
Mp. 74 – 75 °C
IR (KBr) 1591.17 (C=N), 1664 (amide C=O), 3203, 3301 (NH2) cm
-1
. 
1
H NMR (CDCl3) δ 0.93 (3H, t, V = 6.71 Hz, CH3), 1.43 (8H, m, (CH2)4), 1.86 
(2H, m, 2’-H), 3.06 (2H, t, V = 7.99 Hz, 1’-H), 4.92 (2H, s, NH2), 7.41 (1H, m, 
6-H), 7.75 (2H, m, 8-H & 7-H), 8.27 (1H, dd, V = 1.02 & 8.02 Hz, 5-H)
13
C NMR (CDCl3) δ 14.84 (CH3), 22.63, 27.217, 29.06, 29.46, 31.74, 34.62 (6 
x CH2), 119.98 (4°), 126.26, 126.47, 127.10, 134.27 (4 x aromatic CH), 
147.02, 158.55, 161.95 (3 x 4°)
(MS-ES) *01 260.2 (MH
+
, C15H21N3O requires *01 260.35)
Anal. calcd. for C15H21N3O: C, 69.47; H, 8.16; N, 16.20. Found: C, 69.35; H, 
8.26; N, 16.29.
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2-n-Heptyl-3-hydroxy-4(3H)quinazolinone (3.87)
&
&
!
!"
Sodium metal was dissolved in ethanol (20 mL).  Hydroxylamine 
hydrochloride (4 mmol) was added and stirred for 15 min. The solid was 
removed by filtration and 2-!-heptyl-benzo[(][1,3]-oxazin-4-one (0.988 g, 4 
mmol) was added to the filtrate and refluxed for 48 h.  The solvent was 
removed under vacuum to yield a viscous yellow oil, which when triturated 
with ether yielded a beige crystalline solid.  This was collected by filtration.  
Product produced in 29 % yield.  
Mp. 215 - 220 °C
IR (KBr) 1588 (C=N), 1665 (amide C=O), 3432 (OH) cm
-1
1
H NMR (MeOH-d4) δ 1.03 (3H, t, V = 6.81 Hz, 7’-H CH3), 1.41 (8H, m, 
(CH2)4), 1.85 (2H, m, 2’-H), 2.55 (2H, t, V = 7.80 Hz, 1’-H), 5.06 (1H, s, 
NOH), 7.18 (1H, m, 6-H), 7.49 (1H, m, 8-H), 8.18 (1H, dd, V = 1.57 & 7.81
Hz, 7-H), 8.65 (1H, m, 5-H)
13
C NMR (MeOH-d4) δ 14.83 (CH3), 24.08, 24.57, 27.35, 30.56, 30.75, 33.31, 
40.00 (6 x CH2), 120.88, 123.79 (2 x aromatic CH), 125.48 (4°), 132.50, 
132.79 (2 x aromatic CH), 141.68, 174.67, 175.23 (3 x 4°)
(MS-ES) *01 261.58 (MH
+
, C15H20N2O2 requires *01 261.33)
2-n-Nonyl-3-amino-4(3H)-quinazolinone (3.89)
&
&
!
&")
Yield = 46 %
Mpt = 57 – 58 
o
C
(MS-ES) *01 286.37 (MH
+
, C17H25N3O requires *01 287.40)
IR (KBr) 1593 (C=N), 1683 (amide C=O), 2849, 2923 (NH2) cm
-1
1
H NMR (CDCl3) δ 0.88 (3H, t, V = 6.27 Hz, CH3), 1.27 – 1.46 (12H, m, 
(CH2)6), 1.74 – 1.88 (2H, m, CH2), 3.02 (2H, t, V = 7.71 Hz, CH2), 4.86 (2H, s, 
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NH2), 7.41 – 7.47 (1H, m, 7-H), 7.64 – 7.69 (2H, m, 6-H & 8-H), 8.23 (1H, dd, 
V = 0.99 & 8.01 Hz, 5-H)
13
C NMR (CDCl3) δ 14.12 (CH3), 22.17, 22.68, 27.18, 29.29, 29.40, 29.49, 
31.88, 34.64 (8 x CH2), 119.96 (4°), 126.21, 126.42, 127.11, 134.22, (4 x Ar), 
147.03, 155.50, 161.92 (3 x 4°)
2-n-Pentyl-3-amino-4(3H)-quinazolinone (3.88)
&
&
!
&")
Yield = 47 %
Mpt = 60 – 61 
o
C
IR (KBr) 1593 (C=N), 1686 (amide C=O), 2928, 2959 (NH2) cm
-1
1
H NMR (CDCl3) δ 0.95 (3H, t, V = 6.9 Hz, 5’-H), 1.40 – 1.50 (4H, m, (CH2)2), 
1.79 – 1.91 (2H, m, 2’-H), 3.03 (2H, t, V = 1.67 Hz, 1’-H), 4.89 (2H, s, NH2), 
7.42 – 7.49 (1H, m, 7-H), 7.66 – 7.78 (2H, m, 6-H & 8-H), 8.22 – 8.26 (1H, m, 
5-H)
13
C NMR (CDCl3) δ 14.40 (CH3), 22.86, 27.26, 32.04, 35.01 (4 x CH2), 
120.39, (4°), 126.62, 126.85, 127.55, 14.63 (3 x Ar CH), 147.46, 158.83, 12.31 
(3 x 4°)
(MS-ES) *01 232.07 (MH
+
, C13H17N3O requires *01 232.14)
6-Chloro-2-n-heptyl-3-hydroxy-4(3H)-quinazolinone (3.90)
&
&
!
&")'(
Yield = 78 %
1
H NMR (CDCl3) δ 0.91 (3H, t, V = 6.48 Hz, CH3), 1.41 (8H, m, (CH2)4), 1.84 
(2H, m, 2’-H), 3.03 (2H, t, V W 7.72 Hz, 1’-H), 4.88 (2H, s, NH2), 7.65 (2H, m, 
7-H & 8-H), 8.24 (1H, d, V = 2.24 Hz, 5-H). 
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13
C NMR (CDCl3) δ 14.49 (CH3), 23.03, 27.42, 29.45, 29.82, 32.13, 34.98 (6 x 
CH2), 121.38 (4°), 126.10, 129.31 (2 x aromatic), 132.34 (4°), 135.08 
(aromatic), 145.97, 159.11, 161.32 (3 x 4°)
Anal. calcd. for C15H20ClN3O: C, 61.32; H, 6.86; N, 14.30. Found: C, 61.35; H, 
6.80; N, 14.33.
6-Chloro-2-methyl-3-hydroxy-4(3H)-quinazolinone (3.91)
&
&
!
&")'(
Mp. 168 °C
1
H NMR (CDCl3) δ 2.72 (3H, s, CH3), 4.91 (2H, s, NH2), 7.60 (1H, d, V = 8.70 
Hz, 5-H), 7.68 (1H, dd V = 2.42 & 8.73 Hz, 7-H), 8.21 (1H, d, V = 2.24, 8-H)
13
C NMR (CDCl3) δ 22.25 (CH3) 121.07 (4°), 125.78, 128.70 (2 x Ar), 132.06 
(4°), 134.79 (Ar), 145.48, 155.75, 160.62 (3 x 4°)
Anal. calcd. for C9H8N3OCl: C, 51.56; H, 3.85; N, 20.04. Found: C, 51.28; H, 
3.95; N, 19.63.
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Appendix
A1 Raw Data for murine splenocyte assays
Well Test material Conc cpm cpm cpm%
(µM) Mean SD Mean
X1 3.85 7QQQ -) -C -)K- QKO7 7KQ
X2 3.85 CQQ N) NC N)K- QKO7 7K)
X3 3.85 7QQ NC 7-) 7QOK- N)KbC )KQ
X4 3.85 CQ 7LO NP 7QOK- --KPN )KQ
X5 3.85 7Q 7QC7 P7O b)LKQ 7-7KC) 7OKN
X6 3.85 C )OL- )PQ- )OO-KQ L)KLC -)Kb
X7 3.85 7 CbPQ CL77 CNb-K- LQ)KCL OQKL
X8 3.85 QKC NQO7 LLOC -)O)KQ 77)bKbN 7QQK-
X11 3.87 7QQQ LO CP L)K- NKCN QKP
X12 3.87 CQQ bO -b OPKQ )NKPO 7K-
X13 3.87 7QQ -7 -Q -QK- QKO7 7KQ
X14 3.87 CQ CNO )bO CC)KQ LbK-Q NKC
X15 3.87 7Q )bOQ C777 CQLQK- bbKOQ -OKb
X16 3.87 C -7PC LPC) -QQOK- )LPK7b b-KL
X17 3.87 7 -)NN LbLL -7Q-KQ ))OKNb bOKC
X18 3.87 QKC Lb-) NPCP -Pb-KQ 7CCCKNQ 77)KC
X11 3.88 7QQQ LO C) CbK- 7QKN7 -KO
X12 3.88 CQQ -7 CN LCK- 7QKN7 NK)
X13 3.88 7QQ L) -- LPK- bK7b NKb
X14 3.88 CQ LO Lb LPKQ 7KL7 NKb
X15 3.88 7Q 77-L 7L7L 7)PLKQ 7PCKP- 7PLKQ
X16 3.88 C )OC7 L7)C CL)OKQ bPLK)b Lb7KQ
X17 3.88 7 L7Lb CPP- LQ7OKQ 7PNKNP -O-K-
X18 3.88 QKC -L7- LQbC LO-LKQ bCLKPQ NP7K7
X9 Positive -PL7 -7N7 -Qbb
X19 Positive LONQ -))Q -LQb -)LPKC C-bK-) 7QQKQ
X10 Negative LN OP CC -)KC )CK7N 7KQ
X20 Dexamethasone 0.5 OO bP 7C7 7Q)KQ )OK)) 7Kb
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Well Test material Conc cpm cpm cpm%
(µM) Mean SD Mean
X1 3.89 7QQQ CN )b C)K- LKb- QKN
X2 3.89 CQQ C) Cb C-K- LKb- QKO
X3 3.89 7QQ LL 7QP ONKQ L-K)- 7K-
X4 3.89 CQ -QN PbQ NbPKQ )O7K-C 7CKN
X5 3.89 7Q )PCC )-ON )OQLK- 7P7KOC -)K-
X6 3.89 C COLL C-C7 CNCOK- 7-QKN7 OQKN
X7 3.89 7 -OP- LCLP -QNNK- 7Q7NK77 bPKL
X8 3.89 QKC -)LC L-O) LbQOK- LOLKLO b-KC
X11 3.9O 7QQQ CL CL CLKQ QKQQ QKO
X12 3.9O CQQ 7Cb bb 77bKQ )PK)P )KC
X13 3.9O 7QQ PNb bNQ b7LK- NLKC- 7OKP
X14 3.9O CQ 7N-- 7bL7 7ObPKQ )Q)K)C CLKb
X15 3.9O 7Q L)Q- )ObL CLbbK- bbOKOC NOKb
X16 3.9O C L)7O LPPb L--CKQ LO-K7P PPKL
X17 3.9O 7 -N)- LbQb -)NOKQ -QNK)b 7Q)KC
X18 3.9O QKC -777 CbLN L-)PK- P)CKOP POKb
X9 Positive LP7N Lb)) -)N)
X19 Positive Lb-) -7C) -P)7 -7-QKP CNLKb) 7QQKQ
X10 Negative C- 7P )- )NKQ PK-L QK-
X20 Dexamethasone 0.5 P) -O Lb N)KO 7OK)7 7K)
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Well Test material Conc cpm cpm cpm%
(µM) Mean SD Mean
X1 3.91 7QQQ )- 7b ))KQ LK)L QKL
X2 3.91 CQQ CQ)O COL) CCPLK- -Q-K-P NLK7
X3 3.91 7QQ CPQ) L)PC LQL)K- CLQK7) ONKN
X4 3.91 CQ LNNO NLQN --CNK- 7))bKNN 7QLKb
X5 3.91 7Q bbON -7-C O-NLK- CL7QKCP 7LCKC
X6 3.91 C O)CQ L7Lb -NPbK- )7OPKNQ 7QOKP
X7 3.91 7 N7)O LbOP ---)K- P7)KLO 7Q-K)
X8 3.91 QKC -LbO -QCb -)NPKQ C)CKP- bbKP
X11 2.141 7QQQ CC C- CLKQ 7KL7 QKN
X12 2.141 CQQ -7 L- LPKQ LK)L QKb
X13 2.141 7QQ CN NC LbK- 7bKQb QKb
X14 2.141 CQ 7P7N 77bL 7-Q-KQ LCbKP) )PK-
X15 2.141 7Q )P7N )PbC )P-LK- -LKL- -LK7
X16 2.141 C CNOL Lb-7 LC7)K- bQ)KbP P7KO
X17 2.141 7 --Qb LQP- LObOKQ 7QQNKb) bQKb
X18 2.141 QKC LN7C LC-- LLPLKQ 7P)KLC P-KQ
X11 2.104 7QQQ C7 7C ))KQ 7)KOC C)KP
X12 2.104 CQQ O-P NN7 OQbK- NPK-b 7Q-bKQ
X13 2.104 7QQ CN-N --LO LNQ7K- 7CCOK7L NPNOKb
X14 2.104 CQ LQ-- -PLQ LbLOK- 7)N)K7b OCPLKC
X15 2.104 7Q LP77 LLQQ LNQ-K- )bQKN) NPOCKb
X16 2.104 C LP)- -N7- -))QKQ --PKN7 OOb7KQ
X17 2.104 7 LL7O LLLC LLCQKQ 7PKCP NN77Kb
X18 2.104 QKC LNLP -)ON LbN)KQ LLLKQN OLQNKQ
X9 Positive NONL Lb-7 -L7-
X19 Positive -CQ- -7LL LQb7 -)OPKC PNOKCN 7QQKQ
X10 Negative L) )O LC COKC PKbN QKO
X20 Dexamethasone 0.5 NC NN N- NLKO 7K-C 7K)
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Well Test material Conc cpm cpm cpm%
(µM) Mean SD Mean
X1 2.107 7QQQ CO L) CbK- CK-L QKP
X2 2.107 CQQ ON LO N7K- )QK-7 7K)
X3 2.107 7QQ -- bL OLK- )OK-P 7KL
X4 2.107 CQ P- Lb NOKQ )-KLN 7KC
X5 2.107 7Q C-P -LL L-7KQ 7C7K-) PKP
X6 2.107 C Cb7O ))QC CQNQKQ 7)77KbP -bK-
X7 2.107 7 7Q-O) L-7) O-L)KQ L)P-KQO 7LNKO
X8 2.107 QKC CObC P)-) NQ))K- C7-)Kbb 77OK7
X11 2.109 7QQQ CO C7 CLKQ LK)L QKO
X12 2.109 CQQ bL b- bLK- QKO7 7KP
X13 2.109 7QQ NN C- -QK- )7Kb) 7KQ
X14 2.109 CQ PbC PQQ PLNK- N-KON 7NK-
X15 2.109 7Q )NbN LQN- CCPQK- bNPKQC N-KO
X16 2.109 C NL7N NQPP N)-)KQ )C7KbC 7)7KN
X17 2.109 7 L)7L -QNQ LNCOKQ -bPK)7 bQK)
X18 2.109 QKC --bQ -N7Q -NQQKQ 7LK7L 7QPKb
X9 Positive -CNN LbLb LPNL
X19 Positive N7Qb -77) LL-C -7L)K) -N7KC) 7QQKQ
X10 Negative OL CN CC LOKO ))KP- QKb
X20 Dexamethasone 0.5 O- P- PQ PQKQ -KQQ 7KN
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Well Test material Conc cpm cpm cpm%
(µM) Mean SD Mean
X1 2.144 7QQQ -) LP -QKQ )KPC QKb
X2 2.144 CQQ NO O7 NbKQ )KPC 7KC
X3 2.144 7QQ OO Lb) )PLK- )bCKL- -K)
X4 2.144 CQ )CP Ob 7-PK- 77)KLC )Kb
X5 2.144 7Q bN -Q OCKQ C)K-C 7KC
X6 2.144 C OC -N NLK- 7)KQ) 7K)
X7 2.144 7 )OO CCC CQ-KQ CbKNQ -K-
X8 2.144 QKC LQPO LL7L L)-QK- )C7K)) OOKC
X11 2.142 7QQQ bL CC NCK- LCK7C 7K)
X12 2.142 CQQ 7)b 7CO 7CCKQ -KNN )KL
X13 2.142 7QQ -L -O --K- )K7) 7KQ
X14 2.142 CQ -L -P -NKQ )KPC 7KQ
X15 2.142 7Q )L Cb C7K- 7QKN7 QKN
X16 2.142 C -Q NO -PK- 7)KQ) 7K7
X17 2.142 7 7)7Q 7)7b 7)7LK- NKCN ))K7
X18 2.142 QKC CPLb CPLN CPLOK- )K7) OQKQ
X11 2.145 7QQQ Lb CN L)K- bK7b QKP
X12 2.145 CQQ LO OP N)K- )7Kb) PbKC
X13 2.145 7QQ -b -Q -LK- NKCN OOKb
X14 2.145 CQ CP NL -7KQ 7PKCP O)Kb
X15 2.145 7Q LL NQ -)KQ 77KC7 OLKC
X16 2.145 C -) NO -bK- 7QKN7 P-KQ
X17 2.145 7 ))7 7CQ 7O-K- NLKC- )-QKO
X18 2.145 QKC 7C-N 7-)Q 7LCPKQ 77-KbO )Q-LKC
X1 4.4 7QQQ CQ )- )OK- CK-L QKN
X2 4.4 CQQ )N- -P 7N7K- 7LNKCO CKL
X3 4.4 7QQ OO NP O)K- NKCN 7K-
X4 4.4 CQ ON NL OQKQ PKLb 7K-
X5 4.4 7Q Cb CO CPKQ 7KL7 QKP
X6 4.4 C CO P) -bK- C7KP) 7KC
X7 4.4 7 -N PP O)KQ ))KNC 7K-
X9 Positive NQLP -P-7 LPOb
X19 Positive -7QO N)-L LPLP -LbOKP N)-KN- 7QQKQ
X10 Negative OC 7)N CN OPKC L-K)L 7KL
X20 Dexamethasone 0.5 OQ 777 Nb PCKC )CKbO 7K-
